Assessing the Efficacy of Aspirin and Clopidogrel in Patients with Acute Coronary Syndromes by varadharajan, vatchsala sree
 
 
 
 
         Department  
Of infection, 
Immunity and 
Cardiovascular  
Disease. 
 
 
 
 
 
Assessing the Efficacy of Aspirin and Clopidogrel 
in Patients with Acute Coronary Syndromes 
 
 
 
 
 
Dr. Vatchsala Sree Varadharajan M.B.B.S. MRCP. 
 
 
A Thesis submitted for the degree of Doctor in Medicine (MD) 
August 2017 
 
 
 
1 
 
Acknowledgement 
First, I would like to thank Prof. R.F. Storey who has guided, supervised, 
advised and taught me many things without any hesitation whenever I was 
in doubt. He always had the time for me and has remained my biggest 
inspiration in life. I thank him more than anything for giving me an 
opportunity to pursue my higher degree and for the valuable contribution 
he has made towards completing my project. Without him I would have not 
accomplished my project. Thank you, Prof. Storey. 
Next I would like to thank Mr. Braidley for supporting me to undergo my 
research financially through the Transplant Research Fund, Dr. Al- 
Mohammad, Dr. S Campbell and my colleagues and friends in the heart 
transplant unit (Northern General Hospital, Sheffield) namely Helen, Jo, 
Emma and Debby who have supported me professionally during my most 
difficult times.  
I would like to thank all members in the Sheffield Cardiovascular Research 
Unit namely, Mrs. Rose Ecob, Helen Steele, and Rob Buckland who had 
helped me in the lab and also for their support in collecting the data from 
the patients. I thank my close friend and colleague Dr. Sara Rasool for her 
contribution towards my work. During my sample collection I spent long 
time in the cardiac catheter lab waiting for the procedures to be over and 
to obtain my samples from the patients. During those times the staff have 
made me feel comfortable and sometimes would have secured the sample 
for me if I was held up in the research lab doing my experiments. I 
sincerely thank them. 
In India my sincere thanks go to Mr. Rajesh Kanna for his commitment 
and contribution towards my work. I thank Dr. SaiGopal and Dr. 
Dhamodaran for their advice on statistical analysis. 
My parents have always been my greatest motivation in life and their 
dreams about me has made me to accomplish many things in life. It is my 
dad’s long cherished wish that I obtain my master’s degree and when I 
accomplish, that I am sure he will be the happiest person. 
2 
 
Finally, my husband Sathish and son Muhil. I have lived apart from them 
for 5 years to complete my project. My husband’s continuous motivation 
and support in all front has encouraged me to continue my career, the way 
I wanted and to positively contribute to the profession and for the society. 
He has accommodated my busy work schedule and still encourages me 
professionally which I find very unique. He has managed to balance 
between his busy business schedule and little Muhil enabling me to 
complete my work. I completely owe my work to him. My little son Muhil is 
the one who has suffered and missed a lot of me. There are many things 
that we both have missed which we won’t get back again. I only hope that 
he understands me when he grows up and all the sacrifices and the 
compromises that we both have mutually undergone are worth at the end.     
 
  
3 
 
Statement of Originality 
 
I hereby declare that this submission is my own work and to the best of my 
knowledge, it contains no materials previously published or written by 
another person, except where due acknowledgement is made in the 
thesis. The material in this thesis has not previously been submitted for a 
degree to any other University. Any contribution made by others, with 
whom I have worked, is clearly acknowledged in the thesis. I also declare 
that the intellectual content of this thesis is the product of my own work, 
except that full assistance from my supervisor in the project's design, 
conception, execution, presentation and linguistic expression is 
acknowledged. 
 
 
 
 
  
4 
 
Contents 
________________________________________________________________ 
Acknowledgement ………………………………………………………………. 1 
Statement of Originality………………………………………………………… 3 
Contents………………………………………….……………………..…….… 28-219 
Chapter 1 …………………………………………………………………………. 28-93 
Chapter 2 …………………………………………………………………………. 94-108 
Chapter 3 ……………………………………………………………………….. 109-127 
Chapter 4 …………………………………………………………………………. 128-143 
Chapter 5 ………………………………………………………………………… 144-160 
Chapter 6 ………………………………………………………………………… 161-176 
Chapter 7 ………………………………………………………………………… 177-194 
Chapter 8 …………………………………………………………………………. 195-202 
List of Figures…………………………………………………………………… 17-20 
List of Tables…………………………………...……………………………….. 21 
List of Appendix…………………………………...…………………………….. 22 
Abbreviations…………………………………………………….………………. 23-27 
 
 
 
 
5 
 
Chapter 1: Introduction………………………………………………………  28-92 
 
1.1 Introduction…………………………………..……………………………..  28 
1.2 Platelets and Atherothrombosis………………..……….…………………. 28 
1.2.1 History of Platelets…………………………….…………………………  28 
1.2.2 Structure of Platelets …………..………………..…………………….  29 
1.2.3 Platelet Secretions………………………............................................. 31 
1.2.4 Platelet Receptors…………………………………………………….…  33 
 
1.2.4.1. Glycoprotein (GP) Ib-IX-V Complex……………………….  33 
1.2.4.2. Integrins………………………………………………..……..  33 
1.2.4.3. Thrombin Receptors…………………………………………  34 
1.2.4.4. Platelet Purinergic Receptors……………………………..  35 
 
1.2.5. Platelet Functions…………………………….…………………………  35 
1.2.5.1. Role of Platelets in Haemostasis………………………..…  35 
1.2.5.2. Role of Platelets in Thrombus Formation…………………  37 
1.2.5.3. Role of Platelets in Coagulation…………………….…….  37 
1.2.5.4. Role of Platelets in Inflammation………………………….  38 
 
1.3. Process of Atherothrombosis………………………..………………….  39 
1.3.1 Clinical Implications of Atherosclerosis& Thrombosis……………...  42 
1.4 Antithrombotic Medications…….……….……………………………….  43 
1.5 Antiplatelet Medications…………………………..………..…………….  43 
1.6. Aspirin……………………………………………..................................  44 
1.6.1. Mechanism of Action and Pharmacodynamics……………………….. 44 
1.6.2. Aspirin In Primary Prevention………………………………………..….. 45 
1.6.3. Aspirin in Secondary Prevention…………………………………….…. 46 
1.6.4. Limitations of Aspirin…………………………........................................ 46 
1.6.4.1. Aspirin Resistance…………………....................................... 46 
1.6.4.2. Treatment Failure………………………………………..…… 47 
1.6.4.3. Laboratory Resistance……………………………………….. 47 
 
1.7. P2Y12 Receptor Antagonists………………………..……………………..  48 
1.8. Clopidogrel……………………………………………….………………….. 48 
1.8.1. Mechanism of Action and Pharmacodynamics of Clopidogrel…….… 48 
1.8.2. Clinical Trials of Clopidogrel………………………………………………  50 
1.8.3. Limitations of Clopidogrel……………………………………………….… 53 
6 
 
 
1.8.3.1. Inter Individual Variability to Clopidogrel……………………. 53 
1.8.3.2. Factors Influencing Interindividual Variation………………. 54 
1.8.3.3. Genetic Factors………………………………………………… 54 
1.8.3.4. Drug–Drug Interaction……………………………………….. 55 
1.8.3.5. Clopidogrel Hyporesponders-Clinical Implications…..…..  56 
1.8.3.6. Rebound Effect………………………….……….……………. 56 
 
1.8.4 Prasugrel …………………………………………………………………… 57 
1.8.4.1 Mechanism of Action and Pharmacodynamics……………. 57 
1.8.4.2 Clinical Trials of Prasugrel……………………………………. 57 
1.8.4.3. Limitations of Prasugrel………………………………………. 58 
 
1.8.5. Ticagrelor …………………………………………………………………. 59 
1.8.5.1. Mechanism of Action and Pharmacodynamics…………… 59 
1.8.5.2. Clinical Trials of Ticagrelor………………………………….. 59 
1.8.5.3. Limitations of Ticagrelor……………………………………… 60 
 
1.8.6. Indications for Antiplatelets Therapy …………………………………… 60 
 
1.9. Platelet Function Testing (PFT)…………………………………….……..  61 
1.9.1. General Principles……………………………………………………….  64 
1.9.2. Physiological Vs. Non Physiological Environments………….………  64 
1.9.3. Other General Considerations…………………………………………. 64 
1.9.4. Agonists Used…………………………………………………………..  65 
1.9.5. Anti-Coagulants Used………………………………………………….  66 
1.9.6. Turbidometric Aggregometry…………………………………………  67 
1.9.6.1. Light Transmission Aggregometry………………………..  67 
1.9.6.2. Principles of LTA…………………………….......................  67 
1.9.6.3. Limitations and Advantages of LTA……….......................  68 
 
1.9.7. Whole Blood Aggregometry…………………….……………….……… 68 
1.9.7.1. Impedance Platelet Aggregometry………….…………..……...... 68 
1.9.7.2. Principles of Impedance Aggregometry……………………....... 69 
1.9.7.3. Limitations and Advantages of Impedance Aggregometry. 69 
 
 
7 
 
1.9.8. Multiplate Electrode Aggregometry…………………………………….. 70 
1.9.8.1. Principles of MEA………………………………………………. 70 
1.9.8.2. Limitations and Advantages of MEA………….…………  70 
 
1.9.9. Particle Counting Aggregometry………………………………………  70 
1.9.9.1. Whole Blood Single Platelet Counting Assay……................... 71 
1.9.9.2. Principles of WBSPCA………………………………………..... 71 
1.9.9.3. Limitations and Advantages of WBSPCA…………..................... 71 
 
1.9.10. PlateletWorks…………………………………………………….…….. 72 
1.9.10.1. Principles of PlateletWorks………….………………………. 72 
1.9.10.2. Limitations and Advantages of PlateletWorks………………... 72 
 
1.9.11. VerifyNow Assay (Ultegra Rapid Platelet Function Assay) ………..….. 72 
1.9.11.1. Principles of VerifyNow assay…………..………………….…. 73 
1.9.11.2. Limitations and Advantages of VerifyNow Assay………….. 73 
 
1.9.12. Bleeding Time……………………………............................................ 74 
1.9.12.1. Principles of Bleeding Time………….………………..……….. 74 
1.9.12.2. Advantages and Limitations of Bleeding Time…………..……. 75 
 
1.9.13. Platelet Function Analyzer (PFA 100)……………………………..….. 75 
1.9.13.1. Principles of Platelet Function Analyzer-100……………………. 75 
1.9.13.2. Advantages and Limitations of Platelet Function Analyzer-100 75 
 
1.9.14. Cone and Plate(let) Analyzer……………………………..……………. 76 
1.9.14.1. Principles of Cone and Plate(let) Analyzer……………….. 76 
1.9.14.2. Advantages and Limitations of Cone and Plate(let) Analyzer. 76 
 
1.9.15. Flow Cytometry………………………………………………………….. 76 
1.9.15.1. Vasodilator-Stimulated Phosphorylation Cytometric Analysis 77 
1.9.15.2. Principles of VASP Flow Cytometric Analysis…………….... 77 
1.9.15.3. Advantages and Limitations of the VASP Cytometric Analysis. 77 
 
1.9.16. Thromboelastography……….……………………………..………….. 78 
1.9.16.1. Thromboelastography Platelet Mapping System……………… 78 
1.9.16.2. Principles of TEG Mapping System……….………………….. 79 
1.9.16.3. Advantages and Limitations of TEG Mapping System……… 79 
 
1.9.17: Rotational Thromboelastography & Thromboelastometry..................... 79 
8 
 
1.9.18. Thromboxane generation………………………………………………. 80 
1.9.18.1. Serum TXB2…………………………………………………….…. 80 
1.9.18.2. Limitations of Serum TXB2………………………………………. 80 
1.9.18.3. Urinary 11-Dehydro TXB2 Measurements…………………. 80 
1.9.18.4. Advantages and Limitations of Urinary 11-Dehydro TXB2…… 81 
 
1.9.19. Tests to Monitor the Effects of Aspirin……….……………………………… 82 
1.9.20. Tests to Monitor the Effects of Clopidogrel…………………………........ 82 
1.9.21. Studies Linking the Clinical Outcomes and Level of Platelet Inhibition 83 
1.9.22. Accuracy of Individual PFT to Predict Clinical Outcomes for Clopidogrel 85 
1.9.23. Accuracy of Individual PFT to Predict Clinical Outcomes for Aspirin. 87 
1.9.24. Risk Stratification Based on PFT…………………………………………… 87 
1.9.25. Limitations of the Risk Stratification Based on PFT………………...... 88 
1.9.26. PFT- Current Status……………………………………………................ 88 
1.9.27. Cost Effectiveness of PFT…………………………………….................. 91 
1.9.28. Summary of PFT…………………………………………….................. 92 
 
1.10. Cardiac Troponins……………………………………………………….... 92 
1.11. Study aims………………………………………………………………….. 93 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
Chapter 2: Methods and Materials…………………………………………..  94-108 
2.1. Preface………………………………………………………………………  94 
2.2. Patients……………………………………………………………….……… 94 
2.3. Inclusion Criteria………………………………….……………………….  95 
2.4. Exclusion Criteria……………………………………………………….…  95 
2.5. Study Design……………………………………………………………...  95 
 2.5.1 My Role ……………………………………………………………………. 95 
2.6. Sample Collection………………………………………………….……….. 97 
2.6.1. Blood Collection for Assessing the Effects of Aspirin and  
Clopidogrel by WBSPCA……….…………………………………….. 97 
 
2.6.2. Blood Collection for Assessing the Effects of Clopidogrel  
by LTA and WBSPCA………….………………………………………. 98 
 
2.6.3. Blood Collection for Assessment of Inflammatory Markers…….…….. 99 
2.6.4. Blood Collection for Troponin-T Analysis……………………………… 99 
2.6.5. Collection of Urine Sample…………………………………………….… 99 
 
2.7. Materials…………………..…………………………………………………. 99 
 
2.8. Methods………………………………………………………………………. 100 
2.8.1. Whole Blood Single Platelet Counting Assay for Clopidogrel………… 100 
2.8.2. Whole Blood Single Platelet Counting Assay for Aspirin……………….. 101 
2.8.3. Light transmission aggregometry……………………………..……..…….. 101 
2.8.4. Measurement of Serum TXB2……………………………………..……….. 102 
2.8.5. Measurement of cTnT……………………………………………………….. 103 
2.8.6. Enzyme Linked Immunosorbent Assay Test………………………............ 103 
2.8.7. Measurement of Urine 11-Dehydro TXB2 Levels…………………………. 103 
 
2.9. Definitions…………………………………………………………………….. 103 
2.9.1. Clopidogrel Responders and Non-Responders……………..…………. 103 
2.9.2. Aspirin Responders and Low-Responders…………………..….……… 104 
2.9.3. Post PCI Myonecrosis……………………………………………………. 104 
2.9.4. Major Adverse Cardiac Events………………………….………………. 105 
2.9.5. TIMI Major and Minor Bleed………………………………….................... 105 
10 
 
 
2.10. Telephone Interview………………………………..…………………....... 106 
2.11. Statistical Analysis…………………………………………………………. 106 
2.12. Details of the Patient’s Distribution………………………………………. 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Chapter 3: Utility of Whole Blood Single Platelet Counting  
Assay in Predicting the Clinical Outcomes in Acute Coronary  
Syndrome Patients Treated with Clopidogrel……………………………      109-127 
 
3.1. Background and Aim……………………………………………………….. 109 
3.2. Patients and Demographics………………………………………………... 110 
3.3. Descriptive Statistics of Aggregation Data in Response  
to Clopidogrel Using WBSPCA…………………………………………..………. 112 
3.4. Prevalence of Clopidogrel Responders and  
Non- Responders Assessed by WBSPCA……………………………………… 114 
3.5. Interindividual Variation in the Platelet  
Aggregation Response to Clopidogrel…………………………………………. 115 
3.6. Ischaemic Outcomes in Clopidogrel Treated Patients  
Assessed by WBSPCA………………………..………………………………… 115 
3.6.1. Demographic Details…………………………………............................... 115 
3.6.2. Platelet Aggregation Details…………………………................................. 116 
3.6.3. Incidence of Ischaemic Complications in  
Responders and Non-Responders………………………………………….…… 117 
3.6.4. Platelet Aggregation in Patients with and  
With out Ischaemic Complications…………………………………………………. 118 
 
3.7. Bleeding Complications - Details and Demographics of  
the Bleeds and Bleeders……………………………………………………….… 120 
3.7.1. Incidence of Bleeding Complications in Responders and Non-Responders. 120 
3.7.2. Platelet Aggregation in Bleeders and Non-Bleeders………......................... 121 
3.7.3. Platelet Aggregation Compared between Bleeders and Non-Bleeders…. 123 
3.7.4. Platelet Aggregation Compared between Ischaemic and  
Bleeding Complications………………………………………………………………. 123 
 
3.8. Discussion…………………..…………………………………………………..… 124 
3.9. Conclusion…………………………………………………………………….... 127 
 
 
 
 
 
 
 
 
12 
 
Chapter 4: Utility of Whole Blood Single Platelet Counting  
Assay in Assessing the Efficacy of Aspirin………………………………   128-143 
 
4.1. Background and Aim……………………………………………………..… 128 
4.2. Descriptive statistical Data………………………………………………….. 129 
4.3. Interindividual Variation of Platelet Aggregation in  
Patients Treated with Aspirin………………………………………………….… 131 
4.4. Prevalence of Aspirin Responders and Low Responders……………..… 131 
4.5. Incidence of Ischaemic and Bleeding Events…………………………….. 133 
4.6. Ischaemic Events – Platelet Aggregation ………………………………… 133 
4.7. Incidence of Ischaemic Events in  
Aspirin Responders and Low- Responders……………………..……………… 134 
4.8. Bleeding Complications in Responders and Low-Responders to Aspirin… 134 
4.9. Incidence of Bleeding Events in Responders and Low-Responders…... 135 
4.10. Platelet Aggregation - Ischaemic and Bleeding Complications……..… 135 
4.11. Correlation of Platelet Aggregation Assessed by WBSPCA and  
Urine 11-dehydro TXB2 Levels……………………………………………….…… 137 
4.12. Correlation between Platelet Aggregations Assessed by WBSPCA  
and Serum TXB2 Levels…………………………………………………….…… 138 
4.13. Correlation between Urine 11-dehydro TBX2 and Serum TBX2………. 139 
4.14. Discussion…………………………………………………………….…….... 140 
4.15. Conclusion……………………………………………………………..… …… 143 
 
 
 
 
 
 
 
 
 
 
13 
 
Chapter 5: Comparison OF Whole Blood Single Platelet Counting  
Assay and Light Transmission Aggregometry in Assessing Platelet  
Aggregation in Patients Treated with Clopidogrel…………….……          144-160 
 
5.1. Background and Aim…………………………………………………………… 144 
5.2. Results-Demographics……………………………………………………..…… 145 
5.3. Platelet Aggregation Data………………………………………………….... 147 
5.4. Correlation between WBSPCA and LTA…………………………………... 147 
5.4.1. Correlation between 10µmol/L-ADP-WBSPCA and 2µmol/L-ADP-LTA… 147 
5.4.2. Correlation between 5µmol-ADP-LTA and 10µmol/L- ADP –WBSPCA… 147 
5.4.3. Correlation between 20µmol/L-ADP-LTA and 10µmol/L- ADP-WBSPCA… 149 
 
5.5. Agreement between WBSPCA and LTA – The Kappa Statistics……….… 152 
5.5.1. Agreement between 10µmol/L-ADP-WBSPCA and 5µmol/L-ADP-LTA…… 152 
5.5.2. Agreement between 10µmol/L-ADP-WBSPCA and 20µmol/L-ADP-LTA… 153 
 
5.6. ROC Curve Analysis…………………………………………………………… 155 
5.7. Discussion……………….…………………………………………………….… 157 
5.8. Conclusion………………………………………….……………………….… 160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
Chapter 6: Percutaneous Coronary Intervention,  
Related Myonecrosis and its Relationship with Platelet  
Aggregation and Inflammatory Markers……………………………….……      161-176 
 
6.1. Background and Aim………………………………………………………… 161 
6.2. Results – Demography……………………………………………………… 161 
6.3. Procedure Related Elevation in cTnT…………………………....………… 162 
6.4. Incidence of Post PCI Myonecrosis………………………………..………… 163 
6.5. Incidence of Post PCI Myonecrosis in  
Responders vs. Non-Responders……………………………………………..… 163 
6.6. Incidence of Post PCI Myonecrosis in Responders vs.  
Non-Respondersto Clopidogrel………………………………………   165 
6.7. Correlation between Post PCI Myonecrosis and Platelet Aggregation in  
Response to 10µmol/L ADP Assessed by WBSPCA………………………  167 
6.8. Post PCI Myonecrosis and its Relation with Platelet Reactivity in 
 Aspirin Treated Patients………………………………………………...…  168 
6.9. Platelet Aggregation in Response to 0.8mM AA and  
its Relation to Post PCI Myonecrosis……………………………………..…  168 
6.10. Correlation of Post PCI Myonecrosis and Platelet Aggregation in  
Response to 0.8mM AA in Aspirin Treated Patients…………………….…  170 
6.11. Post PCI Myonecrosis Compared between  
Diabetics and Non-diabetics……………………………………………………  171 
6.12. Relationship between Pre PCI Inflammatory Markers  
and Post PCI Myonecrosis…………………………………………..………  171 
6.13. Discussion……………………………………………………………..…   174 
6.14. Conclusion…………………………………………………………..……  176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
Chapter 7: Relationship between Plasma Inflammatory Markers  
and Platelet Aggregation in Patients Undergoing  
Percutaneous Coronary Intervention …………………………….. ……..       177-194 
 
7.1. Introduction……………………………………………………………………. 177 
7.2. Results – Demography……………………………………………….……… 178 
7.3. Descriptive Statistics of Inflammatory Markers………………….......…… 178 
7.4. Post PCI Release in sCD40L and Clopidogrel Response………..….……. 181 
7.4.1. sCD40L-4H and its Relation with Platelet Aggregation in Response to  
10µmol/L of ADP Assessed by WBSPCA……………………………………… 181 
7.4.2. sCD40L-24H and its Relation with Platelet Aggregation in  
Response to 10µmol/L of ADP Assessed by WBSPCA………….………..….. 181 
7.4.3. sCD40L-24H and its Relation with Platelet Aggregation in Response  
to 5µmol/L of ADP Assessed by LTA…………….…………………….………. 183 
7.4.4. sCD40L-24H and its Relation with Platelet Aggregation in 
  Response to 20µmol/L of ADP Assessed by LTA……………………....…… 183 
 
7.5. Correlation between sCD40L and Platelet Aggregation in  
Clopidogrel Treated Patients………………………………………………….… 184 
7.6. CRP and its Relationship with Platelet Aggregation in Response 
 to Aspirin and Clopidogrel………………………………………………………… 185 
7.6.1. Correlation between Platelet Aggregation in Response  
to 0.8mM AA and CRP……………………………………………………….…… 187 
7.6.2. Correlation between Platelet Aggregation in Response  
10µmol/L ADP and CRP……………………………………………………..….. 188 
 
7.7. TNF-α and its Relationship with Platelet Aggregation in Response  
to 0.8mM AA in Aspirin Treated Patients……………………......................… 189 
7.7.1. Correlation between TNF-α and Platelet Aggregation in Response 
 to 0.8mM AA in Aspirin Treated Patients……………………………….…….. 189 
7.8. IL-6 and its Relationship with Platelet Aggregation  
in Response to Aspirin…………………………………………………..….…… 190 
7.8.1. Correlation between IL-6 and Platelet Aggregation in Response  
to 0.8mM AA in Aspirin Treated Patients…………………..…………….……… 191 
7.9. Incidence of MACE………………………………………………...……..… 191 
7.10. Discussion……………………………………………………………..…… 192 
7.11. Conclusion………………………………………………………………..… 194 
 
16 
 
Chapter 8 ………………………………………………………. 195-202 
Reference ……………………………………………………… 203-219 
Appendix ……………………………………………………. 220-227 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
List of Figures 
 
Figure 1.1: Structure of Platelets……………………….………………… 29 
Figure 1.2: Platelet Secretion…………………………………..………… 32 
Figure 1.3: Platelet Receptors………………………………….…….….. 34 
Figure 1.4: Role of Platelets in Inflammation…………………..…………. 39 
Figure 1.5: Role of Platelets in Thrombus Formation…………….……. 41 
Figure 1.6: Platelet Activation Mechanism……………………………….. 49 
Figure 3.1: Platelet Aggregation Assessed by WBSPCA 30 seconds..... 113 
Figure 3.2:  Platelet aggregation assessed by WBSPCA 4 minutes…. 113 
Figure 3.3: Prevalence of Clopidogrel Responders and Non-Responders 114 
Figure 3.4: Interindividual Variation in Clopidogrel Response…….…. 115 
Figure 3.5: Platelet Aggregation Assessed by WBSPCA…………….. 116 
Figure 3.6:  Ischaemic Events in Responders and Non-Responders…… 117 
Figure 3.7: Platelet Aggregation Measured at 30 Seconds….  118 
Figure 3.8: Platelet Aggregation Measured at 4 Minutes………..….. 119 
Figure 3.9: Ischaemic Outcomes………………………………………. 119 
Figure 3.10: Bleeding Complications in Responders and Non-Responders 121 
Figure 3.11: Platelet Aggregation Measured at 30 Seconds….......... 121 
Figure 3.12: Platelet Aggregation Measured at 4 Minutes…………  122 
Figure 3.13:  Platelet Aggregation in Bleeding Outcomes………………. 122 
Figure 3.14: Platelet Aggregation in Patients with Bleeding and Ischaemic 
Complications…………………………………………………………….. 123 
Figure 4.1: Platelet Aggregation in Response to Increasing 
Concentrationsof AA Measured at 30 Seconds by WBSPCA…… 130 
Figure 4.2: Platelet Aggregation to Increasing Concentration of AA  
Measured at 4 Minutes by WBSPCA……………………………………… 130 
Figure 4.3: Interindividual Variation of Platelet Aggregation in  
Patients Treated with Aspirin………………..…………………………... 131 
Figure 4.4: Prevalence of Aspirin and Clopidogrel Non-Responders… 132 
18 
 
Figure 4.5: Platelet Aggregation in Patients who Developed  
Ischaemic Events and Not ……………………………………………… 133 
Figure 4.6: Incidence of Ischaemic Events in Responders and  
Low-Responders………………………………………………………… 134 
Figure 4.7: Platelet Aggregation in Bleeding Complications…………. 135 
Figure 4.8: Bleeding Complications in Aspirin Responders  
and Low-Responders to Aspirin………………………………............. 136 
Figure 4.9: Platelet Aggregation in Ischaemic and Bleeding Events…… 136 
Figure 4.10: Correlation Between Platelet Aggregations in Response 
to AA and Urine 11-dehydro TXB2 Levels……………………………… 137 
Figure 4.11: Correlation between Platelet Aggregations in response  
to 0.8mM AA Measured by WBSPCA at 4 Minutes and Serum TBX2 Level 138 
Figure 4.12: Correlation between Serum and Urine TBX2 Levels  140 
Figure 5.1: Mean Percentage of Platelet Aggregation Assessed by  
WBSPCA…………………………………………………………………. 146 
Figure 5.2: Mean percentage of Platelet Aggregation Assessed by LTA... 146 
Figure 5.3: Correlation between 10µmol/L-ADP-WBSPCA and 5µmol/L-  
ADP-LTA…………………………………………………………………… 148 
Figure 5.4: Correlation between 10µmol/L-ADP-WBSPCA and  
5µmol/L ADP-LTA………………………………………………..…....  149 
Figure 5.5: Correlation between 10µmol/L-ADP-WBSPCA  
and 20µmol/L-ADP-LTA…………………………………………..…….. 150 
Figure 5.6: Correlation between 10µmol/L-ADP-WBSPCA and 
 20µmol/L- ADP-LTA………………………………………………………….. 151 
Figure 5.7: Incidence of Responders and Non-Responders Assessed by 
WBSPCA and LTA……………………………………………………….. 152 
Figure 5.8:Agreement between 5µmol/L-ADP-LTA and 10µmol/L- ADP-
LTA………………………………………………………………..  153 
Figure 5.9: Agreement between 20µmol/L-ADP-LTA and 10µmol/L-ADP-
WBSPCA………………………………………………………..………….. 154 
Figure 5.10: Incidence of Responders and Non-Responders……….. 155 
Figure 5.11: ROC Analysis 20µmol/L of ADP measured at  
Maximum Time LTA as Control………………………..….…………………… 156 
Figure 5.12: ROC Analysis 5µmol/L of ADP measured at Maximum  
Time LTA as Control………………….…………………….……………… 156 
19 
 
Figure 6.1: Troponin T Elevation Related to PCI……………..………. 163 
Figure 6.2: Platelet Aggregation in Post PCI Myonecrosis…………….. 164 
Figure 6.3: Incidence of post PCI Myonecrosis in Responders and Non-
Responders to Clopidogrel ……………………………………………… 164 
Figure 6.4: The Increase in cTnT Compared between Responders and Non-
Responders to Clopidogrel…………………………………………..….. 165 
Figure 6.5: Post PCI Myonecrosis in Responders and Non-Responders… 166 
Figure 6.6: Post PCI Myonecrosis Responders and Non-Responders.. …. 166 
Figure 6.7: Correlation between Post PCI Myonecrosis and Platelet  
Aggregation Assessed by WBSPCA………………………………….. 166 
Figure 6.8: Mean increase in troponin between responders and non-
responders………………………………………………………….…….. 168 
Figure 6.9: Platelet Aggregation in Response to 0.8mM AA in  
Aspirin Treated Patients with Post PCI Myonecrosis………………….. 169 
Figure 6.10: Incidence of post PCI Myonecrosis in Aspirin Treated 
Patients…………………………………………………………..……..…. 169 
Figure 6.11: Post PCI Myonecrosis and its Correlation to Platelet  
Aggregation at the Time of PCI in Response to 0.8mM of AA Measured by 
WBSPCA…………………………………………………………………. 170 
Figure 6.12: Platelet Aggregation in Diabetics and Non-Diabetics with  
or without Post PCI Myonecrosis……………........................................ 171 
Figure 6.13: CRP pre PCI Compared with Post PCI Myonecrosis…….. 172 
Figure 6.14: sCD40L pre PCI Compared with Post PCI Myonecrosis….. 173 
Figure 6.15: IL-6 pre PCI Compared with those who Developed post PCI 
Myonecrosis…………………...……………………………………….... 173 
Figure 6.16: TNF-α pre PCI in those who Developed Post  
PCI Myonecrosis………………………………………………………… 174 
Figure 7.1: CRP………………………………………………………..… 179 
Figure 7.2: sCD40L………………………………………..…………….. 179 
Figure 7.3: TNF-α………………………………………..…………….… 180 
Figure 7.4: IL-6…………………………………………..……..………… 180 
Figure 7.5:sCD40L-4H Compared between All the Groups of Platelet 
Aggregation Assessed by WBSPCA………………………………………… 182 
Figure 7.6: sCD40L-24H Compared between all Groups of Platelet  
20 
 
Aggregation Assessed by WBSPCA……………………………  182 
Figure 7.7: sCD40L-24H Compared between all Groups of Platelet  
Aggregation Assessed by LTA…………………………………………. 183 
Figure 7.8: sCD40L-24H Compared between all Groups of Platelet  
Aggregation Assessed by LTA…………………………………..…….. 184 
Figure 7.9: Correlation between sCD40L-24H and Platelet Aggregation 
Measured by WBSPCA………………………………………..………... 185 
Figure 7.10: CRP-4H………………………………………….………… 186 
Figure 7.11: CRP-24H……………………………………………….…… 186 
Figure 7.12: Correlation between CRP-4H and Platelet Aggregation in 
 Response to 0.8mM AA………………………………………………… 187 
Figure 7.13: Correlation between Platelet Aggregation in Response to  
10µmol/L ADP and CRP-24H…………………………………………... 188 
Figure 7.14: TNF-α 4H…………………………….………………….… 189 
Figure 7.15: TNF-α 24H……………………………..………………..… 189 
Figure 7.16: Correlation between TNF-α-4H and Platelet Aggregation in 
Response to 0.8mM AA in Aspirin Treated Patients……..…………... 190 
Figure 7.17: IL-6-4H………………………………………….…………. 191 
Figure 7.18: IL -6-24H…………………………………..……………..… 191 
  
21 
 
List of Tables 
 
Table 1.1 ………………………………………………………………………… 31 
Table 1.2 ………………………………………………………………………… 45 
Table 1.3 ………………………………………………………………………… 54 
Table 1.4 ………………………………………………………………………… 63 
Table 1.5 ………………………………………………………………………… 66 
Table 1.6 ………………………………………………………………………… 74 
Table 1.7 ………………………………………………………………………… 81 
Table 1.8 ………………………………………………………………………… 82 
Table 1.9 ………………………………………………………………………… 83 
Table 1.10 ………………………………………………………………………… 84 
Table 1.11 ………………………………………………………………………… 85 
Table 1.12 ………………………………………………………………………… 86 
Table 1.13 ………………………………………………………………………… 87 
Table 3.1 ………………………………………………………………………… 110 
Table 3.2 ………………………………………………………………………… 111 
Table 3.3 ………………………………………………………………………… 114 
Table 3.4 ………………………………………………………………………… 120 
Table 4.1 ………………………………………………………………………… 129 
Table 4.2 ………………………………………………………………………… 129 
Table 4.3 ………………………………………………………………………… 132 
Table 5.1 ………………………………………………………………………… 145 
Table 5.2 ………………………………………………………………………… 151 
Table 6.1 ………………………………………………………………………… 162 
Table 6.2 ………………………………………………………………………… 172 
 
 
22 
 
Appendix 
 
Appendix 1 ……………………………………………………………………... 220 
Appendix 2 ……………………………………………………………………... 221 
Appendix 3 ……………………………………………………………………... 222 
Appendix 4 ……………………………………………………………………... 223 
Appendix 5 ……………………………………………………………………... 224 
Appendix 6 ……………………………………………………………………... 225 
Appendix 7 ……………………………………………………………………... 226 
Appendix 8 ……………………………………………………………………... 226 
Appendix 9 ……………………………………………………………………... 226 
Appendix 10 ……………………………………………………………………... 227 
Appendix 11 ……………………………………………………………………... 227 
Appendix 12 ……………………………………………………………………... 227 
Appendix 13 ……………………………………………………………………... 227 
 
 
 
 
 
23 
 
ABBREVIATIONS
 
 
AA   Arachidonic acid  
ACC   American College of Cardiology 
ACE-I   Angiotensin converting enzyme inhibitor 
ACS   Acute coronary syndrome 
ADP   Adenosine diphosphate    
AHA   American Heart Association 
ARB   Angiotensin receptor blockers  
ARU   Aspirin reactive units    
AS   Average size 
AT   Antithrombin   
ATP   Adenosine triphosphate   
ATT   Antiplatelet trialists’ collaboration 
AUC   Area under the curve   
BCSH   British Committee for Standards in Haematology   
BMI   Body mass index 
BMS   Bare metal stent    
BT   Bleeding time 
C/ADP-CT  Collagen /adenosine diphosphate -closure time 
C/EPI-CT  Collagen epinephrine-closure time 
Ca2+   Calcium   
CABG   Coronary artery bypass grafting   
CAD   Coronary artery disease 
24 
 
CADP   Collagen and adenosine diphosphate  
cAMP   cyclic Adenosine monophosphate   
CCB   Calcium channel blocker 
CEP   Collagen and epinephrine   
cGMP   cyclic Guanosine monophosphate  
CLSI   Clinical and Laboratory Standards Institute  
COX   Cyclooxygenase   
CPA   Cone and Plate(let) Analyzer  
CPTP   Cyclopentyltriazolopyrimidine  
CRP   C-reactive protein  
CV   Cardiovascular  
CVD   Cardiovascular disease  
CYP   Cytochrome P450 
DES   Drug eluting stent 
DTI   Direct thrombin inhibitor  
DTS   Dense tubular system  
ECG   Electrocardiogram 
EDTA   Ethylenediaminetetraacetic acid  
ELISA   Enzyme-linked immunosorbent assay 
ESC   European Society of cardiology 
GP   Glycoprotein  
GPI   Glycoprotein inhibitors 
GT   Glanzmann thrombasthenia  
HPR   High-on treatment platelet reactivity 
HT   Hydroxy tryptamine  
25 
 
ICAM   Intracellular adhesion molecule  
IL   Interleukin 
IQ   Interquartile 
ISTH   International Society of Thrombosis and Haemostasis 
IV   Intravenous 
LDL   Low density lipoprotein  
LMWH  Low molecular weight heparin  
LOE   Level of evidence 
LPR   Low platelet reactivity  
LTA   Light transmission aggregometry 
MA   Maximum amplitude 
MACE   Major Adverse Cardiovascular Events 
MCP   Monocytes chemoattractant protein 
MEA   Multiplate Electrode Aggregometry 
MI   Myocardial infarction  
MMP   Matrix mettalloproteinase 
MNS   Methylene dioxy–beta-nitrostyrene   
NSAIDs  Non-steroidal anti-inflammatory drugs   
NSTEMI  Non-ST-elevation myocardial infarction  
OCS   Open canalicular system   
PAI   Plasminogen activator inhibitor  
PAP-4   Platelet aggregator profiler-4 channels 
PAR   Protease activated receptor  
PAU   Platelet aggregation unit  
PCI   Percutaneous Coronary Intervention  
26 
 
PDGF   Platelet-derived growth factor  
PFA   Platelet function analyzer  
PFT   Platelet function test  
PGE   Prostaglandin E  
PGHS   Prostaglandin G/H synthase 
POCT   Point-of-care test  
PON   Paraoxonase  
PPACK  D-Phenyl-Alanyl-L-Prolyl-L-Arginine 
PPI   Proton pump Inhibitors  
PPP   Platelet-poor plasma 
PRP   Platelet-rich plasma   
PRU   P2Y12 reactivity units  
PSGL   P-Selectin glycoprotein ligand   
PTFE   Poly-tetra-fluoro-ethylene  
PVD   Peripheral vascular disease  
RANTES Regulated on activation normal T cell expressed and 
secreted 
RBC   Red blood cells   
ROC   Receiver operating characteristics  
ROS   Reactive oxygen species   
ROTEG  Rotational thromboelastography 
ROTEM  Rotational thromboelastometry 
SEM   Standard error of the mean 
SPSS   Statistical Package for Social Sciences 
STEMI  ST-elevation myocardial infarction  
27 
 
TEG   Thromboelastography   
TFPI   Tissue factor pathway inhibitor  
TGF-β   Transforming growth factor-β  
TIA   Transient ischaemic attack  
TIMI   Thrombolysis in Myocardial Infarction  
TNF-α   Tumor necrosis factor-α 
TRA   Thrombin receptor antagonist  
TRAP   Thrombin receptor activating peptide  
TSP   Thrombospondin  
TX   Thromboxane  
TXA2   Thromboxane A2  
TXB2   Thromboxane B2 
UA   Unstable angina  
UFH   Unfractionated heparin  
VASP   Vasodilator-stimulated phosphoprotein  
VEGF   Vascular endothelial growth factor  
vWF   Von Willebrand factor   
WBC   White blood cells   
WBSPCA  Whole blood single platelet counting assay 
 
  
28 
 
Chapter 1: Introduction 
 
1.1 Introduction 
The development of thrombus is a complex and dynamic process. This 
involves platelet aggregation and generation of thrombus. Platelet 
aggregates are strengthened by a network of fibrin during the formation of 
thrombus. Thrombus predominantly forms at the site of plaque rupture or 
erosion in diseased atherosclerotic arteries. This process is further 
compounded by inflammatory response at the site of plaque disruption 
and thrombus formation. This leads to various clinical presentations 
depending on the affected arterial bed such as acute coronary syndrome 
(ACS, consisting of unstable angina (UA), ST-elevation myocardial 
infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI)), 
acute cerebrovascular events, such as ischaemic stroke and transient 
ischaemic attacks (TIA), and occlusive peripheral vascular disease (PVD). 
These presentations of atherothrombosis are major causes of death and 
disability worldwide(1, 2). 
 
1.2 Platelets and Atherothrombosis 
1.2.1 History of Platelets 
William Osler was probably the first to notice platelets and described them 
in his 1873 and 1874 papers(3). However the first accurate description of 
platelets was given by Max Schultz, who also recommended further 
studies of them(4). Subsequently Giulio Bizzozero, in 1881 and 1882, 
identified the platelets anatomically. He called them “blood plates” and 
was the first to describe the adherence and aggregation of platelets at the 
site of vessel wall injury; he also identified bone marrow megakaryocytes 
but the discovery that megakaryocytes are precursors of platelets was 
made by Wright in 1906(5). 
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1.2.2 Structure of Platelets 
Platelets are small a nuclear cellular component of the blood that are 
released from the megakaryocytes. They measure 2.0 to 5.0 µm in 
diameter, 0.5µm in thickness and have a mean cell volume of 6 to 10 
femtoliters. One giant megakaryocyte produces over 1000 platelets upon 
fragmentation. The lifespan of each platelet is between 7-10 days. Platelet 
structure can be broadly divided into peripheral zone, sol-gel zone, and 
organelle zone and platelet membrane system (6-9). The structure of 
platelets is presented in figure 1.1 
 
Figure 1.1: Structure of Platelets 
 
 
 Figure 1.1 
Schema of platelet ultrastructure integrated with proteomic studies. 
The unshaded panel delineates the proteomic studies involving quiescent 
platelets. The shaded panel represents those studies focusing on 
activation-dependent platelet end points (eg, microparticles, 
exosome/releasates) (10). (Reproduced from Dmitri V. Gnatenko, Journal 
of Blood 2006, DOI 10.1182/blood-2006-06-026518, Copyright @ 2006 by 
The American Society of Haematology) 
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The peripheral zone contains a thick exterior coat or glycocalyx, a lipid 
bilayer upon which the glycocalyx rests and a submembranous area. The 
glycocalyx is a dynamic structure which is constantly in contact with the 
other blood components and hence has major and minor glycoprotein 
receptors necessary for platelet adhesion, aggregation and clot retraction. 
The lipid bilayer is a typical unit membrane that cannot stretch and has an 
open canalicular system (OCS) that provides increased surface area to it. 
The submembranous area has actin filaments that play an important role 
in shape change and translocation of receptors and particles over the 
exterior surface of the cell (11). 
 
The sol–gel zone is the main matrix of the platelet. It is made of a dense 
mat of fibrous elements that supports the platelet discoid shape and 
internal contraction. As this resembles a liquid gel, it has been renamed as 
the sol–gel zone from hyaloplasm. The main components of the sol-gel 
zone are circumferential coil microtubule, actomyosin filament system, 
platelet glycosome and smooth and coated vesicles. The microtubule acts 
as a cytoskeletal support system whereas the actomyosin filament is 
involved in shape change (7). 
 
The organelle zone contains secretory structures, namely α granule, 
dense bodies (δ granules) and lysosomes. The main secretions from 
these structures are discussed below (12, 13). They also have 
mitochondria in small numbers that play a significant role in the energy 
metabolism of the cell, and other membrane-enclosed organelles, namely 
glycosome, electron-dense chains and clusters, and tubular inclusions (7). 
 
The platelet membrane system contains Golgi zones, surface-connected 
OCS and the dense tubular system (DTS). The Golgi zone is normally 
confined to the megakaryocytes and is found only in 1 out of every 100 to 
500 platelets. The OCS and DTS are anatomically situated in the 
peripheral zone (14, 15). 
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1.2.3. Platelet Secretions 
When platelets are activated, they release several granule components. 
The dense bodies are the main storage pool of platelets and release 
adenosine diphosphate (ADP) and serotonin upon activation. ADP, which 
is a prominent amplifier of initial platelet activation, acts on two main ADP 
receptors namely P2Y1 and P2Y12 situated on the platelet surface.  
 
Table 1.1: Major Secretions from the α- Granules 
 
 
Large adhesive proteins  von Willebrand factor (vWF) 
    Thrombospondin-1 (TSP 1) 
    Vitronectin 
    Fibronectin 
 
Mitogenic factors  Platelet-derived growth factor (PDGF) 
    Vascular endothelial growth factor (VEGF) 
    Transforming growth factor β (TGF-β) 
 
Coagulation factors  Factors V, VII, XI, and XIII 
 
Protease inhibitors  Protein C   
    Platelet plasminogen inhibitor -1 (PAI-1)  
    Tissue factor pathway inhibitor (TFPI) 
 
Others   P- selectin 
    Platelet factor 4 
P – Selectin (CD62P), a glycoprotein, is localized on α- granule membrane 
of resting platelets. This, along with other glycoproteins including sCD40L, 
mediates platelet binding to neutrophils and monocytes. Platelet factor 4, 
an α-granule protein, is synthesized by megakaryocytes (16). 
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Serotonin (5-hydroxytryptamine, 5-HT), a strong vasoconstrictor, binds to 
the Gq-coupled 5HT2A-receptors. The DTS also contains a calcium (Ca2+) 
pool which is mobilized during platelet activation. Ca2+ fluxes are central 
triggers in platelet activation, secretion and aggregation(13, 16). The 
major secretions from the α-granule are summarized in table 1.1. Platelet 
lysosomes liberate clearing factors that facilitate the digestion and 
resolution of thrombi (17). A schematic representation of platelet secretion 
is depicted in figure 1.2. 
 
Figure 1.2: Platelet Secretions 
 
 
 
Figure 1.2: 
Platelet activation induced by inflammation. EC – endothelial cell; TXA2 – 
thromboxane A2; vWF – von Willebrand factor; PGI2 – prostacyclin; PAF – 
platelet activating factor; GPIIb/IIIa – glycoprotein complex IIb/IIIa; PDGF – 
platelet derived growth factor; TGF-b - transforming growth factor-beta; EGF – 
epidermal growth factor; IL-1b - interleukin 1beta; PF-4 – platelet factor 4; 
RANTES – CCL5 chemokine; PAI-1 – plasminogen activator inhibitor 1; TF – 
tissue factor (Figure taken from Sandra Margetic. Inflammation and haemostasis. 
Biochemia Medica 2012; 22 (1):49-62. http://dx.doi.org/10.11613/BM.2012.006) 
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1.2.4. Platelet Receptors 
A number of major platelet receptors have been described and detailed 
discussion of all of them is beyond the scope of this review. Important 
receptors relevant to my study are briefly described below. 
 
1.2.4.1. Glycoprotein (GP) Ib-IX-V Complex 
The GP Ib-IX-V complex is a pivotal platelet receptor in initiating platelet 
attachment to injured vessel wall and thus plays an important role in both 
haemostasis and thrombosis. This is the main receptor for vWF and 
deficiency of this receptor causes Bernard Soulier disease, first described 
by Dr. Jean Bernard and Jean Pierre Soulier in 1948 (18). GP Ib-IX-V is 
also a major receptor for TSP, the leukocyte integrin αMβ2, P- selectin, 
and the platelet integrins αIIbβ3 and α2β1. It is essential for platelet 
adhesion under high shear conditions. In addition, it plays a key role in 
promoting procoagulant activity, controls platelet size and shape and 
regulates clearance of platelets from the circulation (19). 
 
1.2.4.2. Integrins 
Integrins are a major class of adhesive and signaling molecules that 
contains heterodimers of α and β subunits and are generally involved in 
linking adhesive molecules to the cellular cytoskeleton. Platelets have 
members of three families of integrins (β1, β2, β3) and in total six different 
integrinsα2β1, α1β5, α6β, αLβ2, αIIbβ3, and αvβ3.αIIbβ3, (GP IIb/IIIa) is the 
major platelet integrin that is expressed uniquely on platelets. Deficiency 
of the GP IIb/IIIa complex leads to Glanzmann thrombasthenia, originally 
described by Eduard Glanzmann, a Swiss pediatrician (20-23). The 
platelet receptors are shown in figure 1.3. 
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Figure 1.3: Platelet Receptors 
 
 
Figure 1.3 : Platelet receptors and its interactions with major ligands (24). 
Reproduced from Haematologica, Journal of The European Haematology 
Association May 2009 94: 700-711; DOI 3324/haematol.2008.003178 
Jose Rivera, Maria Luisa Lozano, Leyre Navarro-Nunez, Vicent. 
 
1.2.4.3. Thrombin Receptors 
Protease-activated receptors (PARs) are the seven transmembrane 
receptors that play dominant roles in the action of proteases such as 
thrombin. 4 PARs have been identified, namely PAR1, PAR2, PAR3 and 
PAR4. PAR1 and PAR4 are present on human platelets. PAR3 is present 
only in mouse but not in human platelets. PARs are activated by a 
tethered-ligand mechanism where a receptor carries its own ligand that is 
silent until the receptor is cleaved. In the case of PAR1 and PAR4, 
thrombin acts as an agonist to the receptors. When these receptors get 
exposed to thrombin, a new amino terminus is revealed due to cleavage 
within the extracytoplasmic portion of the PAR. This ultimately causes 
transmembrane signaling through intramolecular ligation. PAR4 needs 10 
times higher concentrations of thrombin to be stimulated than that needed 
for PAR1. PAR2 is cleaved and activated by trypsin but not by thrombin. 
The selective PAR1 antagonist vorapaxer has shown efficacy in patients 
with a history of atherosclerotic disease, albeit at the expense of increased 
major bleeding, including intracranial haemorrhage (25-30). 
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1.2.4.4. Platelet Purinergic Receptors 
The platelet purinergic receptors that are recognized to have functional 
roles are of three subtypes, namely P2X1, P2Y1, and P2Y12. P2Y1 and 
P2Y12 are ADP receptors, ADP being the primary platelet agonist that is 
present in abundance in the platelet dense granules. P2X1 is an ATP 
receptor and structurally belongs to a different class of receptors. P2Y1 
and P2Y12 are seven transmembrane G-protein-coupled receptors. P2Y1 is 
linked to Gq protein. ADP stimulation of this receptor results in calcium 
mobilization, platelet shape change, and rapidly reversible platelet 
aggregation. On the other hand, P2Y12 receptor is linked to an inhibitory G 
protein (Gi) and, when stimulated by ADP, results in amplification of 
platelet aggregation and secretion and consequent stabilization of platelet 
aggregates (31-33).  
 
1.2.5. Platelet Functions 
Platelets play a key role in protective haemostasis and pathogenic 
thrombosis. Furthermore, they are mediators of inflammation, have 
immunomodulatory activity, and are involved in wound healing and 
haematological malignancies. Platelets are recruited at the site of vessel 
damage to form a haemostatic plug and at the site of ruptured 
atherosclerotic plaque to form thrombus. Both these processes mainly 
involve platelet adhesion and aggregation mediated by several agonists 
that interact with the platelet surface receptors. Platelets thus link 
inflammation, thrombosis and atherogenesis by interacting with 
endothelial cells and leukocytes (34). 
 
1.2.5.1. Role of Platelets in Haemostasis 
Damaged vessel wall exposes subendothelial matrix. Adhesion of 
platelets at this site is the initial step in the formation of haemostatic plug. 
The adhesion of platelets to the subendothelial matrix happens in two 
naturally existing physiological environments, namely high shear 
conditions as found in arteries and low shear conditions as present in 
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veins. The former is mediated mainly by several platelet surface receptors 
that bind to collagen either directly through GPVI and the integrin α2β1 or 
indirectly with the GPIb/V/IX complex and the integrin αIIbβ3 via vWF     
(16,28,34,35). This leads to the formation of a platelet monolayer attached 
to each other by collagen on the subendothelial matrix. Activated platelets 
are involved in a series of further complex dynamic processes. These 
include: a) Shape change contributed to by the formation of pseudopodia 
originating from the plasma membrane due to the change in the 
configuration of the cytoskeletal proteins (36), b) secretion of various 
granular components as discussed above (34), and c) Rolling of platelets 
on the endothelium and their binding to neutrophils and monocytes 
facilitated by endothelial P-selectin. These lead to accumulation of 
activated platelets on the already formed monolayer of platelets and 
collagen (34). 
 
A haemostatic plug caused by accumulation of platelets is the hallmark of 
platelet aggregation. The key receptor in this process is GP IIb/IIIa which 
links activated platelets through fibrinogen bridges. The GP IIb/IIIa 
receptors are inactive in a resting platelet. However, when platelets are 
activated this leads to augmentation and activation of surface exposed GP 
IIb/IIIa molecules via α-granule exocytosis. Activated GP IIb/IIIa 
complexes interact with ligands leading to molecular conformational 
changes that end in firm connection and high affinity binding sites for 
fibrinogen. Thus, a primary haemostatic plug is formed. This process is 
commonly called  inside–out signaling (28, 37). 
 
The haemostatic plug is further strengthened by the mechanisms called 
outside-in signaling mediated by integrins. In this process direct interaction 
between platelets occurs, ultimately leading to stabilization of the platelet 
plug that prevents premature disaggregation of platelets (28, 38). 
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1.2.5.2. Role of Platelets in Thrombus Formation 
Platelets play an extended role in converting the protective haemostatic 
plug into a pathological occlusive platelet rich thrombus. Various factors 
play a key role in this process. In addition to platelet shape change, 
platelet secretions, activation of GP IIb/IIIa receptors mentioned above 
that are important in the formation of haemostatic plug, expression of 
proinflammatory molecules such as P-selectin and CD40 ligand (CD40L) 
and expression of platelet procoagulant activity are important in the 
stabilization of the growing haemostatic plug and progression to 
pathological thrombus. Fibrin generated from fibrinogen that is cleaved by 
thrombin is also important in the formation and consolidation of the 
haemostatic plug (39, 40). 
 
1.2.5.3. Role of Platelets in Coagulation 
Activated platelets have an ability to support the coagulation process. 
Coagulation factors bind to the platelets either by their own glycoprotein 
receptors or indirectly to the platelet membrane facilitated by 
aminophospholipid exposure on the surface of activated platelets. The 
interaction between collagen and platelet GPVI plays a crucial role in the 
above-mentioned process and also in the formation of membrane blebs 
that provides procoagulant microvesicles.  
 
 
Intracellular increase in calcium is important for bleb formation and 
exposure of aminophospholipids such as phosphatidylserine. The 
increase in intracellular calcium is, in turn, caused by activation of platelet 
receptors for ADP, thromboxane A2 (TXA2), thrombin and collagen. 
Shedding of membrane blebs into the circulation initiated by the collagen -
GPVI interaction and the interaction of ADP with P2Y1 and P2Y12 supports 
this platelet procoagulant activity.  Activated platelets also play an 
extended role in coagulation by secreting factor V, factor VIII and 
fibrinogen and by providing binding sites for factor XI and prothrombin (33, 
34, 41, 42). 
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1.2.5.4. Role of Platelets in Inflammation 
Platelets in general do not have any effect on the intact and inactive 
endothelium. Platelets adhere to the inflamed endothelium in a similar 
fashion to damaged endothelium by a multi-step process that involves 
tethering, rolling and firm adhesion (16, 43). Platelet tethering is mediated 
by P-selectin and E-selectin on the endothelial cells, whereas platelet 
rolling is caused by the interaction of GPIb and P-selectin glycoprotein 
ligand-1 (PSGL-1). Both these processes are reversible. The GP IIb/IIIa 
receptor along with fibrinogen plays a vital role in the firm adhesion of 
platelets to the inflamed endothelium which is an irreversible process    
(34,44,45). 
 
CD40L present on the activated platelets causes the endothelium to 
produce reactive oxygen species (ROS), adhesion molecules, chemokines 
and tissue factor. The ROS may have a role in recruiting more platelets to 
a growing thrombus. The interaction between CD40 on the endothelium 
and the CD40L on the platelet surface results in the recruitment of 
neutrophils and monocytes. This mediates the release of interleukin-8 (IL- 
8) and monocyte chemoattractant protein-1 (MCP-1). Ligation of CD40L 
also results in release of matrix metalloproteinase (MMP)-2 which is a 
platelet stimulator and MMP- 9 that has an inhibitory role on platelets (39). 
The role of platelets in inflammation is shown in figure 1.4. 
 
Activated platelets secrete various inflammatory factors that augment 
inflammation and thrombosis. These factors include growth factors, 
chemokines, cytokines and coagulation factors. Regulated on activation, 
normal T-cell expressed and secreted (RANTES), secreted by the 
activated platelet, causes monocytes to arrest, either on its own or in 
conjunction with platelet factor 4 (47). Thus platelets play an important role 
in attracting leukocytes including monocytes and neutrophils at the site of 
endothelial inflammation. Platelet P-selectin is vital for this recruitment. 
The end result of these events is the infiltration of inflammatory cells into 
the vessel wall which is critical in atherosclerosis (48). 
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Figure 1.4:Role of Platelets in Inflammation 
 
 
 
 
Figure 1.4: 
Platelets inflame their cellular interaction partners. Platelets can induce a 
variety of inflammatory responses in monocytes, neutrophils (PMN), 
endothelial cells, or endothelial progenitor cells (EPC), resulting in key 
inflammatory processes, such as adhesion, chemotaxis, migration, 
proteolysis, thrombosis, or even cell differentiation to macrophages or 
foam cells. These processes provide an atherogenic milieu at the vascular 
wall that supports plaque formation (46) . Reproduced from the Journal of 
Arteriosclerosis, Thrombosis, and Vascular Biology published 3 Jan 2008; 
28; s5-s10. Andreas E.May, Peter Seizer and Meinard Gawaz. 
 
 
1.3. Process of Atherothrombosis 
Atherogenesis, the development of atheromatous plaques, evolves 
through various phases, including the initial phase of atherosclerosis that 
ultimately leads to the formation of occlusive thrombus called 
atherothrombosis (1, 49). 
 
Atherosclerosis is fundamentally a disease involving the intima of the 
muscular and elastic arteries that are lined by endothelial cells.  These 
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cells, under normal physiological conditions, provide a nonthrombogenic 
surface that acts as an effective permeability barrier (50). Many factors 
can damage the endothelium including oxidized lipoproteins, smoke, 
glycosylation products in diabetes mellitus, infection by Chlamydia or 
viruses and elevated shear stress. When the endothelium is damaged, a 
series of changes takes place that results in intimal proliferative lesions of 
atherosclerosis (50, 51). 
 
The initial step is an inflammatory process that is mediated by 
proinflammatory cytokines that have both autocrine and paracrine actions. 
Arfors et al in 1987 first demonstrated that gradual recruitment of white 
blood cells is the primary event in the inflammatory atheromatous 
sequence (52). Due to the high velocity of the red blood cells (RBCs) 
compared with the white blood cells (WBCs) in the vessel lumen, the 
RBCs tend to move to the centre of the vessel lumen whereas the WBCs 
are naturally pushed towards the periphery of the vessel lumen.  
 
This enables the leucocytes to be in contact with the endothelial cells. 
Under pathological conditions, further contact of the leucocytes with the 
vessel wall endothelium is facilitated by L-selectin, E-selectin, and 
integrins (β2-β3 and α4). IL-8, MCP-1 and RANTES make the leucocytes 
roll over the endothelium at a very slow speed.  Also, activation of 
integrins and intracellular adhesion molecules (ICAM)-1 results in 
synthesis of various chemokines by the inflammatory cells that not only 
causes adhesion of leucocytes to the endothelium but also results in 
shape change of the leucocytes enabling increased surface area contact 
of the leucocytes with the endothelium. The process of atherothrombosis 
is shown in figure 1.5. 
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Figure 1.5: Role of Platelets in Thrombus Formation 
 
 
 
Figure 1.5:  
Schematic representation of the progression of atherosclerotic plaque 
from initial stages of endothelial dysfunction to advanced stages with the 
presence of complicated plaques. M-CSF indicates macrophage colony 
stimulating factor; MCP-1, monocyte chemotactic protein 1; MMP, 
metalloproteinases; PAI-1, plasminogen activator inhibitor 1; PDGF, 
platelet-derived growth factor; TF, tissue factor; UPA, urokinase 
plasminogen activator (53). Reproduced from Rev Esp Cardiol. 2009; 62 
(10); 1161-78-vol.62 Num.10 DOI; 10.1016/S1885-5857 (09)73331-6. 
 
 
5-Hydroxytryptamine, histamine, bradykinin, prostaglandins and nitric 
oxide along with proinflammatory cytokines and growth factors increase 
the permeability of the endothelium, causing extravascularisation of the 
leucocytes into the subendothelial matrix. The differentiation of the 
monocytes into macrophages and subsequent loading with oxidized low- 
density lipoprotein (LDL) results in the formation of foam cells, a hallmark 
of atherosclerosis. Fatty streaks, the first macroscopic appearance of 
atherosclerosis, are due to foam cells (51, 54-56). 
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The next step involves activation and proliferation of smooth muscle cells. 
This is facilitated by the growth factors. Accumulation and concentration of 
more inflammatory cells leads to the formation of atheromatous plaque, 
the typical feature of advanced atherosclerosis. The fibrous plaque 
consists of a thin fibrous cap of proliferated smooth muscle cells 
surrounded by relatively dense connective tissues that separates the 
contents of fibrous plaque from the vessel lumen and hence prevents its 
contact with the platelets. This cap covers a massive deeper fatty nucleus 
with atherothrombotic properties consisting of smooth muscle cells and 
macrophages, many of which contain large accumulation of lipids. Such 
atheromatous plaques may regress, remain dormant or advance to the 
most advanced lesions that consist of necrotic debris, cholesterol crystals 
and deposits of free lipid in the deeper recesses of the plaques (57, 58). 
When macrophages get activated they release metalloproteinase, a 
proteolytic enzyme. Thinned and disintegrated fibrous cap gets ruptured 
by the action of metalloproteinase which is the preliminary step in the 
formation of occlusive thrombus. Apart from the process of rupture and 
formation of occlusive thrombus, the atheromatous plaque can also 
become calcified, ulcerate or bleed (1, 58). 
 
Upon rupture of the atherosclerotic plaque, micro lesions of the vascular 
lining, thrombogenic matrix and platelets come into contact. This leads to 
platelet adhesion, activation and aggregation leading to thrombus 
formation and micro embolization. The thrombi impede blood flow and 
oxygen supply in the affected arteries resulting in clinical manifestations of 
atherothrombotic disease (59, 60). 
 
1.3.1 Clinical Implications of Atherosclerosis and Thrombosis 
Once atherosclerosis develops, stenosis may occur in the lumens of 
various arteries of the living body. The spectrum of clinical manifestations 
depends on the arteries affected and the extent of the luminal obstruction.  
The three major manifestations of this spectrum include coronary artery 
disease (CAD), cardiovascular disease (CVD) and PVD. In addition, the 
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aorta and other systemic blood vessels like the mesenteric arteries can 
also be involved.  The spectrum of CAD includes UA, NSTEMI and 
STEMI, all three collectively called ACS. Similarly, the carotid and the 
vertebrobasilar systems can be involved in compromise to the 
cerebrovasculature causing TIA and stroke. The clinical manifestations of 
PVD includes intermittent claudication, non-healing ulcerations and 
infection of the extremities, and impotence (59). 
 
1.4 Antithrombotic Medications 
A thrombus consists of both fibrin and platelets. Hence antithrombotic 
strategies involve anticoagulants and anti-platelets alone or in 
combination. The European Society of Cardiology (ESC) practice 
guidelines recommend antithrombotic therapy as a cornerstone of ACS 
management (61, 62). Despite the abundance of antithrombotic therapies, 
ACS is tempered by the frequent recurrences of ischaemic events and by 
the bleeding complications inherent to these therapies (63). 
 
1.5 Antiplatelet Medications 
 
Thrombus formation at the site of atherosclerotic plaque rupture involves 
three steps, namely platelet adhesion, activation and aggregation. Each of 
these processes can be potentially targeted for pharmacological treatment 
to inhibit thrombus formation. Inhibitors of platelet adhesion are still in the 
investigational stage and are not currently available for clinical use. GP 
IIb/IIIa inhibitors that inhibit platelet aggregation are reserved for acute 
phase treatment. Platelet activation inhibitors namely COX -1 inhibitor and 
P2Y12 antagonists are currently licensed for clinical use. Newer agents, 
particularly prasugrel has gained acceptance for use in ACS during 
percutaneous coronary intervention (PCI) in STEMI and ticagrelor has 
been adopted for use across the ACS spectrum (64, 65). 
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1.6. Aspirin 
Aspirin is derived from acetyl and spirasaure (German word for salicylic 
acid). A French chemist Charles Frederic Gerhardt first discovered aspirin, 
but Felix Hoffman first synthesized it in 1897 at the Bayer Pharmacological 
Research Laboratories. Originally used for its analgesic and antipyretic 
effect, the effect of aspirin on haemostasis was discovered by Sir John 
Vane in 1971. The field of antiplatelet therapy was dominated by the 
monopoly of aspirin for nearly 50 years until the introduction of P2Y12 
inhibitors (66). 
 
1.6.1. Mechanism of Action and Pharmacodynamics 
TXA2 is both a potent platelet agonist and a vasoconstrictor. It is produced 
from prostaglandin, which itself is derived from arachidonic acid. The 
conversion is catalyzed by COX enzyme that has two isoenzymes namely 
COX-1 and COX-2. Aspirin permanently inhibits both the COX 
isoenzymes. However, the antiplatelet properties of aspirin are due to the 
permanent acetylation of the serine residue (Ser-529) in COX-1 present in 
platelets. The anti-inflammatory properties are due to its action on COX-2 
(67). The action of aspirin on COX-1 is 166-fold higher than its effect on 
COX-2, which explains why a lower dose of aspirin is sufficient to achieve 
antiplatelet activity whereas a higher dose is required for anti-inflammatory 
properties. Aspirin also causes a change in fibrin clot structure by 
acetylation of fibrinogen (64,68,69). Other mechanisms of action of aspirin 
include modulation of thrombin generation and inhibition of coagulation 
factor XIII activation (69). 
 
Aspirin is administered orally in two formulations, namely dispersible and 
enteric-coated. The bioavailability of dispersible preparations is superior to 
enteric-coated. Aspirin is predominantly metabolized by the liver and 
intestinal human carboxyesterase -2 into acetyl and salicylate moieties. It 
has a half-life of 15 to 20 minutes and peak plasma levels are reached in 
40 minutes. The action of aspirin lasts the lifespan of platelets (70). 
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1.6.2. Aspirin and Primary Prevention 
Primary prevention aims to prevent disease or injury before it occurs. This 
is achieved by avoiding exposure to stimulus that causes disease or 
injury, making necessary changes in behaviour and eating habits that can 
lead to disease or injury and increasing the resistance to disease or injury 
should the exposure occur. In this context, aspirin has long been used for 
its antithrombotic properties to prevent cardiovascular events in patients 
with no previous history of cardiovascular disease. 
Results from three meta-analyses have consistently shown that aspirin 
reduces the risk of cardiovascular events by 10% to 12% (table 1.2). This 
benefit is largely due to reduction in the incidence of non-fatal MI, but not 
fatal MI, stroke, cardiovascular death, or all-cause mortality. It is also well 
demonstrated that aspirin significantly increases the incidence of bleeding. 
Based on these findings, the cardiovascular benefit of aspirin must be 
weighed against bleeding risk when considered for use in primary 
prevention.  
Table 1.2 
 
Parameters 
 
ATT-2009 (71) Seshasai –2012 (72) USPSTF-2015 (73) 
No of studies 6 9 10 
RR for CV 
events 12% 10% 11% 
Reduction in 
non-fatal MI 
0.18% for  Aspirin 
Vs.0.23%  for 
Placebo P<0.001 
RR = 0.80, CI = 0.67-
0.96 
RR =0.80, CI 
=0.72-0.88 
Reduction in 
overall 
mortality 
0.19% for Aspirin 
Vs. 0.19% for 
placebo P=0.7 
OR =0.93, CI =0.84-
10.03 
No significant 
reduction in all-
cause mortality 
Bleeding 
events 
0.10% for Aspirin 
Vs. 0.07 % for 
placebo P =0.7 
OR 1.70, CI 1.17-
2.46 
Significant increase 
in bleeding events 
 
ATT = Antithrombotic Trialists' Collaboration 
USPSTF = U.S. Preventive Service Task Force 
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1.6.3. Aspirin in Secondary Prevention: 
Secondary prevention aims to reduce the impact of a disease or injury that 
has already occurred. This is done by detecting and treating disease or 
injury as soon as possible to halt or slow its progression, encouraging 
personal strategies to prevent reinjury or recurrence and implementing 
programs for people to return to their original health and function in order 
to prevent long term problems. Unlike the controversy in the use of aspirin 
in primary prevention, the benefits of aspirin in secondary prevention are 
well established. Compelling data from hundreds of clinical trials have 
clearly proved that low-dose aspirin is effective in reducing vascular 
events (MI, stroke, and vascular death) in patients who have experienced 
an MI or a stroke, or who are high risk of vascular disease by Framingham 
risk score. The absolute risk reduction for treatment over 2 years is 36 ± 5 
per 1,000 in patients who have had an MI, 36 ± 6 per 1,000 in patients 
who have had a stroke or transient ischaemic attack, and 22 ± 3 per 1,000 
in other high-risk patients. Doses below 162 mg have shown to be 
beneficial in reducing bleeding events without increasing ischaemic 
vascular complications (74). Given this information, the American College 
of Cardiology/American Heart Association (ACC/AHA) guidelines include a 
level A, class I recommendation for the use of daily aspirin (75–162 mg) in 
both men and women with known coronary heart disease or 
atherosclerotic vascular disease (75). 
 
1.6.4. Limitations of Aspirin 
1.6.4.1. Aspirin Resistance 
The terminology of “aspirin resistance” lacks clear and consensus 
definition. If at all any exists, it can be classified in to clinical presentation, 
more appropriately referred to as “treatment failure”, and laboratory 
phenomenon. The occurrence of ischaemic CV-events whilst on aspirin is 
termed treatment failure, and the failure of aspirin to inhibit platelet 
aggregation or platelet TXA2 release, as proven by a relevant laboratory 
test, is called laboratory resistance (76-79). 
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1.6.4.2. Treatment Failure 
The prevalence of treatment failure on aspirin is 5% to 45% depending on 
the risk of the treated population. Laboratory resistance to aspirin is one of 
the reasons for treatment failure, but the latter could be due to several 
other clinical reasons. They include poor compliance, use of enteric-
coated preparations with low bioavailability compared with dispersible 
form, concomitant use of NSAIDs which compete with the  aspirin for the  
COX-1 enzyme, diabetes mellitus, raised body mass index (BMI), acute 
inflammation or infection associated with high C-reactive protein (CRP) 
levels, smoking and hypertension  (76, 78). 
 
1.6.4.3. Laboratory Resistance 
 
Laboratory resistance to aspirin has been defined as ≥ 20% platelet 
aggregation when using 0.5 to 1.6mg/mL arachidonic acid (AA) as the 
agonist. The prevalence of aspirin resistance varies between 5 % and 
60% depending upon the platelet function test that was used for 
assessment. The lowest prevalence was found when platelet aggregation 
is assessed by light transmission aggregometry (LTA) following addition of 
AA (1-4%) and highest for PFA-100 test (60%) (76, 80). The phenomenon 
of laboratory resistance can be a dynamic process in an individual, 
showing poor response to aspirin during the acute phase as compared 
with findings at a later stable phase. 
 Again, there may be many reasons why this laboratory finding might have 
significant clinical implications. Amongst the most disputed ones are 
increased platelet turnover, genetic pleomorphism to COX-1 or platelet 
hyper reactivity (81-83). Other possible reasons for aspirin resistance that 
lacks clinical evidence are increased platelet stimulation with other non- 
AA-dependent mechanisms like adenosine diphosphate (ADP), collagen 
and epinephrine. 
Non-standardized use of assays and the absence of a formal definition 
explain the wide range in the prevalence of aspirin resistance. LTA with 
AA as the agonist typically assess the COX pathway and hence this 
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method has the lowest prevalence of aspirin resistance. Similarly, AA 
induced whole blood aggregometry and VerifyNow Aspirin assay are more 
sensitive in detecting aspirin inhibition and demonstrate lower proportions 
of aspirin resistance. PFA-100 that is a non-specific PFT shows higher 
prevalence of aspirin resistance. None of the available PFT either 
correlates or agrees with the gold standard which is the LTA (84). Hence 
the reasons for the wide difference in aspirin resistance could be 
multifactorial including dosage of aspirin, method of defining resistance, 
type and concentration of the agonist used, baseline platelet reactivity, 
and the type of population selected (stable or unstable CAD, post CABG, 
post PCI etc.). In one study, family history of CAD, previous history of MI, 
history of PCI, were found to be strong predictors of aspirin resistance 
(85). 
 
1.7. P2Y12 Receptor Antagonists 
The P2Y12 receptor plays a key role in platelet activation, aggregation and 
granule secretion. It is also is involved in the amplification of procoagulant 
and pro-inflammatory responses. Hence, it has become one of the major 
targets for antiplatelet medications. Thienopyridines (ticlopidine, 
clopidogrel, prasugrel) were the first P2Y12 receptor antagonists to be 
developed. Clopidogrel, prasugrel and ticagrelor are the main oral drugs in 
this category that are in current clinical practice. 
 
1.8. Clopidogrel 
1.8.1. Mechanism of Action and Pharmacodynamics of Clopidogrel 
Clopidogrel is an oral second generation thienopyridine which has 
replaced ticlopidine due its better safety margin, tolerability and side effect 
profile (64, 86). Clopidogrel binds irreversibly to the P2Y12receptor and 
inhibits its activation by ADP in a non-competitive fashion. Thus it 
indirectly inhibits the activation of the GP IIb-IIIa receptor which is the final 
pathway in platelet aggregation (87). Clopidogrel is a prodrug that needs 
conversion to its active metabolite. 85% of the prodrug is inactivated by 
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esterases. Hence, only 15% is available for conversion to its active form. 
This is accomplished by two sequential oxidative steps by the cytochrome 
P450 enzyme in the liver (88). The first step involves conversion of 
clopidogrel to 2-oxo-clopidogrel by the cytochrome P450 pathway. The 
second step is the formation of a highly labile thiol derivative by hydrolysis 
that binds to the P2Y12 receptors (86, 89). Paraoxonase-1 (PON1) is an 
esterase synthesized in the liver that was postulated to play a role in the 
formation of the thiol active metabolite from clopidogrel but this has not 
subsequently been confirmed (90). The mechanism of action of 
clopidogrel is shown in figure 1.6.  
 
 
Figure 1.6: Platelet Activation Mechanism 
 
 
 
Figure1.6: Platelet activation mechanism and the role of the P2Y12 receptor. 
Platelet activation leads to dense–granule secretion of ADP, which activates the 
P2Y12 receptor. P2Y12 antagonists, namely clopidogrel, prasugrel, ticagrelor, 
cangrelor and elinogrel, all act by blocking the P2Y12 receptor (65, 91). 
Reproduced from BMJ Heart 2011.  Limitations of clopidogrel, R.F. Storey.
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1.8.2. Clinical Trials of Clopidogrel 
The two landmark trials that demonstrated the benefit of clopidogrel in the 
management of ACS were the CAPRIE and CURE trial.  
    
In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic 
Events) trial, clopidogrel was found to be superior to aspirin in preventing 
ischaemic stroke, MI or vascular death in 19,185 patients who were known 
to have atherosclerotic disease of some form. In patients treated with 
clopidogrel, the incidence of ischaemic stroke, MI and vascular death was 
5.32% as compared with aspirin which was 5.83% (p=0.0431)(92). 
    
The CURE Study (Clopidogrel in Unstable Angina to Prevent Recurrent 
Events) evaluated 12552 patients in total, including patients treated 
medically-(N=7,985) and patients treated either by PCI or CABG, 
(N=4,577). Patients with UA or NSTEMI were randomized to receive either 
300mg loading plus 75 mg daily maintenance doses of clopidogrel along 
with standard doses of aspirin or aspirin and placebo. Dual antiplatelet 
therapy with aspirin and clopidogrel was effective in reducing recurrent 
events by 20% (RRR, P<0.001) compared with aspirin alone. This benefit 
was observed in all groups of patients regardless of their treatment 
modality. There was no significant increase in life-threatening bleeding 
although the incidence of major and minor bleeding was high. The CURE 
trial established the role of clopidogrel with aspirin in the medical 
management of ACS in high risk individuals (93). 
    
In the PCI–CURE analysis of a subset of 2,658 patients of the CURE 
population who underwent PCI, 1313 patients received clopidogrel + 
aspirin and the rest received aspirin with placebo. There was a significant 
reduction (P=0.03, RR= 0.70) in the incidence of CV death, MI or urgent 
target vessel revascularization in the clopidogrel group compared with the 
placebo group (93). 
 
The ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage 
during Angioplasty) trial tested the hypothesis that aggressive platelet 
inhibition might reduce myocardial injury and early cardiac events after 
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coronary intervention. The rationale behind the hypothesis was the fact 
that platelet reactivity plays a key role in the pathogenesis of ischaemic 
complications. Different loading doses of clopidogrel (600mg vs. 300mg) 
were compared in 255 patients who underwent PCI. The incidence of 
death, MI and target vessel revascularization at 30 days was 12% in the 
group treated with 300mg of clopidogrel compared to 4% in the 600mg 
group (P = 0.041) (94). The benefit obtained was largely due to the 
decreased incidence of periprocedural MI. 600mg of clopidogrel did not 
cause any increased incidence of bleeding compared to 300 mg. 
 
The CREDO (Clopidogrel for the Reduction of Events during Observation) 
study was aimed at finding the optimal time for loading and continuation 
treatment for clopidogrel. One group received 300 mg of clopidogrel 3-24 
hours prior to PCI, and continued to receive 75 mg of clopidogrel for 12 
months post PCI. The second group received placebo prior to PCI, 75 mg 
of clopidogrel from day 1 post PCI until 28 days and then continued to 
receive placebo until 12 months. 85% of the study population underwent 
PCI in both the groups. There was no statistically significant reduction in 
death, MI, urgent target vessel revascularization at 28 days compared 
between the groups (6.8% pretreatment vs. 8.5% no pretreatment P= 
0.23). However, there was a 38.6% relative reduction in the combined end 
point in patients who received 300 mg of clopidogrel at least 6 hours prior 
to PCI reaching a borderline statistical significance (P= 0.051). This finding 
supports the hypothesis that achieving optimal platelet aggregation 
inhibition prior to PCI is crucial in preventing vascular events post PCI.  
There was 26.9% reduction in the relative risk of death, MI and stroke at 1 
year (P=0.02) in patients who continued to receive 75 mg of clopidogrel 
post procedure compared with those who received placebo. This 
happened at the expense of a trend towards an increase in major bleeding 
(8.8% clopidogrel Vs.6.7 placebo P= 0.07) (95). 
 
In the CLARITY-TIMI 28 (The Clopidogrel as Adjunctive Reperfusion 
Therapy-Thrombolysis in Myocardial Infarction 28) trial, clopidogrel (300 
mg loading only) followed by 75mg daily was compared with placebo in 
3,491 patients with STEMI. All of them received standard treatment for 
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STEMI including aspirin. A clear benefit in the combined end point of 
occluded infarct-related artery on angiography, death or recurrent MI 
before angiography was observed in the clopidogrel group ( 15% vs. 
21.7% P= 0.001) with similar bleeding rates in both groups (96). 
 
PCI-CLARITY-TIMI 28 was a sub-analysis of the CLARITY-TIMI 28 study 
in which 933 patients with STEMI who were not pre-treated with 
clopidogrel were compared with 930 patients with STEMI in whom 
clopidogrel was commenced before the PCI procedure. The incidence of 
CV death, recurrent MI or stroke at 30 days from the time of PCI was 
higher (6.2%) in the patients who were not pre-treated compared with 
those who were pre-treated (3.6%) (P=0.008) (96). 
 
COMMIT (CLOpidogrel and Metoprolol in Myocardial Infarction Trial): This 
was a very large multicentre trial that established the mortality benefit of 
clopidogrel. STEMI patients (N=45,852) were randomized to receive 75mg 
of clopidogrel for 28 days without loading dose and compared with 
placebo. All patients otherwise received standard treatment for STEMI 
including aspirin and thrombolytic treatment with or without heparin. The 
incidence of all-cause mortality in the aspirin plus clopidogrel group was 
7.5% compared with aspirin plus placebo 8.1% (P=0.03). There was no 
significant increase in the risk of major bleeding (97). 
 
The CHARISMA (The Clopidogrel for High Atherothrombotic Risk and 
Ischaemic Stabilization, Management, and Avoidance), included 15,000 
patients with clinical evidence of CVD or multiple risk factors for CVD who 
were randomized to receive 75mg of clopidogrel plus aspirin up to 28 
months or aspirin plus placebo. This study tested the hypothesis that long- 
term treatment with a combination of clopidogrel plus aspirin may provide 
better protection against CV events than aspirin alone. Three quarters of 
the study population had established CVD and the remaining had multiple 
atherothrombotic risk factors. There was no statistically significant 
reduction in the first occurrence of heart attack, stroke or CV death in the 
DAPT group compared with aspirin plus placebo (6.8 % in the clopidogrel 
group vs. 7.3% in the placebo group P= 0.22). But the former group had 
an increased risk of bleeding according to the GUSTO definition (1.7% in 
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the clopidogrel group Vs. 1.3% in the placebo group P= 0.09). In 
summary, the combination of clopidogrel plus aspirin was not significantly 
more effective than aspirin alone in reducing the rate of myocardial 
infarction, stroke, or death from cardiovascular causes among patients 
with stable cardiovascular disease or multiple cardiovascular risk factors. 
Furthermore, the risk of moderate-to-severe bleeding was increased (98). 
 
1.8.3. Limitations of Clopidogrel 
1.8.3.1. Interindividual Variability in Response to Clopidogrel 
The main caveat for clopidogrel is its broad interindividual response due to 
unfavourable pharmacokinetic and pharmacogenetic properties among 
some treated patients. This was reported first by Jaremo et al (99). 
Different terminologies have been applied to describe this variability, 
including clopidogrel resistance, clopidogrel treatment failure, clopidogrel 
hypo-responsiveness and hyper-responsiveness and the recently 
introduced high on-treatment platelet reactivity (HPR) to ADP. 
Unfortunately the definition of this clinical entity is yet to be agreed (100, 
101), although the recent ACC guidelines have  recommended that   
receiver-operator characteristic (ROC) curve analysis be used to define 
the HPR  to ADP (102). The ROC curve analysis provides the cut-off value 
of platelet reactivity that is associated with the lowest false negative and 
false positive rates for ischaemic events (102). 
 
The incidence of clopidogrel hypo-responders ranges from 5%-30% 
depending on the PFT and the cut-off value. The current ACC guidelines 
recommends the following cut-off values by ROC curve analysis to define 
HPR to ADP in the setting of PCI (102). 
 
1)  PRI 50% by VASP-P analysis 
2) 235 to 240 P2Y12 reaction units by VerifyNow P2Y12 assay  
3) 46% maximal 5 µmol/l ADP induced aggregation 
4) 468 arbitrary aggregation units/min in response to ADP by Multiplate 
analyzer. 
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1.8.3.2. Factors Influencing Interindividual Variation 
Several reasons are implicated in the aetiology of variable response to 
clopidogrel. Table 2 summarizes them (101). 
 
1.8.3.3. Genetic Factors 
Of the several genetic polymorphisms that have been implicated in the 
variability of clopidogrel response, the strongest evidence is available for 
the CYP2C19 isoform of the CYP enzyme, particularly the CYP2C19*2 
loss-of-function variant allele. In a study by Simon et al, there was an 
increased incidence of major adverse cardiovascular events (MACE) at 12 
months in patients who underwent PCI who carried any two CYP2C19 
loss of function alleles (*2, *3,*4, or *5). Similar results were obtained from 
a sub study of the TRITON-TIMI 38 trial. Bouman et al found that the 
individuals who developed increased incidence of stent thrombosis 
following PCI tended to have lower levels of PON1 activity related 
predominantly to reduced activity of the QQ192 isoenzymes (Table 1.3). 
Table 1.3:  Factors Associated with Clopidogrel Response Variability 
 
Genetic Factors Cellular Factors Clinical Factors 
Polymorphisms Accelerated platelet turnover 
Poor 
compliance 
MDR1  Increased ADP exposure 
Drug 
interaction 
 
Cytochrome P450(CYP) 
Isoform  
 
Reduced CYP 
activity Smoking 
P2 Y12 
Up regulation of 
P2Y12 Pathway 
P2Y1 Pathway 
 
ACS 
GP IIb-IIIa P2Y-Independent Increased BMI 
 
MDR1 = Multi- Drug Resistance Gene -1 
ADP= Adenosine diphosphate 
ACS= Acute coronary syndrome 
BMI= Body mass index 
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However, these results have been called into question by other research 
groups that have not been able to reproduce them (90).  
1.8.3.4. Drug–Drug Interaction 
Clopidogrel is metabolized by CYP enzymes and hence theoretically any 
drug that is metabolized by the same enzymes can potentially compete 
with the enzyme for its metabolism and reduce the conversion of 
clopidogrel to its active metabolite.  
 
However, this theoretical possibility, at least for statins and calcium 
channel blockers particularly dihydropyridines, has not been corroborated 
in any clinical studies or post hoc analysis of large-scale clinical trials or 
registries. Concomitant use of clopidogrel and proton pump inhibitors 
(PPI), particularly omeprazole, raised a lot of safety concerns recently 
(80). This is because at least some PPIs are inhibitors of CYP2C19, which 
plays a major role in converting clopidogrel to its active metabolite. PPIs 
differ in their ability to inhibit CYP2C19 and omeprazole is the most potent 
inhibitor in this class. Hence the antiplatelet activity of clopidogrel can be 
significantly attenuated by omeprazole. 
 
COGENT study (Clopidogrel and the Optimization of Gastrointestinal 
Events), which is the only placebo-controlled randomized study, in 3627 
patients who received clopidogrel for 12 months aimed to throw light on 
this controversy. There was no increase in the primary CV outcome of a 
composite of CV death, nonfatal MI, coronary revascularization and 
ischaemic stroke (4.9% omeprazole vs. 5.7 % placebo P= 0.96). However, 
this finding of the COGENT study has several limitations. Firstly, the study 
was stopped prematurely due to funding issues. As the study showed a 
wide confidence interval in CV outcome (0.68 to 1.44), absence of 
interaction between clopidogrel and omeprazole cannot be definitively 
ruled out. The pill used in the study was a combined pill of clopidogrel and 
omeprazole which might have a different kinetic property compared to the 
generic omeprazole pill.  The study did not compare between various PPIs 
and finally the follow up time was not of sufficient duration. In view of 
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these limitations concomitant use of clopidogrel and omeprazole is not 
recommended in any guidelines and the FDA still issues a safety warning 
on this combination (103). 
 
1.8.3.5. Clopidogrel Hypo-responders-Clinical Implications 
Gurbel et al first demonstrated the association of high platelet reactivity 
despite clopidogrel treatment with increased incidence of recurrent 
ischaemic events (104). Since then several clinical studies using various 
platelet function tests have established the increased risk for recurrent 
ischaemic CV events in clopidogrel hyporesponders (80).  
 
1.8.3.6. Rebound Effect 
The phenomenon of rebound effect is characterized by a transient 
increase in platelet hyper-aggregability upon cessation of drug resulting in 
increased incidence of thrombotic events (105). Rebound effect following 
cessation of clopidogrel has conflicting evidence. The PACT (Platelet 
Activity after Clopidogrel Termination) study did not demonstrate any 
increase in platelet hyperactivity upon cessation of clopidogrel (106). On 
the other hand, clustering of clinical events after cessation of clopidogrel 
has been documented where there was an increased incidence of 
recurrent CV events in PCI patients following discontinuation (107). 
However, a subgroup analysis of the CHARISMA trial did not show any 
increased event rate following discontinuation of clopidogrel. There is 
some evidence to suggest that this phenomenon might exist in selected 
high-risk populations, particularly such as those with diabetes or who have 
a history of ACS or demonstrate HPR on aspirin (108, 109). 
 
The ONSET/OFFSET trial and ISAR–CAUTION trial also did not 
demonstrate any rebound effect measured by PFT over 10 days after 
discontinuation of clopidogrel (110, 111). 
 
The DAPT trial (Twelve or 30 Months of Dual Antiplatelet Therapy (DAPT) 
after Drug-Eluting Stents (DES)) was an international, multicenter, 
randomized, placebo-controlled trial that was designed to determine the 
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benefits and risks of continuing dual antiplatelet therapy beyond 1 year 
after the placement of a coronary stent. A total of 25,682 patients who 
received drug eluting stent (DES) for treatment of CAD were randomized 
to revive either clopidogrel 75 mg of prasugrel 10 mg along with 75 mg 
aspirin following PCI. At the end of 12 months 9961 of these 25,682 
patients underwent further randomization to continue to receive aspirin 
plus a thienopyridine therapy or aspirin plus placebo. Although there was 
a reduction in the incidence of ischaemic events and this was consistent 
across stent types, the clinical benefits were tempered by an increase in 
all-cause mortality in the group that received DAPT compared to those 
who received aspirin alone. The incidence of bleeding events was also 
high in the group that received DAPT compared to aspirin alone (112). 
 
1.8.4. Prasugrel 
1.8.4.1 Mechanism of Action and Pharmacodynamics  
 
Prasugrel, a third generation thienopyridine, induces irreversible blockade 
of the P2Y12 receptor. It achieves a better and more consistent inhibition of 
platelet aggregation (IPA) than clopidogrel. Like clopidogrel this is a 
prodrug that needs conversion to its active metabolite. However, unlike 
clopidogrel it has a higher rate of conversion to its active metabolite. In 
addition, its effects are not so susceptible to variation in the activity of 
individual CYP isoenzymes. Prasugrel is particularly resistant to 
inactivation by plasma esterase. Moreover, the activation of prasugrel 
requires only one oxidative step through CYP isoenzymes for its 
conversion to active metabolite. These two reasons help the drug to have 
a better pharmacokinetic profile than clopidogrel and hence achieve a 
more rapid and effective platelet inhibition. (65, 113, 114) 
 
1.8.4.2 Clinical Trials of Prasugrel 
TRITON-TIMI 38 Trial: The TRITON –TIMI 38 trial compared clopidogrel 
with prasugrel in 13,608 patients treated for ACS. All of them received 
aspirin. The incidence of primary endpoint of cardiovascular death, MI and 
stroke was lower in the prasugrel group compared with the clopidogrel 
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group (12.1% vs. 9.9%). In addition, the incidence of stent thrombosis was 
half in the prasugrel group compared with clopidogrel group (1.1% vs. 
2.4%). However, the incidence of major and fatal bleeding was higher in 
the prasugrel group compared with the clopidogrel group (2.4% vs 1.8%, 
0.4% vs 0.1%). Hence, there was no difference in the overall mortality rate 
between the two groups. The best balance between safety and efficacy 
was observed in diabetics and patients who underwent primary 
percutaneous coronary intervention (PPCI ) for STEMI (115). 
 
TRILOGY–ACS: Targeted Platelet Inhibition to Clarify the Optimal 
Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY 
ACS) study tested the hypothesis that a combination of prasugrel and 
aspirin is superior to aspirin and clopidogrel in preventing ischaemic 
events in medically managed ACS (UA/NSTEMI) patients who are less 
than 75 years of age.  9326 patients were randomized to receive aspirin 
pus clopidogrel or aspirin plus prasugrel. At a median follow-up of 17 
months, the primary end point occurred in 13.9% of the prasugrel group 
and 16.0% of the clopidogrel group P=0.21. In this large randomized trial, 
prasugrel was not superior to clopidogrel in preventing primary end points 
in medically managed ACS patients without STMEI.  Although there was 
no significant increase in major bleed, the more intense platelet inhibition 
with prasugrel was established by the observation of higher rates of minor 
or moderate bleeding (116) 
 
 
1.8.4.3. Limitations of Prasugrel 
The risk of bleeding with prasugrel is high in patients who are aged more 
than 75 years, weigh less than 60 kg and have a previous history of TIA or 
stroke. Prasugrel is contraindicated in patients with a previous history of 
stroke or TIA. Limited information is available currently as the benefit of 
prasugrel is driven from only one trial namely the TRITON TIMI although it 
is a large trial. The TRITON population included a very small number of 
African and Asian populations. Therefore, whether the benefits of this trial 
can be applied to those groups needs further clarification. In addition, the 
populations with renal impairment and with hepatic dysfunction were 
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underrepresented in this trial, and as the risk of bleeding with prasugrel is 
higher, further studies are needed in this high-risk group for bleeding (117, 
118). 
 
1.8.5. Ticagrelor 
1.8.5.1. Mechanism of Action and Pharmacodynamics 
Ticagrelor is a direct-acting P2Y12 antagonist, which does not require liver 
biotransformation for activation. It reversibly binds to the P2Y12 receptor in 
all the exposed platelets. The degree of platelet inhibition directly reflects 
plasma levels. It causes an earlier and more consistent platelet inhibition 
compared to clopidogrel. Ticagrelor takes 2-3 hours to reach peak plasma 
levels. The plasma level of the drug directly correlates with the IPA. On 
cessation of the drug, the platelet function totally reverses to baseline. The 
IPA achieved is more consistent and greater than clopidogrel. Its plasma 
half-life is 12 hours and hence twice-daily dosages are needed (63, 119-
121). 
 
 
1.8.5.2. Clinical Trials of Ticagrelor 
DISPERSE2: In this trial clopidogrel was compared with ticagrelor at 
varying doses (75mg of clopidogrel, 90 mg of ticagrelor BD, 180 mg BD) in 
patients treated for NSTE-ACS. A total of 999 patients with NSTE-ACS 
were randomized in a 1:1:1 fashion to receive twice-daily ticagrelor 90 mg, 
ticagrelor 180 mg, or clopidogrel 300-mg loading dose plus 75 mg once 
daily for up to 12 weeks. The primary end point, the rate of major or minor 
bleeding through 4 weeks, was 8.1% in the clopidogrel group, 9.8% in the 
ticagrelor 90-mg group, and 8.0% in the ticagrelor 180-mg group (p = 0.43 
and p = 0.96, respectively, vs. clopidogrel); the major bleeding rates were 
6.9%, 7.1%, and 5.1%, respectively (p = 0.91 and p = 0.35, respectively, 
vs. clopidogrel). Although not statistically significant, favorable trends were 
seen in the rates of myocardial infarction (MI) over the entire study period 
(MI: 5.6%, 3.8%, and 2.5%, respectively; p = 0.41 and p = 0.06, 
respectively, vs. clopidogrel) (120, 122). 
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PLATO (Platelet Inhibition and Patients Outcome Trial): The study 
included 18,624 ACS patients treated medically, and by percutaneous and 
surgical revascularization. Ticagrelor (180 mg loading and 90 mg twice 
daily maintenance) was compared with clopidogrel (300-600mg loading 
with 75 mg daily dose). The combined end point of CV death, MI and 
ischaemic stroke at 12 months was less in the ticagrelor group compared 
with clopidogrel group. (9.8% vs. 11.7% P< 0.001). Overall ticagrelor did 
not increase major or fatal bleeding risk in comparison to clopidogrel 
(11.6% vs11.2% P=0.43), but significantly increased the risk of fatal 
intracranial bleeding. Significant number of patients were noncompliant 
with ticagrelor (7.4% vs. 6.0% P< 0.001) compared with clopidogrel mainly 
due to the increased incidence of dyspnoea (13.8 % vs. 7.8% P< 0.001) 
and ventricular pauses ≥ 3 seconds in the ticagrelor group (p=0.01). 
79/13339 ( 5.9%) of patients taking ticagrelor discontinued the medication 
prematurely due to dyspnoea as compared to 13/798 ( 1.6%) of patients 
taking clopidogrel ( P< 0.0001) (119). 
 
 
1.8.5.3. Limitations of Ticagrelor 
Dyspnoea of mild to moderate severity may lead to discontinuation of drug 
in a small proportion of patients. Increased incidence of ventricular pauses 
of > 2.5 seconds was also noted during continuous ECG monitoring. The 
incidences of these side effects were directly proportional to the dose of 
ticagrelor. Increased serum level of creatinine and uric acid was also 
noted in this study population. The dyspnoea and ventricular pauses may 
be due to an effect of ticagrelor on adenosine metabolism (123). 
 
1.8.6. Indications for Antiplatelets Therapy 
 
 Aspirin should be given at the time of suspected acute MI 
 Once MI or ACS is confirmed, a second oral antiplatelet agent such 
as clopidogrel or ticagrelor can be considered.  
 If a coronary stent is deployed then a second antiplatelet agent is 
mandatory and in ACS patient this can be clopidogrel, prasugrel or 
ticagrelor. 
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 A P2Y12 inhibitor is recommended in addition to aspirin, for 12 
months following NSTE-ACS unless there are contraindications. 
Clopidogrel (300-600 mg loading dose, 75 mg daily dose) is 
recommended for patients who cannot receive ticagrelor or 
prasugrel or who require oral anticoagulation (Class I, Level of 
Evidence B). Prasugrel is contraindicated in patients with prior 
stroke/transient ischaemic attack; and there is no apparent benefit 
with prasugrel in patients >75 years of age or with low bodyweight 
(60 kg). Previous intracranial haemorrhage is a contraindication to 
the use of ticagrelor. 
 This dual antiplatelet therapy (DAPT) should continue for at least a 
year unless major bleeding issues arise 
 After the first year of an ACS, options include aspirin monotherapy 
or clopidogrel monotherapy 
 In patients with low risk for bleeding and high risk for ischaemic 
events, DAPT with aspirin plus clopidogrel 75 mg or aspirin plus 
ticagrelor 60 mg twice daily can be considered 
 For patients who undergo elective coronary stenting for stable 
ischaemic heart disease, current guidelines recommend 6 months 
of DAPT if a second-generation drug-eluting stent is utilized. 
 For bare metal stents, one month of DAPT is the minimum 
sufficient period per the guidelines 
 For patients with stable angina treated medically or who have had 
coronary artery bypass surgery, aspirin is recommended with stable 
angina treated medically or who have had coronary artery bypass 
surgery, aspirin is recommended with stable angina treated 
medically or who have had coronary artery bypass surgery, aspirin 
is recommended (124-126). 
 
1.9. Platelet Function Testing (PFT) 
The history of PFT dates back 100 years. Traditionally PFT was only used 
in the management of acquired and inborn bleeding diathesis as opposed 
to thrombosis (127). Since the role of platelets was established in the 
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pathogenesis of atherothrombosis, antiplatelet medications have become 
the cornerstone in the management of CVD (128, 129). However, the 
novel antiplatelet medication that achieves optimum platelet inhibition 
without causing bleeding complications is yet to be identified. This has 
paved the way for the increasing use of already existing and newer point-
of-care, PFT tools in the context of monitoring the efficacy and safety of 
antiplatelet medications both during their developmental stage and in 
clinical settings. 
PFT is used in diverse clinical contexts to study the multitude of functions 
of platelets. Although an overview of the available tests is briefed, detailed 
discussion is restricted to those used to analyze the effects of various 
antiplatelet medications, particularly aspirin, P2Y12 inhibitors (clopidogrel, 
and GPI). 
The two main potential indications for PFT, at least in CV settings, are to 
predict bleeding and thrombotic events. Bleeding risk may be assessed in 
patients with platelet defects or postoperative hypocoagulable states, (e.g. 
Post CABG surgery) and to monitor the safety of antiplatelet medications. 
The bleeding risk of an individual, particularly when treatment with 
antithrombotic medications are considered in case of AF and other 
conditions, can be calculated using clinical scoring systems like the HAS-
BLED scoring system. The HAS-BLED scoring system is well validated 
and overcomes the limitations of some prior scores. This scoring system 
has a good predictive value for intracranial bleeding both when warfarin 
and aspirin is used. The following parameters are taken into consideration: 
Uncontrolled blood pressure, abnormal renal function, stroke, bleeding 
tendency, labile INR, age > 65, concomitant use of drugs like aspirin, 
NSAID and alcohol all score 1 point. Abnormal liver function scores 2 
points. A total of 9 points is possible. However, a score ≥ 3 is indicative of 
the need for regular clinical review and follow up (130). Similarly, 
thrombotic risk is assessed in high-risk patients, for platelet hyper 
reactivity and efficacy of antiplatelet medications in medical management, 
during and after interventional procedures(132). The classification of 
platelet function tests is presented in table 1.4. 
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Table 1.4: Classification of Platelet Function Tests (131) 
 
i) In Vivo  
(a) Bleeding time (BT) 
ii) In Vitro 
(a) Platelet aggregometry 
1. Turbidometric aggregometry 
2. Light transmission aggregometry (LTA) 
(b) Impedance aggregometry 
1. Multiplate electrode aggregometry (MEA) 
(c) Particle counting aggregometry 
1. Whole blood single platelet counting assay (WBSPCA) 
2. PlateletWorks 
3. Verify Now Point-of-care (POC) assay 
(d) Shear dependant platelet function within whole blood 
1. Platelet Function Analyser- 100 (PFA- 100) 
2. Cone and Plate(let) assay (CPA) 
(e) Flow cytometry 
1. Platelet surface P-selectin, platelet surface–activated GP IIb-
IIIa, and leukocytes-platelet aggregates 
2. Phosphorylation of vasodilator-stimulated phosphoprotein 
(VASP) 
3. Platelet derived microparticles 
(f) Global haemostasis tests 
1. Thromboelastography 
2. Thromboelastography (TEG) platelet mapping system 
3. Thromboelastometry 
4. Rotational Thromboelastometry (ROTEM) 
(g) Thromboxane (TX) measurements 
1. Serum thromboxane B2 measurement (TXB2) 
(h) Urinary thromboxane measurement  
1. Urinary 11- dehydrothromboxane B2 measurement 
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1.9.1. General Principles 
1.9.2. Physiological Vs. Non-Physiological Environments 
The major drawback of all the available PFT with the exception of BT is 
failure to mimic the complex physiological environment in which platelet 
activation and aggregation takes place. There are several factors that 
need careful consideration. Firstly, the in vitro tests do not consider the 
influence that endothelial cells, collagen or vWF have on the process of 
platelet aggregation. Secondly, in LTA, analysis is carried out using 
platelet-rich plasma (PRP). The PRP is depleted of WBCs and RBCs. In 
addition, only 61% to 90% of the whole platelet population is represented 
in the PRP. Often the giant platelets are removed from the PRP which 
may be hypo or hyper-active. These factors put together have a great 
influence on the validity of the results obtained by these tests. Tests 
performed in whole blood is theoretically assumed to be better than LTA 
for the above reasons. Thirdly, with the exception of the PFA and the cone 
and plate(let) method, none of the other tests consider the effect of shear 
rate on the thrombus formation in CAD. The difference in the velocity of 
the blood flow between the centre and near the wall of the vessel 
produces a shearing effect that plays an important role in the formation of 
platelet aggregation in CAD. The formation of platelet aggregates normally 
happens in a high shear environment whereas the LTA and impedance 
aggregometry are done in low shear pressure environments and are 
therefore less physiological (133). 
 
1.9.3. Other General Considerations 
It is recommended that blood is collected via a 19 to 21-gauge needle 
using a single syringe. Collection of blood in a Vacutainer may cause 
turbulence with associated platelet activation and hence is not 
recommended. All samples should be handled gently avoiding any abrupt 
movement as this can induce platelet aggregation. The tubes used to 
prepare samples for aggregation studies should ideally be made of plastic 
or siliconised glass as uncoated glass can induce spontaneous platelet 
activation. Double pipetting technique is advised to avoid any air bubble in 
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the analysis tube. A true point-of-care test is one that does not use 
pipetting. In that respect, VerifyNow and PFA 100 are the only point-of-
care tests available as all other tests involve pipetting. Platelet 
aggregation studies are normally done at 37○C to simulate the in vivo 
environment. Any diluents added should be at room temperature. When 
platelets are exposed to cold temperature, then rewarmed and stirred, 
spontaneous platelet aggregation can take place. Strict thermostatic 
measures should be in place for impedance aggregometry as the change 
in impedance between the electrodes is particularly sensitive to change in 
temperature. Ineffective stirring or non-addition of stir bars will result in a 
flat curve. Water as a diluent is not recommended as it causes lysis of 
RBCs and release of ADP. Normal saline or phosphate buffered saline are 
the commonly used diluents (134-137). 
 
1.9.4. Agonists Used 
ADP interacts with P2Y1 and P2Y12 receptors on the platelet surface. 
Hence it is used to study the effect of clopidogrel and GP IIb-IIIa inhibitors. 
Also at lower concentrations in citrate-anticoagulated samples it can 
stimulate formation of TXA2 and hence has been used to study the effect 
of aspirin(138). TXA2, a potent platelet agonist, is formed as arachidonic 
acid (AA) interacts with COX. AA is used to evaluate the effect of drugs 
that acts by inhibiting the production of TXA2, particularly aspirin (139). 
Collagen has two type of action depending on the dose used. At low 
concentration (e.g. 0.2µg/mL), it causes mobilization of AA from the 
platelet membrane that is converted to TXA2. This in turn causes release 
of ADP. At high concentration (e.g.5µg/mL), collagen causes direct 
release of ADP. Collagen is used to test the antiplatelet effect of aspirin 
and GP IIb-IIIa inhibitors (140). 
 
Thrombin receptor activating peptide (TRAP) is a synthetic peptide that is 
consistent with at least the first five N-terminal amino acid sequence 
generated after the proteolysis of the thrombin receptor PAR1.TRAP 
(10µmol/L) produces similar strong platelet aggregation response to 
thrombin. It is used to study the effects of GP IIb/IIIa inhibitors and has 
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also been used to study the pharmacodynamic effects of the newer PAR1 
antagonists (139, 140). Epinephrine is occasionally used to study the 
effects of aspirin. It is typically used in the concentration of 5-10µmol/L. 
The other drugs that can influence the aggregation response to 
epinephrine are nonsteroidal anti-inflammatory drugs, antihistamines, 
some antibiotics and other over-the–counter medications. Of the agonists 
for platelet aggregation, epinephrine is the most unpredictable and 
inaccurate (139, 140). The agonists used in platelet function analysis are 
summarized in table 1.5. 
 
Table 1.5: Summary of the Agonists Used 
 
Agonist Concentration Mechanism of action Sensitive Not sensitive 
ADP 0.5-20µM 
Interacts with the 
P2Y12 and P2Y1 
receptor and 
causes platelet 
aggregation via 
the GP IIb /IIIa 
pathway 
Clopidogrel, GP 
IIb-IIIa inhibitors Aspirin 
AA 0.5-2.5mM Converted to TX A2 Aspirin 
Clopidogrel, 
GPIIb-IIIa 
inhibitors 
TRAP 1-5µg/mL 
Synthetic 
derivative of 
thrombin, the most 
potent platelet 
aggregator 
GP IIb/IIIa 
inhibitor 
Aspirin, 
Clopidogrel 
Collagen 0.2-5µg/mL 
Through the action 
on the collagen 
receptor causes 
release of TX A2 
Aspirin, GP IIb-IIIa 
inhibitors Clopidogrel 
Epinephrine 10-18µg/mL 
Weak and less 
consistent agonist 
of COX-1 
Aspirin Clopidogrel,GPIIb-IIIa inhibitors. 
 
 
1.9.5. Anticoagulants Used (136,141,142) 
The choice of in vitro anticoagulant used can have an effect on the platelet 
function. The majority of regulatory events appear to require free calcium. 
Ionized calcium is the primary bioregulator for platelet activation. A variety 
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of biochemical mechanisms modulate the level and availability of free 
cytosolic calcium. Most of the anticoagulants either increase or decrease 
the blood levels of ionized calcium than the ideal concentration and hence 
have an indirect effect on the platelet function. Sodium citrate, 
ethylenediaminetetraacetic acid (EDTA), heparin, hirudin and PPACK (D-
Phenyl-alanyl-L-prolyl-L-arginine) are the common anticoagulants in use. 
EDTA and heparin are less favoured as the former decreases the 
concentration of calcium ions too low to support platelet aggregation and 
the latter enhances platelet reactivity and may reduce platelet counts in 
PRP. Hirudin and PPACK are direct thrombin inhibitors that achieve a 
more physiological concentration of calcium and hence may be favoured, 
although they are more expensive than other anticoagulants and are not 
used on routine basis. Sodium citrate is the most commonly used 
anticoagulant (9). 
 
1.9.6. Turbidometric Aggregometry 
1.9.6.1. Light Transmission Aggregometry (LTA) 
This technique was introduced 50 years ago (1962) by Gustav Born and 
John O’Brien (143). Originally introduced to study primary haemostatic 
defects and not as a predictor of thrombosis (144, 145), this method 
measures the GP IIb-IIIa dependent platelet to platelet aggregation (146).  
It has since been widely used to assess platelet aggregation response to 
various antiplatelet medications including (aspirin, clopidogrel and GP IIb-
IIIa inhibitors) and to predict clinical outcomes. Incorporation of newer 
technologies like multi-channel capability, computer control and the 
potential to measure ATP release via luminescence have enabled this 
technique to still remain a valuable tool to get information about different 
aspects of platelet function in specialized laboratories (129). 
 
1.9.6.2. Principles of LTA 
This is an in vitro test. PRP and platelet poor plasma (PPP) are obtained 
from anticoagulated blood by low force (135-175g) and high force (2700g) 
centrifugation, respectively. The platelet count in the PRP is standardized 
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to (250 x 10-9 /l) by addition of PPP. The PRP is in turn stirred in a cuvette 
at 370C between a light source and a measuring photocell (147). Addition 
of a panel of agonist (ADP, AA, collagen and TRAP) at a range of 
concentration initiates platelet–platelet aggregation and induces a 
difference in the light transmission. The rate and extent of the increase in 
light transmission is measured. Typical curves are obtained for an agonist 
at a particular concentration. Deviation from the normal curve helps in the 
identification of abnormal platelet function (133). 
 
1.9.6.3. Limitations and Advantages of LTA 
When the platelet count in the PRP is less than 100x 10-9/L, then the 
results are less reliable. Similarly, the test cannot be performed if the 
plasma is lipaemic (148). It is not a whole blood assay and hence less 
physiological. It also does not take into account the effect of shear stress 
and platelet–endothelial cell interaction and hence not sensitive to monitor 
the early phase of aggregation which is particularly important in studying 
patients with platelet hyperreactivity (129,133,136). LTA is insensitive to 
microaggregate formation  and hence may  not provide a complete picture 
of platelet reactivity, such as in the assessment of the  antiplatelet effect of 
GP IIb-IIIa inhibitors (148)(141). LTA needs large a relatively large sample 
volume, is labour-intensive and time consuming, requires technical 
expertise, and  lacks standardization (148). The main advantages include 
being historical gold standard and proven ability to measure the effects of 
aspirin, clopidogrel and GP IIb-IIIa inhibitors (131). 
 
1.9.7. Whole Blood Aggregometry 
 
1.9.7.1. Impedance Platelet Aggregometry 
The measurement of platelet aggregation by impedance method was 
introduced by Cardinal and Flower in 1980. This was further refined by 
Mackie in 1984.  Analysis is done in whole blood. This allows the 
physiological milieu to be preserved and hence the platelets are 
biologically more sensitive to particular agonist (149, 150). 
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1.9.7.2. Principles of Impedance Aggregometry 
Diluted (to correct the haematocrit to 0.300) anti coagulated blood in a 
cuvette is stirred at 37○C by placing in the impedance aggregometer. Two 
palladium electrodes are inserted into the cuvette and alternating current 
is passed through the blood into the electrodes. The electrodes that are 
positively charged attract the negatively charged platelets which form a 
monolayer on the electrode. Upon addition of the agonist, platelet 
aggregation is induced and aggregates accumulate around the monolayer 
producing an increase in the impedance between the electrodes. The 
difference between the impedance in the two electrodes is recorded as a 
deflection in trace either by a conventional chart recorder or by a 
computerized system (149-151). 
 
1.9.7.3. Limitations and Advantages of Impedance Aggregometry 
Like LTA, this technique also is not sensitive enough to detect platelet 
microaggregation. Platelets are aggregated at low shear rate. Correction 
of haematocrit is vital as a high or low haematocrit can cause poor 
precision of the aggregation values. The aggregometer needs calibration 
for every new sample either from the same patient or from a different 
patient which is time consuming.  Meticulous measures have to be taken 
to clean the electrode after every test so that there are no aggregated 
cells from previous samples left which is a possible source of error (151). 
The advantages are whole blood assay which can be used when the 
platelet count is less than 100 X 109/l giving good response at a count as 
low as 50 X 109/l and also when the plasma is lipaemic (131). Impedance 
aggregometry can be used to measure the effect of aspirin, clopidogrel, 
and GP IIb-IIIa inhibitors. It has also been used to study the effect of 
dipyridamole (152). Conflicting evidence exists about its correlation with 
LTA some suggesting good correlation (153), and few suggesting poor 
correlation (141). Hence conventional impedance aggregometry has been 
taken over by more modified technique which is user friendly. 
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1.9.8. Multiplate Electrode Aggregometry 
Introduced in 2005 by Orsolya and colleagues, Multiplate electrode 
aggregometry works on the principle of impedance aggregometry. It is 
currently one of the most commonly used point-of-care devices at least in 
Europe, to predict both the efficacy (thrombotic risk) and safety (bleeding 
risk) of antiplatelet medications (http://www.multiplate.net).  
 
1.9.8.1. Principles of MEA 
A disposable test cell with four electrodes (two pairs) per cell instead of 
two makes the multiple electrode aggregometry different from the 
conventional impedance aggregometry. The device has the potential to 
analyze five samples at a time. The blood is diluted with warmed saline at 
370C, anticoagulated with hirudin and placed in the test cell. The samples 
are stirred using a disposable Poly-tetra-fluoro-ethylene (PTFE) coated 
magnetic stirrer. Addition of agonists induces typical changes in 
impedance that is detected by individual sensor units. The duplicate 
sensor acts as an internal quality control. The analysis delivers a kinetic 
signal which is described as area under the curve (AUC) (154). 
 
1.9.8.2. Limitations and Advantages of MEA 
The use of MEA is restricted to patients with normal platelet count as its 
use the context of low platelet count or low haematocrit is not validated. 
The general limitations of any aggregometry technique apply to MEA. 
Also, there is no option of luminescence available. The advantages are 
whole blood analysis, fast and convenient. Results correlate well with LTA 
(131,133,155). 
 
1.9.9. Particle Counting Aggregometry 
Whole blood aggregometry using particle counting technique to represent 
platelet aggregation was introduced by Lumley and Humphrey in 1981. 
This comprises incubating whole blood and an agonist at 370C in shaking 
water bath and withdrawing consecutive aliquots for platelet counting 
(156). 
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1.9.9.1. Whole Blood Single Platelet Counting (WBSPC) Assay 
This was first introduced by Professor Stan Heptinstall from the University 
of Nottingham in 1982. Although any automated platelet counter can be 
employed to assess aggregation, the Ultra–flow 100 whole blood platelet 
counter was the one originally used in this method. The Ultra–Flo itself 
has been described in detail by Bacus et al (157). 
 
1.9.9.2. Principles of WBSPCA 
 
This assumes that, as platelets aggregate, the count of single platelets in 
the sample is reduced. Anticoagulated blood is stirred and incubated at 
370C. It is then allowed to interact with a specific agonist for a particular 
period of time. Samples are then mixed with a fixative to prevent further 
interaction with the agonist. This is then processed by the Ultra–flo 100 
whole blood platelet counter which uses hydrodynamic focusing to bring 
the cells into the centre of a counting aperture. As each particle travels 
through the aperture it evokes a change in the electronic conductance that 
enables a count based on the size of the cell. In that respect cells at the 
size of RBC and platelets are counted. The machine then works out the 
proportion of the platelets to RBC. The real RBC count in the sample is 
obtained by a different method and when this information is provided, the 
machine gives an automatic display of the number of the platelets. The fall 
in platelet count is expressed as percentage of aggregation where a count 
of zero is equal to 100% aggregation. In further experiments using this 
technique, the Sysmex K-100 analyzer has been used to count platelets 
and proved to correlate well with the Ultra-flo 100 counter 
(148,151,152,157). 
 
1.9.9.3. Limitations and Advantages of WBSPCA 
This method is sensitive in detecting micro-aggregation which may be an 
advantage for analyzing GP IIb-IIIa inhibitor effect. It is also less 
expensive than most other methods and rapid. It is a whole blood assay 
and can also be used to study the effect of aspirin and clopidogrel (141, 
158). As this method has not been widely studied, limited information is 
available about its limitations. 
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1.9.10. Plateletworks 
The Plateletworks assay was first devised by Carville and colleagues in 
1998. It is based on the standard haematology cell counting principle 
(159). 
 
1.9.10.1. Principles of Plateletworks 
Platelet aggregation to a particular agonist is estimated by the difference 
in the cell count before and after the addition of an agonist. Standard 
agonists are used, e.g. collagen for assessment of response to aspirin, 
and ADP for assessment of clopidogrel. Controls are placed in tubes 
containing EDTA and test samples in tubes containing citrate. The tubes 
are simply inverted several times to mix with the anticoagulant and 
agonist. Exposure to an agonist initiates platelet aggregates that are 
bigger in size compared to the single platelet and are no longer counted 
as single platelets. The difference in the platelet count between the control 
and the sample is represented as platelet aggregation (% maximum) and 
is calculated using the following formula (159, 160). 
 
% maximum aggregation= (baseline platelet count-agonist platelet count) X100 baseline 
platelet count. 
 
1.9.10.2. Limitations and Advantages of Platelet-Works 
With limited data, it does not seem to correlate well with LTA. Counting is 
the key principle; a good calibrated platelet counting tool is absolutely 
imperative. The assay is not well standardized as it relies on the user to 
invert the tubes for mixing of blood and reagents. The main advantages 
are  whole blood assay, simple and easy to perform (131). 
 
1.9.11. VerifyNow Assay (Ultegra Rapid Platelet Function Assay) 
Originally devised by Barry S Coller in late 70s and early 80s when he was 
trying to understand the pathophysiology of thrombasthenic disease and 
subsequently discovered GPIIb/IIIa receptors. Hence the preliminary 
assays had the ability to check the effect of GP IIb-IIIa inhibitors only (161-
163). The system has since been reconfigured with incorporation of 
modern technology and was adopted as point-of-care device by Steven R. 
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Steinhubl and colleagues, having the potential to test not only the GP IIb-
IIIa inhibitors but also aspirin and clopidogrel (164). 
 
1.9.11.1. Principles of VerifyNow assay 
This assay is an amalgamation of turbidometric principle and whole blood 
assessment. It relies on the basis that activated platelets in whole blood 
have the ability to agglutinate with fibrinogen-coated beads. Hence when 
platelets are exposed to the antiplatelet agent of interest (to be studied) 
there are receptors that are not inhibited by the drug still available for 
agglutination. This is achieved by activating the uninhibited receptors by 
addition of specific agonist and providing fibrinogen coated beads for 
agglutination. When platelet agglutination occurs, there is gradual 
increase in light transmission that is measured against time. The rate of 
agglutination is ultimately expressed as agonist specific units. When assay 
for clopidogrel is conducted the addition of prostaglandin E1 suppresses 
the intracellular calcium levels and augments the inhibitory effects of 
P2Y12 receptor antagonists, which yields results with higher precision 
values as it is a more accurate estimate of the inhibition of the P2Y12 
receptor. Summary of the three assays available are presented below 
(162, 164). 
 
1.9.11.2. Limitations and Advantages of VerifyNow Assay 
The main advantage of this assay includes whole blood assay, rapid, 
simple and accurate. Small sample volume is needed for analysis. The 
system has the potential to measure the effects of aspirin, clopidogrel and 
GP IIb-IIIa inhibitors individually. The assays correlate well with LTA. It is a 
true point-of-care device, as no pipetting is involved. On the other hand, 
the downsides include restrictions to the range of acceptable haematocrit 
values and platelet counts. The assay is low shear dependent hence does 
not mimic the actual physiological environment (132). The greatest 
limitation is high cost of the assay consumables. The details of VerifyNow 
assay is summarized in table 1.6. 
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Table 1.6: Summary of the VerifyNow Assay 
 
Name of the assay Agonist used Agent tested Final result 
VerifyNow GP IIb-
IIIa TRAP GP IIb-IIIa inhibitors PAU 
VerifyNow Aspirin AA Aspirin ARU 
VerifyNow P2Y12 ADP + PGE1 Clopidogrel PRU 
 
PAU Platelet aggregation unit 
ARU Aspirin reaction units 
PRU P2Y12 reactive units 
PGE1 Prostaglandin E1 
 
 
1.9.12. Bleeding Time 
This is the only in vivo test available to assess platelet function. The first 
published paper about bleeding time is from a French physician called 
Milan 1901. However, it was Duke’s (1910) description that gained wide 
acceptance amongst the medical professionals (165). This has been 
modified to achieve better standardization by the Ivy technique, and 
further improvement by Mielke et al (166, 167). The test described below 
is the one adapted by Thiagarajan and Wu. 
 
1.9.12.1. Principles of Bleeding Time 
The time taken to arrest bleeding after an incision is made to the skin is 
called bleeding time. This is measured by inflating a blood pressure cuff to 
40mmHg in the upper arm. An incision of 10mm in length and 1mm in 
depth is made to the volar surface of the forearm. The wound is blotted 
every 30 seconds until bleeding stops. The normal bleeding time is less 
than 10 minutes (136). 
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1.9.12.2. Advantages and Limitations of Bleeding Time 
The main merits of BT include assessment of natural haemostasis, less 
expensive, simple and not prone to anticoagulation artifacts (133). The 
main limitations are non-specific, insensitive, lack of reliability, scar 
formation and operator dependence (132). The three major shortcomings 
of the bleeding time as recognized by The College of American 
Pathologists and the American Society of Clinical Pathologists includes 
(168), 
 It performs poorly as a pre-surgical screening test  
 A normal BT does not mean that a patient will not bleed 
 The BT does not reliably identify those subjects who have recently 
ingested antiplatelet drugs such as aspirin. 
1.9.13. Platelet Function Analyzer (PFA 100) 
1.9.13.1. Principles of Platelet Function Analyzer- 100 
This system basically tests bleeding time in an in vitro high shear 
ambiance (5000 - 6000 s-1.). Citrated blood is warmed at 370 C in a 
reservoir in the disposable test cartridge. This is sucked into a capillary 
tube of internal diameter 200 µm with a smaller aperture of 150 µm. The 
inner aspect of the capillary tube is either coated with collagen and 
epinephrine (CEPI) or collagen and ADP (CADP). Thus, the platelets are 
exposed to a combination of agonist and high shear stress at the same 
time that promotes platelet activation and aggregation. This in turn 
occludes the blood flow through the aperture which is measured as the 
closure time (169). 
 
 
1.9.13.2. Advantages and Limitations of Platelet Function Analyzer-100 
The main advantages of this assay are rapid, simple and no sample 
preparation. It can be used as a point-of-care tool that assesses the 
platelet function in a high shear climate particularly in whole blood. The 
closure time is dependent on the von Willebrand factor and the 
haematocrit and hence could not be used in situations where these factors 
are abnormal. The PFA 100 system is not sensitive enough to detect the 
effect of clopidogrel (169). 
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1.9.14. Cone and Plate (let) Analyzer 
Einav S, Dewey C F & Hartenbaum were the first to use the cone and 
plate(let) device to study platelet function in whole blood under normal 
flow conditions (169). This method has been further modified by David 
Varon and Naphtali Savion from Israel into the cone and plate (let) 
analyzer (170). 
 
1.9.14.1. Principles of Cone and Plate (let) Analyzer 
The device consists of a polystyrene coated plate and a rotating cone. The 
polystyrene plate enables formation of a thrombogenic surface by 
immobilization of fibrinogen and the vWF. The cone is used to deliver the 
shear pressure. The citrated blood samples of patients are incubated with 
specific agonist (depending on the drug of interest to be studied e.g. ADP, 
TRAP, AA) for one minute.  The blood sample is then poured on the plate 
and subjected to standard shear rate of 1800 s-1 for 2 min prior to staining. 
Platelets in whole blood on exposure to an agonist under shear 
circumstances get activated and form aggregate that are picked up by 
staining. The percentage of surface covered (SC) by stained object and 
the average size (AS) of the object are recorded using an image analyzer 
(170-172). 
 
1.9.14.2. Advantages and Limitations of Cone and Plate (let) Analyzer 
This is a whole blood assay that tests platelet function under high shear 
conditions. The procedure is simple, rapid and has the potential to be 
used as a point-of-care instrument. Limited information is available 
regarding its disadvantages. However, this is  not a true point-of-care 
instrument as pipetting is needed (172). 
 
1.9.15. Flow Cytometry 
One of the biggest advances in the quest for the novel PFT tool is the 
ability to apply whole blood flow cytometry technique for assessment of 
platelet functions. This was first introduced by Shattil et al. It is a 
multifaceted tool having the facility to evaluate diverse properties of the 
platelet. Flow cytometry uses fluorescently labeled antibody and non-
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antibody-based probes to determine platelet reactivity or evidence of in 
vivo platelet activation. A unique advantage of flow cytometry is its ability 
to assess reliable platelet function in thrombocytopenic samples (173). 
 
1.9.15.1. Vasodilator–Stimulated Phosphorylation Cytometric Analysis 
Thienopyridines indirectly promote phosphorylation of vasodilator-
stimulated phosphorylation (VASP) and this phosphorylation can be 
determined by cytometric analysis (174). This is the rationale for 
measuring the antiplatelet activity of the thienopyridines using the flow 
cytometric analysis.   
 
1.9.15.2. Principles of VASP Flow Cytometric Analysis 
In this assay, the VASP is converted to phosphorylated VASP (VASP-P) 
by the PGE -1. This is achieved by a multistep process. The initial step 
involves binding of the PGE-1 to the inositol phosphate receptor on the 
platelet surface which converts the ATP to cyclic AMP. This conversion is 
signaled through G stimulatory protein and adenyl cyclase. The cyclic 
AMP thus formed converts VASP to VASP-P through protein kinase A. 
ADP, via P2Y12 receptor activation, inhibits the PGE-1 induced signaling 
through adenyl cyclase. Therefore, in the presence of a P2Y12 inhibitor the 
measure of the VASP-P in the blood is directly proportional to the degree 
of P2Y12 antagonism. 
 
 
1.9.15.3. Advantages and Limitations of the VASP Cytometric 
Analysis 
The advantages of this method are that it is a whole blood assay and 
small sample volume is needed. The limitations includes need to prepare 
sample and the requirement of a flow cytometer and an experienced 
technician both of which could be expensive (129). The sample 
processing and analysis may increase the risk of error. 
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1.9.16. Thromboelastography 
This was first discovered by a German scientist Dr. Hellmut Hartert in the 
year 1948.Thromboelastography (TEG) is a method of testing the 
efficiency of blood coagulation. It is a test mainly used in surgery and 
anesthesiology, More common tests of blood coagulation include 
prothrombin time (PT,INR) and partial thromboplastin time (aPTT) which 
measure coagulation factor function, but TEG also can assess platelet 
function, clot strength, and fibrinolysis which these other tests cannot. 
Whole blood is inserted in the cup. A torsion wire suspends a pin 
immersed in the cup and connects with a mechanical–electrical 
transducer. The cup rotates through 4°45′ to imitate sluggish venous flow 
and activate coagulation. The speed and strength of clot formation is 
measured in various ways (now usually by computer), and depends on the 
activity of the plasmatic coagulation system, platelet function and 
fibrinolysis (175). 
The initial application of this system was restricted to study haemostasis 
as a dynamic process. Many studies were conducted in perioperative 
settings to predict bleeding using this technique. ROTEM is a modification 
of thromboelastography (TEG), which also measures the efficiency of 
coagulation in the blood like the TEG. TEG platelet mapping assay is a 
further development of the TEG that allows study of the antiplatelet 
medications by addition of specific agonist that is described further. This 
was first developed by Robert M Craft and colleagues from Illinois in 2004 
(176). 
 
1.9.16.1. Thromboelastography Platelet Mapping System 
This method uses clot strength to study platelet function. Heparin 
annihilates thrombin activity in the blood and hence is used as the 
anticoagulant. The fibrin’s contribution to the clot strength is studied by 
adding reptilase and factor IIIa (activator F) which generates a cross 
linked fibrin clot. Similarly, the role of P2Y12 receptor or the COX pathway 
to clot formation is measured by the addition of ADP and AA respectively. 
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1.9.16.2. Principles of TEG Mapping System 
Blood is added to a rotating sample cup that may or may not be coated 
with heparin and has a suspended pin that is connected to a chart 
recorder. As the clot is formed in the cup the motion of the cup is 
transmitted to the pin by the strengthening clot which is recorded and thus 
Maximum amplitude (MA) is documented (177, 178). 
Three types of MA are obtained (178). 
 
MAthrombi: Thrombin induced clot strength is analyzed by adding 
neutralized blood to heparin coated sample cup. 
 
MAfibrin: Whole blood fibrin cross linked clot in the absence of thrombin 
generation or platelet activation is obtained by adding heparinized blood to 
reptilase and activator F in the rotating sample cup. 
 
MA AA: Whole blood fibrin cross linked clot in the absence of thrombin but 
presence of platelet activation is achieved by adding heparinized blood to 
AA and factor F.  
 
Similarly, MA ADP can also be obtained. Platelet aggregation in response 
to AA is obtained by the formula 
 
% of aggregation = [(MAAA - MAFibrin ) / (MAThrombin - MAFibrin) /100. 
 
1.9.16.3. Advantages and Limitations of TEG Mapping System 
In addition to testing the platelet function it also specifically analyses the 
platelet contribution to clot strength. This is a whole blood assay which 
has the ability to monitor all 3 classes of antiplatelet therapy.  Limited 
numbers of literature are available to weigh the merits against demerits 
(178). 
 
1.9.17: Rotational Thromboelastography& Thromboelastometry 
This is an adaptation of the TEG in which the sample cup remains 
stationary and the suspending pin rotates. The application of this method 
is largely restricted to estimate blood loss in operative settings and data 
about its utility in analyzing the effects of antiplatelet medications are 
limited (177). 
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1.9.18. Thromboxane generation 
Thromboxane A2(TXA2) was first described as a biologically active 
compound by Hambergin the year 1975. Its measurement in serum and 
urine has been employed to directly study the effect of aspirin on the 
platelets. TXA2 is produced by platelets in its active form and its local 
release recruits’ additional platelets to the site of clot formation via 
activation of platelet TP receptors. It is metabolized from AA by the 
coordinated action of COX-1 and TX synthase. As AA is derived via the 
COX-1 pathway, measuring TXA2 release gives an indirect assessment of 
the COX-1 pathway and aspirin’s effect on the same. TXA2 is rapidly 
converted to its active metabolite TXB2 in the serum. The stable urinary 
metabolite of TXA2 is called urinary 11- de-hydro TXB2 (179). 
 
1.9.18.1. Serum TXB2 
Immuno assay or mass spectrometry can be used to ascertain the level of 
TXB2 in the serum. This could either be measured in whole blood or in 
PRP. When measured in whole blood, serum is obtained by allowing 
blood to clot at 370 C for 30 minutes. Similarly, PRP is obtained after 
standardized procedures to induce platelet activation (179). 
 
1.9.18.2. Limitations of Serum TXB2 
The actual biosynthesis of TXA2 does not match the estimated 
biosynthesis and this forms an insurmountable source of artifact. This 
problem is overcome by measuring the stable metabolite TXB2. Two main 
metabolites that are validated for measurement includes 2, 3 dinor TXB2 
and 11-dehydro TXB2. Additionally, TXB2 levels may not be entirely COX-
1 specific. This is because the serum level of TXB2  is influenced by the 
prostaglandins that are by products of the leukocyte derived COX-2 (180). 
 
1.9.18.3. Urinary 11-Dehydro TXB2 Measurements 
Estimates of the urinary level of 11-de-hydroxy TXB2, a stable metabolite 
of TXB2 can also be used to assess the platelet activation in vivo. Neither 
the serum nor the urinary form is formed in the kidney and hence its 
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estimation in the urine is predominantly but not solely a non-invasive 
assessment of the serum TXA2 level. The plausible effect of renal function 
is precluded by measuring the ratio of urinary 11- dehydroTXB2 to 
creatinine (181). 
 
1.9.18.4. Advantages and Limitations of Urinary 11-Dehydro TXB2 
This is a simple noninvasive measuring tool. It is an indirect way of 
assessing in vivo thromboxane production and hence may not be platelet 
specific although it is aspirin specific. It is not suitable to monitor the 
effects of clopidogrel and GP IIb-IIIa inhibitors. There is a substantial 
discrepancy in the serum and urinary levels of TXB2 levels. At least 30% 
of the urinary TXB2 is obtained from extra platelet resource whose 
contribution increases during inflammatory states. The details of all PFT 
are summarized in table 1.7. 
 
Table 1.7: Summary of the PFT 
 
 
Principle PFT ASA Clop GP IIb-IIIa Inhibitor 
Platelet- Platelet 
Aggregation 
LTA Yes Yes Yes 
IPA Yes Yes Yes 
Plateletworks Yes Yes Yes 
VerifyNow Yes Yes Yes 
Shear Induced Platelet 
Adhesion 
CPA Yes Yes NR 
PFA-100 Yes NR NR 
Flow Cytometry 
VASP P2Y12 NR Yes NR 
P-Selectin Yes Yes Yes 
Platelet Contribution to 
Clot TEG Yes Yes Yes 
COX-1 Dependent 
Serum TXB2 Yes No No 
Urinary TXB2 Yes No No 
 
 
ASA= Aspirin 
Clop= clopidogrel 
NR= Non-Reactive 
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Table 1.8: Summary of the PFT that Measures the Effects of 
Aspirin(133) 
 
1. Thromboxane as the end point 
a. Serum TXB2 
b. Urinary 11- dehydro TXB2 
2. Arachidonic acid as the stimulus 
a. Turbidometric aggregometry 
b. Impedance aggregometry 
c. VerifyNow aspirin assay 
d. Plateletworks 
e. TEG platelet mapping system 
f. Impact cone and plate(let) analyser 
g. Platelet surface-activated glycoprotein IIb-IIIa, platelet surface P-  
selectin, leukocyte- platelet aggregates 
3. Others 
a. Platelet function analyser – 100
 
1.9.19. Tests to Monitor the Effects of Aspirin 
PFT that can monitor the effects of aspirin  belong to three main 
categories (133).  
1) Test that can measure thromboxane 
2) Test using AA as the agonist to stimulate platelet activation 
3) Tests that do not use AA to stimulate platelet activation, Table 1.8. 
 
 
1.9.20. Tests to Monitor the Effects of Clopidogrel (133) 
The tests to monitor the effects of clopidogrel can be classified in to two 
1) Tests that specifically measure inhibition of the P2Y12receptor 
2) Test that uses ADP to activate platelets and hence assess the effects of 
the drug on the contribution of the P2Y12 receptor to ADP-induced platelet 
responses 
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The disadvantage of the second method is that the ADP has two types of 
receptors namely P2Y1 and P2Y12. By measuring the overall effect on the 
ADP receptor, the precision of the test’s outcome to truly reflect the effect 
on P2Y12 receptor blockade is subjected to scrutiny. This is shown in table 
1.9. 
 
Table 1.9: Summary of the PFT to Study the Effects of Clopidogrel 
(133) 
 
1. P2Y12 specific test 
i. VASP phosphorylation test 
2. ADP stimulated tests 
i. Turbidometric platelet aggregation 
ii. Impedance platelet aggregation 
iii. VerifyNow P2Y12 assay  
iv. TEG platelet mapping system 
v. Impact cone and plate(let) analyser 
vi. Platelet surface activated GP IIb/IIIa platelet surface P- 
selectin 
vii. Leukocyte platelet aggregates 
 
 
1.9.21. Studies Linking the Clinical Outcomes and Level of Platelet 
Inhibition 
Several studies have been conducted using the above-mentioned platelet 
function testing tools that are done to see how a newer technique 
compares with the old conventional methods in the prediction of MACE. 
PCI related complications like stent thrombosis and periprocedural 
myonecrosis and bleeding complications. An overview of some of the 
studies that have been conducted that outlines the utility of the available 
platelet function testing tools to predict MACE have been briefed in table 
1.10 and 1.11.   
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Table 1.10: Studies Linking Clopidogrel Hypo responsiveness and 
Clinical Outcomes 
 
Methods Outcomes assessed Study 
Patient 
cohort P. No Ref 
LTA using 
ADP as 
agonist to 
study 
clopidogrel 
MACE up to 
30 days 
Frere et al NSTEMI/ACS/PCI 195 (182) 
Geisler et al CAD/PCI 1092 (183) 
Hochholzer et 
al Elective PCI 802 (184) 
MACE within 6 
months 
Gurbel et al Elective PCI 192 (185) 
Matetzky et al PCI/STEMI 60 (186) 
Geisler et al CAD/PCI 379 (187) 
Late MACE 
Up to 3 years 
Bliden et al Elective PCI 100 (188) 
Gurbel et al Elective PCI 297 (189) 
Migliorini et al PCI/DES/ULMD 215 (190) 
Periprocedural 
myonecrosis 
Gurbel et al Elective PCI 120 (191) 200 (192) 
Lev et al Elective PCI 150 (193) 
Cuisset et al NSTEMI/ACS/PCI 190 (194) 
Stent 
thrombosis 
(ST) 
Gurbel et al Stenting 120 (189) 
Buonamici et al PCI/DES 804 (195) 
VASP-PRI 
One-month 
MACE Bonello et al PCI/Stenting 144 (196) 
6-month 
MACE Bonello et al PCI/Stenting 162 (197) 
Stent 
Thrombosis 
Bonello et al PCI Stenting 214 (198) 
Barragan et al PCI 46 (199) 
Blindt et al High risk ST/PCI 99 (200) 
Cuisset et al NSTEMI/Stenting 598 (201) 
VASP –PRI Periprocedural Myonecrosis Cuisset et al 
NSTEMI/AC
S/PCI 190 (194) 
VerifyNow 
P2Y12 assay 
One-month 
MACE Patti et al PCI 160 (202) 
6 MACE 
including ST Price et al PCI 380 (203) 
One-year 
MACE 
Marcucci et al PCI/ACS 683 (204) 
Breet et al Elective PCI 1069 (205) 
Post PCI 
Myonecrosis 
Cuisset et al PCI/SA 120 (206) 
Valgimigli et al Elective PCI 1277 (207) 
Multiplate 
Platelet 
analyser 
One-month ST Sibbing et al PCI/DES 1608 (208) 
85 
 
Table 1.11: Summary of Clinical Studies Correlating Aspirin Hypo 
responsiveness and Adverse Cardiac Events 
 
 
Study Cohort N PFT Events monitored OR P 
Anderson et al(209) CAD 71 PFA -100 MI/Stroke/RV 1.8 .28 
Eikelboom et al(210) CVD 488 U TXB2 MACE (5y) 1.8 .01 
Gum et al(211) CVD 326 LTA MACE (2y) 2.9 .09 
Cotter et al(212) CAD 73 Serum TXB2 MACE (1y) 6.5 .01 
Cheng et al(213) CAD 422 ASA ARU MACE 2.9 .002 
Pamukcu et al(214) CAD 105 PFA -100 MACE ( 1y) 6.1 <.001 
Stejskal et al(215) CAD 103 LTA MACE (4y) 8.5 <0.001 
Chen et al(216) PCI 151 ASA ARU Periprocedure Myonecrosis 2.9 <0.004 
Lev et al(213) PCI 150 LTA ASA ARU 
Periprocedure 
Myonecrosis 2.9 .045 
Chu et al(217) ACS+/- PCI 314 VerifyNow MACE ( 6mon) 10.0  
Chen et al(218) Stable CAD 468 
VerifyNow 
ASA MACE(1Y) 3.12 0.003 
Marcucci et al(219) AMI +/-PCI 146 PFA-100 MACE (1Y)  <0.05 
 
1.9.22. Accuracy of Individual PFT to Predict Clinical Outcomes for 
Clopidogrel 
In a recent single centre prospective study of 1069 consecutive patients 
undergoing PCI, various platelet function test were conducted to 
determine their ability to accurately predict both ischaemic and bleeding 
end points in patients treated with clopidogrel. In this study, only LTA, 
VerifyNow P2Y12 assay and Plateletworks were significantly associated 
with the primary endpoint for ischaemic events. However, the predictive 
accuracies of these tests were only modest. None of the tests provided 
accurate prognostic information to identify low risk patients at high risk of 
bleeding following stent implantation. This study did not include the VASP 
P2Y12 assay and the Multiplate platelet analyzer (220). This is presented 
in table 1.12. 
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Table 1.12: Accuracy of Specific Platelet Function Test to Predict 
Clinical Outcomes for Clopidogrel 
 
 
Platelet Function Test P value AUC-ROC 
LTA 20 µmol/L 0.001 0.63 
Verify Now P2Y12 <0.001 0.62 
Plateletworks 0.001 0.61 
PFA-100 Collagen/ADP 0.15 0.50 
Innovance PFA P2Y 0.27 0.56 
IMPACT–R ADP Stimulated 0.83 0.53 
 
 
PFT has only modest ability to predict ischaemic events. The reasons for 
this are multifactorial and the main issue is the inability of any single PFT 
to assess platelet function precisely. This is contributed by the fact that in 
vitro PFT does not reflect what happens in vivo.  This can be overcome by 
using native blood instead of using citrated or anticoagulated (heparin, 
thrombin inhibitors) blood. Secondly thrombus formation is a complex 
process that happens in a high shear state augmented by many stimuli 
including thromboxane, ADP and thrombin. Hence PFT should be done 
under high shear conditions with the agonist that can stimulate the 
receptor globally. Currently none of the PFT offers this combination. Also, 
clear definition of safety/efficacy threshold and evaluation of clinical 
usefulness is lacking for any test. Timing of the PFT also is crucial. In an 
ASC setting which is an inflammatory process, patients receive a 
combination of antiplatelets and anticoagulants at varying dose. Hence 
PFT performed at this clinical scenario might not reflect the underlying 
platelet activity of that individual accurately which is not ideal to predict his 
future ischaemic events. The common shortcoming of all point –of-care 
PFT is that they use different agonists in separate cartridge to assess 
different platelet receptor antagonists. In order to monitor DAPT, 4 agonist 
namely ADP, AA, collagen and thrombin should be measured 
simultaneously  (221) 
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1.9.23. Accuracy of Individual PFT to Predict Clinical Outcomes for 
Aspirin 
In a recent study conducted on 951 consecutive patients who underwent 
PCI, PFT specific for inhibition of the COX-1 pathway were used to assess 
HPR to aspirin and clinical outcomes both ischaemic and bleeding. Only 
platelet function tests based on aggregation like the LTA and VerifyNow 
ASA assay correlated well with predicting ischaemic events. Shear-based 
tests like PFA-100 and Impact-R AA did not show statistically significant 
results. None of the tests were capable of predicting bleeding events, 
either major or minor (222, 223). The results are summarized table 1.13. 
 
Table 1.13: Correlation of PFT’s Ability to Predict Adverse Cardiac 
Events for Aspirin 
 
Platelet Function Tests P value AUC 
LTA 0.03 0.73 
VerifyNow ASA Assay 0.02 0.78 
IMPACT-R AA 0.94 0.72 
PFA-100 Collagen/Epinephrine 0.44 0.72 
 
 
1.9.24. Risk Stratification Based on PFT 
One of the approaches that has been widely  recognized to combat the 
hypo or hyper responsiveness to the available antiplatelet medications 
particularly clopidogrel and aspirin is an individually tailored approach to 
assess the risk for ischaemic and bleeding events based on PFT (208). 
Although this approach seems logical, only very limited data are available 
to justify such an approach towards better patient care. The preliminary 
studies conducted by Boneilloet al (197),and Fontana et al (224), have 
shown some promising results. Larger, well designed multicentre trials 
that address this issue are needed (102). Never-the-less such an 
approach has some limitations (80). 
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1.9.25. Limitations of the Risk Stratification Based on PFT 
Although several PFT are in existence there is only moderate correlation 
amongst them which makes their overall use very difficult. For a particular 
test there has been varying definitions or cut-off values that determine an 
individual to be poor responder for a specific antiplatelet medication. The 
recent consensus document published by ACC tries to resolve this issue 
atleast with clopidogrel. However, their validity in general and in high risk 
individuals (like the high-risk ACS and diabetics) in particular is still 
questionable. Moreover this does not address the issue with aspirin (102). 
Additionally, the relationship between platelet inhibition and bleeding risks 
needs further investigations. This is particularly important as bleeding has 
been identified as an independent risk factor for mortality and morbidity in 
individuals treated with antiplatelet medications for ACS (225). Moreover 
as discussed before there is no consensus about the best test available 
and with the cornucopia of the options available choosing the best test still 
remains an area of great debate and confusion (80). Considering these 
factors a general implementation of PFT as a standard approach in the 
treatment algorithms for ACS is not recommended in any  international 
guidelines (ACC,AHA) (226). 
 
 
1.9.26. PFT- Current Status 
The GRAVITAS (Gauging Responsiveness with A VerifyNow assay-
Impact on Thrombosis And Safety) study that enrolled 5429 patients on 
standard dose of clopidogrel underwent PFT with VerifyNow assay 12 to 
24 hours post PCI. Patients (41%), who demonstrated high residual 
platelet activity (PRU ≥ 230), were randomized to receive another 600 mg 
loading of clopidogrel with 150mg maintenance and the rest continued 
standard treatment. Majority of these patients were relatively at low risk 
and had stable coronary artery disease. At six months of follow-up, the 
composite end points of cardiovascular death/MI/stent thrombus were 
identical in both groups at 2.3%. Stent thrombosis occurred in 0.5% of the 
high-dose group and 0.7% that was not significant. There was no 
difference in bleeding. The absolute platelet reactivity was reduced from 
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an average of about 280 PRU at baseline to 200 PRU in the high-does 
clopidogrel group, vs.240 PRU in the standard-dose group. Despite a 
reduction in the platelet reactivity, there was no clinical benefit obtained by 
doubling the dose of clopidogrel in this study. The reasons for this could 
be that, the study populations were of low risk category. The study was 
not adequately powered to pick up event rates. The reduction in platelet 
reactivity obtained was only modest and not sufficient enough to reduce 
ischaemic events supported by the fact that there was no increased 
incidence of bleeding in this study. A much aggressive reduction in platelet 
reactivity can be a strategy that could be adopted in future studies. Also, in 
this study only one PFT was conducted, may be an alternative PFT could 
also be employed to see if the outcomes would be consistent. From the 
GRAVITAS we learned that when a patient is not responding to 
clopidogrel doubling the dose of clopidogrel although is safe is not efficient 
enough. Employing another much potent antiplatelet like prasugrel or 
ticagrelor would be a better choice (227-229). 
The TRIGER–PCI (Testing Platelet Reactivity In Patients Undergoing 
Elective Stent Placement on Clopidogrel to Guide Alternative Therapy 
With Prasugrel) study compared prasugrel with clopidogrel in patients with 
HPR after elective PCI with DES. HPR was assessed with VerifyNow test 
and a cut-off of < 208 PRU was used to define HPR. Patients were then 
randomized to receive 10 mg of prasugrel or 75 mg of clopidogrel and 
were followed up at 3 months and 6 months. In 212 patients who received 
prasugrel the PRU decreased from a baseline of 245 PRU to 80 PRU at 3 
months. In 211 patients who took clopidogrel the HPR reduced to 241 
PRU form a baseline of 249 PRU. At 6 months efficacy end point occurred 
in no patients on prasugrel and happened in one patient on clopidogrel. 
Major bleeding at 6 months occurred in three patients in prasugrel and in 
one patient on clopidogrel. The study was terminated early due to less 
than anticipated efficacy end points (230). 
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The ARCTIC Study aimed at the evaluation of PFT guided dose 
adjustment in sub optimal responders compared to a more conventional 
strategy without monitoring and without dose adjustment to reduce 
primary end points after 1 year in patients who underwent PCI and had a 
DES implanted. 2466 patients with stable angina/ ischaemia or NSTEMI 
undergoing PCI with DES were enrolled. PFT with VerifyNow assay was 
performed at the time of PCI and repeated 2 to 4 weeks after PCI.  600 
mg of loading clopidogrel with 150 mg of maintenance was compared to 
10 mg of prasugrel. After one-year primary efficacy end point were 31.6% 
in clopidogrel vs. 31.1% in prasugrel group P= 0.10. Major bleeding 
happened in 2.3% in clopidogrel compared to 3.3% in prasugrel (P= 0.12) 
(231) 
The ANTARCTIC study enrolled 877 patients aged 75 years or more.  All 
underwent coronary stenting with DES. All patients received 5 mg of 
prasugrel. 442 patients were randomized to no dose adjustment and the 
remaining 435 to monitoring and treatment adjustment. VerifyNow assay 
was used to define HPR (208 PRU).  PFT was performed on day 14 in the 
monitoring arm. Depending on their platelet reactivity they were either left 
on 5 mg of prasugrel, or changed to 75 mg of clopidogrel if showed low 
platelet reactivity below the range or the dose of prasugrel was increased 
to 10 mg if they demonstrated high platelet reactivity. For patients who 
had dose adjustment made, PFT was repeated again on day 28. The 
primary end point of the trial was the composite of cardiovascular death, 
MI, stroke, stent thrombosis, urgent revascularization, and further bleeding 
complication at 1 year. This end point occurred at a similar rate in both 
arms of the study: 27.6% in the monitoring group and 27.8% in the 
conventional group (HR 1.003, 95% CI 0.78–1.29; P=0.98). There was 
similarly, no significant difference in rates of the main secondary end point 
(a composite of cardiovascular death, MI, stent thrombosis, or urgent 
revascularization), which occurred in 9.9% and 9.3%, respectively (HR 
1.06, 95% CI, 0.69 to 1.62; P=0.80). Rates of major bleeding, minor 
bleeding, or either type of bleed also did not differ between the two groups 
(232). 
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A class IIb recommendation with level-C evidence is given for potentially 
high-risk situations, including suspicion of resistance to treatment or high 
bleeding risk. After the ANTARCTIC study whether this recommendation 
would be modified needs to be watched for. A class IIa recommendation 
with level C evidence was issued for platelet-function monitoring to guide 
antiplatelet interruption before coronary arterial bypass graft surgery. This 
recommendation would also deserve a specific randomized study (233). 
The ARCTIC demonstrated that there no benefit in PFT monitored 
modification of antiplatelet agent in low risk ACS patients. In the 
ANTARCTIC a similar strategy in high risk individuals is also not 
beneficial. The latest 2014 and 2016  ACC guidelines do not recommend 
the routine use of platelet-function test before or after stenting ( class III 
LOE A) (234). 
1.9.27. Cost Effectiveness of PFT 
The cost saving potential of individualizing antiplatelet therapy remains to 
be determined. Cost-effectiveness in such situations must include both 
cost saving driven by the use of generic clopidogrel and the cost 
associated with adverse events including bleeding and thrombotic 
complications (235). Straub et al. studied the economic impact of 
personalized antiplatelet treatment based on PFT with Multiplate analyzer 
as opposed to unrestricted use of prasugrel and ticagrelor ACS patients 
undergoing PCI. He found that PFT guided therapy with clopidogrel is cost 
effective compared to the routine use of prasugrel or ticagrelor (generic 
clopidogrel id 20 times less expensive compared to prasugrel and 
ticagrelor) and reduces the incidence of adverse events in clopidogrel 
treated patients (236). This concept is now being tested in a large 
multicenter trial the TROPICAL-ACS study. This aims to switch patients 
between clopidogrel and prasugrel based on the Multiplate analyzer test. If 
this study meets its end point the, the tailored antiplatelet therapy will carry 
a significant cost saving potential alongside the benefit to the patients 
(237). 
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1.9.28. Summary of PFT 
The main aim of PFT is to indicate bleeding and thrombotic risk both in 
natural and iatrogenic settings. Despite the field’s advancement the quest 
for the ideal test continues. No particular test has gained wide acceptance 
and been recommended for routine use in clinical practice. LTA is no 
longer considered to be a gold standard test at least to test for HPR to 
ADP (102). Traditional impedance aggregometry has been subjected to 
very limited studies to assess its utility to foresee such conditions. The 
new point-of-care tests look promising; however, large multicentre 
randomized trials are highly needed to support its routine use. Flow 
cytometry techniques are definitely a major revolution that has the 
potential of being turned into the ideal test-but it is labour intensive and 
can be at best a research tool rather than a clinical tool. 
 
1.10. Cardiac Troponins 
Cardiac specific troponins play a crucial role in the diagnosis and risk 
stratification of ACS patients. Troponin is a protein complex of three 
subunits (T, I, C) that is involved in the contractile process of skeletal and 
cardiac muscle. Troponin C is expressed both in cardiac and skeletal 
muscle. Troponin T (cTnT) and I (cTnI) are generally considered to be 
cardiac specific. Indeed, cTnT has not been identified outside the 
myocardium. cTnT and cTnI are cardiac regulatory proteins that promote 
the calcium-mediated interaction between actin and myosin. 
Cardiac troponins are detected in the serum by the use of monoclonal 
antibodies to epitopes of cTnI and cTnT. When cardiac injury occurs, 
troponins are released from cardiomyocytes. Troponin levels increases 
within 3 to 4 hours after the onset of damage and remain high for up to 4 -
7 days in case of cTnI or 10 to 14 days for cTnT. 
Analysis of troponin provides diagnostic and prognostic information in 
patients with ACS.  Cardiac troponins also offer clinicians a valuable tool 
for therapeutic decision making. ACS patients who are troponin positive 
are more likely than troponin negative patients to have more complex 
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lesions with greater thrombus burden, a greater propensity for platelet 
embolization and distal microvascular obstruction as well as depressed LV 
function. 
For diagnosis of ACS, a stipulated rise in cardiac troponin is necessary. 
Previous guidelines recommended that a change of 20% at 3 to 6 hours 
from a previous sample is necessary for diagnosis with sampling at 
baseline, approximately 6 to 9 hours later and again between 12 and 24 
hours from the baseline. Newer studies have supported more rapid 
algorithms even employing a change between baseline and 1 hour later. 
An elevated troponin level that is relatively constant over an appropriate 
sampling interval is more likely to be caused by chronic diseases like renal 
failure, heart failure etc. Although the recommended change in troponin is 
suggestive of acute myocardial injury, it does not discriminate acute injury 
as a result of ACS from other causes of acute myocardial injury 
(pulmonary embolism or myocarditis). Hence troponin evaluation should 
be performed only if clinically indicated and elevated troponin must be 
interpreted in the context of the clinical presentation. 
 
1.11. Study aims 
 To describe the variability in response to clopidogrel between 
individuals and its potential clinical relevance using WBSPCA 
 To describe the variability in response to aspirin between 
individuals and its potential clinical relevance using WBSPCA. 
 To assess the inhibition of thromboxane A2 generation by aspirin in 
patients with ACS and obtain pilot data for the relative clinical 
importance in terms of safety and efficacy. 
 To validate further the utility of WBSPCA in patients with ACS. 
 To assess the relationship with post PCI myonecrosis and level of 
inhibition of platelet function at the time of the intervention in 
patients with ACS 
 To assess the relationship between levels of inhibition of platelet 
function and changes in inflammatory markers over time in patients 
with ACS. 
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Chapter 2: Methods and Materials
 
2.1. Preface 
This chapter has been structured in such a way that all necessary 
information regarding experiments conducted, other tests performed and 
statistical analysis for the whole document are all explained in this chapter 
in a sequential manner. No repetition of the information is provided in 
other chapters unless it is relevant to do so. 
2.2. Patients 
This is a prospective single centre study. Patients admitted to Northern 
General Hospital, Sheffield from November 2005 until November 2007 
with a diagnosis of ACS including UA, NSTEMI and STEMI were included 
in this study.  The following baseline data were recorded for all patients: 
age; sex; risk factors for CAD, including family history; hypertension; 
diabetes mellitus; smoking history; antiplatelet therapy used prior to 
admission; previous history of CAD; previous history of CVD; previous 
history of haemorrhage or peptic ulcer disease. History and duration of 
chest pain, cardiac enzyme levels including troponin and CK-MB, 
electrocardiogram (ECG) changes, chest X-ray findings and 
echocardiogram findings if available were collected for all patients. Co-
medications administered to the patients other than antiplatelets and other 
antithrombotics were also collected. 
Written informed consent was obtained from all patients according to a 
protocol approved by the North Sheffield Research Ethics Committee 
(REC), reference number NS2003 11 1800 (Appendix 1). As the period of 
the study was extended for follow up to 12 months, the appropriate 
amendments to the consent form were made in agreement with the 
Central Office of Research Ethics Committee (Appendix2). 
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2.3. Inclusion Criteria 
 All patients who were able to give written informed consent  
 Patients who were admitted to hospital for ACS and received both 
aspirin and clopidogrel as part of their standard treatment. 
2.4. Exclusion Criteria 
 Patients who had active infection, inflammatory or autoimmune 
conditions. 
 Patients who were on steroids or immunosuppressive treatment. 
 Platelet count of < 125,000/mm3. 
2.5. Study Design 
The study was designed as two phases. In the first phase patients with 
ACS who were treated with aspirin and clopidogrel were selected. They 
underwent PCI if that was the treating physician’s decision, but there were 
a substantial number of patients who were managed medically without 
intervention. For the phase one patients’ only platelet aggregation studies 
with WBSPCA was performed. In phase two, patients with ACS who 
received aspirin and clopidogrel and were planned for PCI were included. 
For these patients both WBSPCA and LTA were performed and blood was 
collected for analysis of inflammatory markers. The results of troponin 
measurements done as part of their routine treatment were simultaneously 
collected. All patients were followed up for 12 months. 
2.5.1. My Role in this Project 
The study protocol was written by Professor Storey and request for ethical 
approval was obtained by him. My role involved identifying the suitable 
patients for the study, performing the study procedures and collating and 
analyzing the results. Firstly, this included screening patients on 
presentation in the casualty and patients admitted to the cardiology ward 
at the Northern General Hospital including coronary care unit. 
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Once the right patient was identified who met the inclusion and exclusion 
criteria, they were approached and written informed consent was 
obtained. Then blood was collected from these patients according to the 
study protocol. 
 I then conducted platelet aggregation studies in the lab. In the research 
lab, my role involved preparing the agonist at the specified dilution and 
storing them in the freezer for later use. Conduction of WBSPCA assay on 
the samples and of course cleaning the lab equipment used to enable 
other candidates to perform their study. The data obtained from the 
experiments were entered electronically on the same day for analysis at a 
later date. Any spurious results were discussed with Professor Storey, or a 
member of his laboratory team for any error in the conduction of the 
experiment. 
 For the second phase of the study, blood was collected from patients who 
underwent coronary stenting. It involved waiting in the cath lab for the 
diagnostic angiogram to be over. Once the patient was found to have a 
lesion requiring stenting, blood was collected before the administration of 
heparin. Hence all patients undergoing angiogram were consented, but 
only those who had a stenting procedure done were taken for the study. I 
conducted both WBSPCA and LTA on these patients. Blood samples 
collected for inflammatory markers were centrifuged and stored in the 
freezer for later analysis. 24 hours later from the time of PCI, blood was 
collected for troponin analysis, and inflammatory markers. This involved 
stepping in over the weekend. A pot was given to the patient to collect 
their early morning urine sample, and these samples were collected from 
them and stored in the freezer for later analysis 
 Clinical details about the patients were collected from the medical 
records. Information regarding their intervention was obtained from the 
hospital cathlab database Infoflex. Follow-up of the patients involved 
telephoning them at one month, three months and 12 months for any 
ischaemic and bleeding complications. Their compliance to medications 
was also checked during these phone calls. All steps were taken to ensure 
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that the patients were alive before calling them which involved, checking 
the hospital database for their last attendance and calling their respective 
general practitioners for any reported/documented death. All the 
information collected was entered into an electronic database. 
Statistical analysis was done by me, taking advice from Professor Storey 
about the type of statistical test to be used. I am also thankful to Dr. 
Saiganesh, biostatistician and epidemiologist for his input in advising the 
best analysis to be performed. I spent a lot of time learning basic statistics, 
and attended tutorials about the usage of SPSS and PRISM software.  I 
also enhanced my experience with Microsoft Word and Excel software 
To summarize, my role in this work was substantial that involved recruiting 
patients, collection of samples, conduction of experiments, collection of 
data in hard copy, follow up through telephone calls, data entry into Excel 
sheets, data analysis and interpretation of results and writing up of the 
work done. 
 
2.6. Sample Collection 
2.6.1. Blood Collection for Assessing the Effects of Aspirin and 
Clopidogrel by WBSPCA 
 At baseline, 10 ml venous blood was collected from the antecubital fossa 
using a 19G - 21 G needle and syringe and anticoagulated with hirudin for 
platelet function testing analysis.  The timing of this sample collection was 
dependent on the dose of clopidogrel given. Blood samples were collected 
at least 24 hours, 48 hours and 5 days following 600mg loading dose, 300 
mg loading dose and 75 mg daily maintenance dose respectively.  These 
time points reflect the time taken for the drug to reach steady state 
inhibition of platelets (33). Hence samples may have been taken at later 
time points but not less than the time points mentioned above.  According 
to the study protocol it was mandatory to ensure that samples were 
collected once steady state of platelet aggregation inhibition was 
achieved. This was accomplished by ensuring, that samples were taken at 
least 24 hours later if 600 mg loading dose of clopidogrel was given, and 
at least 48 hours later if 300 mg loading dose of clopidogrel was given. 
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Care was taken that all continued with 75 mg of maintenance dose. 
However, no emphasis was given about the duration of exposure to study 
medications (aspirin/clopidogrel) particularly whether exposure was long-
term or short term. Moreover, as the sample size was small and patients 
received various dose of medications for varying period it was difficult to 
categorize them into group.    
Careful precaution was taken to ensure that the effect of other 
antiplatelets/anticoagulants (glycoprotein inhibitors (GPI), thrombolytic, 
intravenous (IV) heparin) did not influence the PFT done for clopidogrel. IV 
heparin has a modest effect on platelet function and the effects wear off in 
2 hours from stopping the infusion. Thrombolytic agents may have some 
weak effect for 24 hours. Abciximab is a monoclonal antibody that binds 
noncompetitively with high affinity to the GP IIb/IIIa receptor. The 
biological half-life of this agent is 2 hours and it takes 8-12 hours for 
restoration of normal haemostatic function. Eptifibatide is a peptide that 
competitively inhibits the GP IIb/IIIa receptor. The plasma elimination half-
life is approximately 2.5 hours. 3-4 hours is needed for normalization of 
haemostatic function. Tirofiban is a nonpeptide that competitively inhibits 
the GP IIb/IIIa receptor with high specificity and low affinity. The plasma 
half-life of tirofiban is short (1.6 hours). After 4 hours the haemostatic 
function returns to normal (238). Samples were collected keeping these 
time points as reference. Another 3ml of blood was collected into a serum 
tube and allowed to clot at room temperature. The serum was separated 
and stored at - 20ºC for analysis of serum TXB2. 
 
2.6.2. Blood Collection for Assessing the Effects of Clopidogrel by 
LTA and WBSPCA 
After informed consent, 20 ml of blood was collected from the arterial 
sheath before any interventional procedure and before heparin was given. 
The first 3ml of blood was always discarded. 8ml of blood in a polystyrene 
tube (Sarstedt) was anticoagulated with 80µl of hirudin for WBSPCA and 
another 8ml of blood in a separate polystyrene tube was anticoagulated 
with 80µl of hirudin for LTA analysis. 
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2.6.3. Blood Collection for Assessment of Inflammatory Markers 
Blood for assessment of plasma levels of sCD40L and CRP was collected 
in a blue top Vacutainer (BD biosciences) tubes. These tubes contained 
0.109M sodium citrate; an inhibitor of platelet aggregation. Within an hour 
of collection, the samples were centrifuged at 1500 g for 15 minutes and 
the plasma removed. The separated plasma was stored at -80º C for 
analysis of CRP and sCD40L at a later stage. The samples were collected 
at baseline before PCI and 2-4 hours and 18-24 hours following PCI.  
Another 5ml of blood was collected in a serum tube and allowed to clot at 
room temperature. The serum was separated using a pipette and stored at 
-80ºC for analysis of inflammatory markers, namely tumour necrosis 
factor-α (TNF-α) and IL-6.  
2.6.4. Blood Collection for Troponin-T Analysis 
No blood was collected for analysis of cTnT. As part of the hospital 
protocol cTnT was routinely measured in all patients who underwent PCI. 
Assays were done at baseline at the time of presentation and at 18-24 
hours post PCI. The available information was utilized with the consent of 
the treating physician and the patient. 
2.6.5. Collection of Urine Sample 
Early morning urine samples were collected in sterile sample pots. 
Aliquots of urine were frozen at -80ºC within an hour of collection for 
analysis of 11-dehydro TXB2. 
2.7. Materials 
Hirudin, a potent thrombin inhibitor used as an anticoagulant for the study, 
was a gift from Novartis. This was a recombinant desulphato hirudin 
(Revasc). 5µg of hirudin was diluted with 3ml of 0.9% saline. 10 mL of 
whole blood was anticoagulated with 100µl of hirudin. Hirudin was 
preferred over citrate as it prevents artefactualTXA2 formation that 
happens with citrate(239). ADP and AA were from Sigma. AA is from 
Sigma.  Fixing solution (Solution A) consisted of saline with 4.6 mM 
sodium EDTA, 4.5 mM Na2HPO4, 1.6mM KH2PO4 and 0.16% (w/v) 
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formaldehyde, pH 7.4. Other materials used included polystyrene tubes, 
magnetic stir bars, water bath at 37ºC. Normal saline was used as diluents 
for the reagents. A Sysmex KX21 haematology analyzer was used for 
platelet counting. Materials used for LTA includes Biodata-platelet 
aggregator profiler (PAP)-4 optical aggregometry, chart recorder, LP3 
tubes, large magnetic stir- bars and centrifuge. 
2.8. Methods 
Concentrations of 0.3,1,3,10 and 30µmol/L ADP were prepared by 
diluting, 100µmol/L ADP with 0.9% saline at the required proportions. 
Similarly, concentrations of 0.1, 0.2, 0.4, 0.8, 1mM of AA were prepared 
by diluting AA with the required volume of normal saline. 
2.8.1. Whole Blood Single Platelet Counting Assay for Clopidogrel 
 10 mL of whole blood was transferred into a polypropylene tube 
containing 100µL of hirudin and mixed by gentle inversion and transferred 
to the lab, carefully avoiding any physical stimulation of the platelets 
 The blood was incubated in a preheated water bath at 37 ºC 
 6 LP3 polystyrene tubes were filled with 20µL of increasing 
concentrations of ADP (0.3, 1, 3, 10, 30,100µmol/L) along with small 
magnetic stir bars and placed in a stirring water bath (stirring speed 
1000rpm) 
 Aliquots (480µL) of whole blood taken from the anticoagulated 
sample (by using a double pipetting technique) was added to each tube 
containing ADP and magnetic stir bar and allowed to interact with the 
agonist at set time points. 
 At 30 seconds, 20µL of blood from each concentration of ADP was 
removed and added with 40µL of solution A which arrests the interaction 
of blood with the agonist 
 At 2 minutes 20µL of 30ADP was removed and fixed with 40µL of 
solution A 
 At 4 minutes 20µL of the blood from each concentration of ADP 
was removed and fixed with 40µL of  solution A 
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 The samples thus obtained are added with 460µL of cell pack 
buffer to make the volume of the sample to 520µL enabling analysis in the 
Sysmex analyser.  
 The number of platelet and RBC in the whole blood sample is 
obtained by adding 20µL of whole blood with 500µL of cell pack buffer and 
processing in the Sysmex analyser. 
 The RBC count is used to adjust the platelet count for variations 
between samples (e.g. irregular mixing) by the following formula, Adjusted 
platelet = sample platelet x (Whole Blood RBC/ sample RBC). Aggregation 
can then be expressed as a percentage. 
 % Aggregation = 100 x (Whole Blood Platelet - Adjusted Platelet) 
Whole Blood Platelet   
RBC = Red Blood Count. 
The percentage of aggregation for each concentration of ADP (0.3, 1, 3, 
10, 30, 100µmol/L of ADP) was thus determined after 30 seconds and 4 
minutes. 
2.8.2. Whole Blood Single Platelet Counting Assay for Aspirin 
The same protocol as above was followed but except for step 3, where 
increasing concentrations of AA (0.1, 0.2, 0.4, 0.8, 1mM) were added 
instead of ADP. Percentage of platelet aggregation in response to aspirin 
was thus determined.  
2.8.3. Light transmission aggregometry 
 PRP was prepared by centrifuging whole blood at 200g for 12 minutes at 
room temperature. The PRP thus made was stored in a caped polystyrene 
tube at room temperature. 
 Platelet poor plasma (PPP) was prepared by centrifuging the residual 
blood at 1500g for 10 minutes. 
 The platelet count in the PRP was analysed using a platelet analyser. A 
platelet count of 300 000 platelets/µL was acceptable. If the platelet count 
was more than 400 000 platelets/µL it was diluted to approximate a count 
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of 300,000/mm3 by adding PPP. Samples with a PRP platelet count of < 
200,000/mm3 were not considered for analysis. 
 2, 5 and 20 µmol/L concentrations of ADP were prepared by mixing 
100µmol/L of ADP in normal saline at required dilutions. 
 The optical aggregometer is warmed at 37ºC and set to stir at a speed of 
900 rpm 
 The chart recorder is set at 10 mv and 3cm/minute speed 
 LP3 tube containing 500µl of PPP is placed in one well 
 Three LP3 tube with 480µl of PRP along with magnetic stir bars were 
placed in three consecutive wells. 
 All the tubes containing PRP and PPP were warmed for 1 mint. 
 At 15 second intervals the tubes were transferred to the front wells and 
baseline tracing of LTA before adding the reagent was recorded for one 
minute and observed for any oscillations and stability. 
 30µl of 2, 5, 20µmol/L concentration of ADP were added to the three tubes 
with PRP 
 Platelet aggregation was recorded for 5 minutes 
 Maximum percentage of platelet aggregation and the percentage of 
platelet aggregation at the end of the monitoring period (5th minute) were 
recorded 
 Care was taken that all aggregation studies were performed within 2 hours 
of the preparation of the PRP. 
Note: One patient had a platelet count of 598 in the PRP. 1.7ml of PPP 
was added to the PRP to make the platelet count 300,000/mm3. Three 
samples had a platelet count less than 300,000/mm3 but more than 
200,000/mm3 hence considered for analysis. 
2.8.4. Measurement of Serum TXB2 
Serum TXB2 was measured using a commercially available ELISA kit 
(Cayman Chemical Company, Michigan, and USA). Serum samples were 
centrifuged at 2000 g for 10 minutes and stored at -20ºC for analysis at a 
later stage. The manufacturer’s guidelines for assessment were adhered 
to. 
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2.8.5. Measurement of cTnI 
 cTnI was measured by the hospital laboratory according to its standard 
clinical protocol. The assay used was the ADVIA Centaur cTnI assay and 
were carried out using serum samples. The assays were able to measure 
cTnI concentrations up to 50ng/ml with lower limit of detection of 0.1ng/ml. 
2.8.6. Enzyme Linked Immunosorbent Assay Test 
Blood for inflammatory markers were collected 30 minutes before PCI 
and, 2-4hours and 18-24 hours after PCI. These time points were selected 
on the basis of previous evidence (240). Inflammatory markers sCD40L, 
IL-6 and TNF-α were measured with enzyme linked immunosorbent assay 
(ELISA) kit from Bender MedSystem (Burlingame, California). Plasma 
samples were used to measure IL-6 (BMS213), TNF-α (BMS223/3) and 
sCD40L (BMS293) with ELISA. Assays were performed in accordance 
with manufacturer’s guidelines.  
2.8.7. Measurement of Urine 11-Dehydro TXB2 Levels 
Urine samples were analyzed by commercially available ELISA kit 
(Cayman Chemical Company, Michigan, USA) for estimation of 11-
dehydro TXB2 levels. 
 
2.9. Definitions 
2.9.1. Clopidogrel Responders and Non-Responders 
At the beginning of 2005 when this study was started, there was a lack of 
consensus regarding clear definition about clopidogrel resistance. In fact, 
the terminology of clopidogrel resistance by itself was not universally 
accepted and alternative terminologies were used like clopidogrel hyper-
responders, hypo-responders and clopidogrel resistance. However, by 
2010 a clearer definition on the terminology namely high on therapy 
platelet reactivity (HPR) was postulated and accepted. Similarly, a clear 
cut of value for individual test to define HPR for P2Y12 blockade was 
proposed by Bonello et al based on numerous studies using receiver 
operating characteristic (ROC). The consensus values for HPR for various 
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PFT are (1) >46% maximal for a 5-µmol/L ADP-induced aggregation; (2) > 
50 % PRI using the platelet VASP test; (3) 230-240 PRU by VerifyNow 
P2Y12 assay (241). 
However, defining clopidogrel hypo- and hyper responders based on 
WBSPCA was difficult given the fact that there was no agreed upon cut-off 
value, and this tool has been studied less compared to other PFT. For 
WBSPCA, the principal measurement for all analyses was percentage 
platelet aggregation at 4 minutes after the addition 10µmol/L of ADP to 
whole blood. Clopidogrel responders were defined as those who had a 
percentage of platelet aggregation < 60%. Non-responders were defined 
as those whose percentage of platelet aggregation was ≥ 60%. 
For LTA, the principal measurements for all analyses were the final 
platelet aggregation response at 6 minutes after the addition of ADP 
5µmol/L, and the maximum aggregation response after the addition of 
ADP 20µmol/L. For ADP 5µmol/L, clopidogrel responders were defined as 
percentage of platelet aggregation < 14% and non-responders as those 
whose percentage of platelet aggregation was ≥ 14%. For 20µmol/L of 
ADP, patients with a percentage of platelet aggregation < 50% were 
defined as responders and ≥ 50% were defined as non-responders. 
2.9.2. Aspirin Responders and Low-Responders 
Aspirin responders were defined as patients whose percentage of platelet 
aggregation was < 30% measured at 4 minutes with 0.8mM AA assessed 
by WBSPCA. Likewise, low-responders were defined as percentage of 
platelet aggregation ≥ 30%.  
2.9.3. PCI Related Myonecrosis 
The 2012 Third Universal Definition of MI formulated by a joint 
ESC/ACC/AHA/World Health Federation task force arrived at the following 
definition. MI associated with PCI is arbitrarily defined by elevation of cTn 
values >5 x 99th percentile upper reference limit (URL) in patients with 
normal baseline values (≤99th percentile URL) or a rise of cTn values >20 
% if the baseline values are elevated and are stable or falling. In addition, 
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either (i) symptoms suggestive of myocardial ischaemia, or (ii) new 
ischaemic ECG changes or new LBBB or (iii) angiographic loss of patency 
of a major coronary artery or a side branch or persistent slow- or no-flow 
or embolization, or (iv) imaging demonstration of new loss of viable 
myocardium or new regional wall motion abnormality are required. The 
incidence of periprocedural MI using this new definition has not yet been 
well described (242). 
The above-mentioned definition was clearly not in existent when the study 
was conducted and hence no information regarding the symptoms, ECG 
findings and angiographic findings of the study population is available. For 
the study purpose periprocedural MI is defined as elevation of cTn values 
>5 x 99th percentile upper reference limit (URL) in patients with normal 
baseline values (≤99th percentile URL) or a rise of cTn values >20 %if the 
baseline values are elevated and are stable or falling. 
 
2.9.4. Ischaemic Events 
An Ischaemic event for the study is defined as death due to cardiovascular 
cause, non-fatal MI including NSTEMI and STEMI and ischaemic stroke. 
Procedure related complications like in-stent restenosis and stent 
thrombosis were also included. Troponin elevation following PCI was not 
taken as ischaemic events unless patient developed clinical symptoms of 
ACS supported by ECG and angiographic findings. 
 
2.9.5. TIMI Major and Minor Bleed 
Thrombolysis in Myocardial Infarction (TIMI) major bleeding is defined as 
a drop in haemoglobin >5g/dL (with or without an identified site), 
intracranial haemorrhage or cardiac tamponade. TIMI minor bleeding is 
defined as a haemoglobin drop of > 3 g/dL but ≤ 5g/dL, with bleeding from 
a known site or spontaneous gross haematuria, haemoptysis or 
haematemesis. For study purposes, bleeding was entirely assessed using 
the TIMI criteria. However, more up-to-date bleeding classifications are 
now being adopted. 
106 
 
In 2011, the Bleeding Academic Research Consortium (BARC) published 
a consensus classification for bleeding. BARC has been prospectively 
validated and BARC type 2, 3, or 5 bleeding is associated with increased 
one- and two-year mortality. In addition, BARC has a comparable 
predictive ability to the TIMI and GUSTO (Global Utilization of 
Streptokinase and TPA for Occluded Arteries), scales. While not 
universally accepted, BARC provides a contemporary standard and has 
been commonly used in clinical trials published after 2013 (243). However, 
BARC bleeding classification refers to procedure related bleeding 
complications when antithrombotic medications are given. 
 
2.10. Telephone Interview 
Patients were followed up for a total of 12 months (at 30 days, 3 months 
and 12 months) through telephone interviews and routine outpatient visits. 
Information regarding recurrent ischaemic events and bleeding 
complications were collected and compliance with clopidogrel was 
established through these telephone interviews. When telephone interview 
was not possible, information was collected from medical records and 
hospital database. All efforts were taken to confirm that the patient was 
alive before contacting them through telephone by checking in the hospital 
database and confirming with their respective general practitioners. If, 
during the telephone interview, it was found that the patient was not taking 
clopidogrel any more, no further phone calls were made to them. The 
details of the phone call protocol is attached (Appendix 3). 
2.11. Statistical Analysis 
As this study was a pilot study, a sample size calculation to address 
outcome objective was not done. Normality test was performed with 
Shapiro-Walk test. Continuous variables of normally distributed data are 
presented as mean. For non-normally distributed data median with 
intergroup (IQ) range is presented. Categorical variables are presented as 
percentage and frequencies.  Comparison between two means was done 
with student’s t test if the variables were normally distributed and with 
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Mann Whitney U test or, Wilcoxon- Signed rank test for non-normally 
distributed variables. When comparing more than two means, analysis of 
variance (ANOVA) was used. Student’s t test was used to estimate odds 
ratio for normally distributed data and Fishers exact test was used for data 
that was not normally distributed. 
Linear correlation was performed using Pearson’s correlation for normally 
distributed data and Spearman’s non-linear correlation test for non-
normally distributed data. A correlation co-efficient of 0.00-0.19 was 
classed as very weak correlation, 0.20-0.39 as weak, 0.40-0.59 as 
moderate, 0.60-0.79 as strong and 0.80-1.0 as very strong. Agreement 
between the two tests was calculated using the kappa statistics. A kappa 
statistic value of < 0.40 typify poor-to-fair agreement, a value of 0.41-0.60 
match moderate agreement, a value of 0.61 – 0.81 is treated as strong 
agreement, and a kappa value of 0.81-1.00 is taken as excellent 
agreement.  
 Receiver Operating Characteristics (ROC) curve analyses using LTA as 
comparison was performed to identify the cut- off in WBSPCA that is most 
sensitive and specific in identifying responders and non-responders. The 
AUC for each concentration of ADP namely, 2, 5 and 20µmol/L using LTA 
was compared with 10µmol/L ADP in WBSPCA.  An AUC of 0.91-1 was 
considered to be excellent. 0.80-0.90 was classed as good and 0.70-0.80, 
0.60-0.70, 0.50-0.60 were categorized as fair, poor, and fail respectively. 
A two tailed P value of < 0.05 was considered to be significant. All 
statistical analysis was carried out either with Statistical Package for 
Social Sciences (SPSS, version 20, IBM New York, NY) or with Prism 
(version 6, GraphPad, SanDiego, CA). 
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2.12. Details of Patients Distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
No of patients who had 
complete data on inflammatory 
markers and CTnT 
238 
Total numbers of patients recruited 
224  
 Only WBSPCA done 
63 
Both WBSPCA & LTA done 
14 Patients Dropped out 
cTnT 
55 
CRP 
51 
 
sCD40L 
52 
 
IL-6 
52 
TNF-α 
49 
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Chapter 3: Utility of Whole Blood Single Platelet Counting Assay in 
Predicting the Clinical Outcomes in Acute Coronary Syndrome 
Patients Treated with Clopidogrel
 
3.1. Background and Aim 
Patients admitted to the hospital for ACS receive a combination of 
antiplatelets and anticoagulant medications. The oral antiplatelets include 
aspirin and clopidogrel or more recently aspirin and newer P2Y12 inhibitors 
like prasugrel and ticagrelor.  The anticoagulants include fondaparinux, 
LMWH and unfractionated heparin. Some patients may also receive an 
intravenous GP IIb/IIIa inhibitor for additional antiplatelet effect. The 
optimal strategy for combining these agents is yet to be defined. 
Interindividual variability in the effect of clopidogrel is a well-documented 
phenomenon. HPR has clearly been linked to increased incidence of 
MACE in patients undergoing PCI. Similarly, hyperresponders to the 
medication have increased incidence of bleeding complications. This has 
led to the concept of individually tailored treatment as decided by the PFT 
results.  
Mixed evidence exists regarding adoption of this strategy with some 
limitations.  This has led to the invention and use of newer antiplatelet 
agents like prasugrel and ticagrelor, but due to cost factors and concerns 
about bleeding complications, at least in the elderly population, clopidogrel 
still remains one of the commonly used P2Y12 inhibitors in conjunction with 
aspirin globally. Still there is no routine method used in clinical practice for 
monitoring the effect of these medications and more research is required 
to establish whether there is a cost-effective way of assessing response to 
clopidogrel and adapting therapy accordingly. The low cost of WBSPCA 
and ready availability of materials for performing this assay make it 
potentially suitable for assessing clopidogrel response, particularly in 
health care systems with very restricted budgets or those that require 
patients to pay for treatment.  
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We aimed to study the utility of WBSPCA in predicting the risk of both 
ischaemic and bleeding events in patients treated with clopidogrel for 
ACS. 
Results 
3.2. Patients and Demographics 
A total of 238 patients were recruited for this study. Patients were treated 
either medically or by intervention. 14 patients were found to be ineligible 
for analysis either because they had received other antiplatelet 
medications that would interfere with the platelet function test performed 
for clopidogrel, or they dropped out of the study after the collection of the 
initial sample.  224 patients had whole blood single platelet counting assay 
performed and were followed up by telephone interviews. Only those 
patients who were proven to be taking clopidogrel at the time of 
occurrence of complications (ischaemic and bleeding) were considered for 
final analysis in determining the utility of the WBSPCA in assessing the 
response to clopidogrel. In that respect data for clinical outcome was 
assessed in 189 patients out of 224 patients. This is represented in table 
3.1. 
Table 3.1: Study Design and Details of Patients Studied 
 
 
 
 
 
 
 
 
 35 Patients not taking 
clopidogrel on follow up 
238 
Total numbers of patients recruited 
224  
WBSPCA Done 
189 
Assessed for outcomes 
14 Patients Dropped out 
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Table 3.2: Demographic Data/ Investigations and Treatment Given for 
All Assessed Patients and in the Subgroup, who sustained an 
Ischaemic Event or a Bleeding Event 
 
Demographic data N = 189 Ischaemia 
N= 20/189 
Bleed 
N= 21/189 
Age (Median + range) 60(31-87) 57(45-80) 62(37-83) 
Risk Factors    
Diabetes Mellitus 17% 25% 19% 
Hypertension 52% 45% 57% 
Smoking 61% 50% 66% 
Dyslipidaemia 60% 50% 57% 
Family History 41% 30% 48% 
Previous H/o IHD 21.2% 35% 29% 
Investigations    
aPositive ECG 83% 93% 66% 
bCXR evidence of LVF 34% 13% 14% 
cECHO - LV dysfunction 23% 40% 14% 
dTroponin positive 97% 100% 76% 
Medications on Discharge    
Β blockers 91% 70% 100% 
ACE – I 85% 75% 85% 
Statins 94% 100% 100% 
CCB 21% 15% 14% 
Diuretics 7% 1% 0% 
ARB  6% 1% 0% 
 
a Positive ECG finding include ST elevation, ST depression and significant T wave 
inversion 
b Pulmonary venous congestion or florid pulmonary edema 
c Left ventricular dysfunction (LVF) proved by assessment of ejection fraction 
d Troponin > 0.04ng/ml 
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Of the 189 patients on whom complete demographic details are available 
(Table 3.2), more than three-quarters were male (163 out of 189). 50 
patients were more than 65 years of age.  Mean age was 60 years (range 
31-87). Smoking and hypercholesterolaemia were the two major risk 
factors identified. 61% of the study groups were smokers and 60% of the 
patients were found to have raised cholesterol. 17%, 52% and 41% of the 
patients had diabetes, hypertension, and positive family history 
respectively. A minor proportion of them had suffered previous 
cerebrovascular or CV events, 8 patients had suffered previous stroke/TIA 
and 44 patients had suffered previous MI. 
83% of the study population had significant ECG changes (ST elevation, 
ST depression and pathological T wave changes). 23 % of the patients 
had echocardiographic evidence of left ventricular dysfunction out of which 
34 % had clinical and/or CXR evidence of left ventricular failure. 3% of the 
patients had a negative troponin result and the rest (97%) had raised 
levels of troponin either at the time of admission or 12 hours after the 
onset of symptoms. 
91% of patients received β blockers. 85 % of the patients were treated 
with angiotensin converting enzyme inhibitors (ACE–I) whereas 6% were 
given angiotensin receptor blockers (ARB). 94% of the patients were 
established on statins. 21% of the patients were treated with a calcium 
channel blocker (CCB) and 7% had received diuretic. 64% of the patients 
had received 300 mg loading dose of clopidogrel followed by 75 mg of 
maintenance dose. 22% received 600 mg loading and 75 mg 
maintenance. 14% received 75 mg of maintenance dose only. The 
demographic data are presented in table 3.2. 
 
3.3. Descriptive Statistics of Aggregation Data in Response to 
Clopidogrel Using WBSPCA 
Platelet aggregation data was assessed by WBSPCA in 224 patients to 
increasing concentrations of ADP (0.3, 1, 3, 10, 30, and 100µmol/L) at 
different time points, namely 30 seconds and 4 minutes. The mean 
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percentage of platelet aggregation (±SD) in response to 10µmol/L of ADP 
in patients receiving clopidogrel at 4 minutes was 46 ± 28% (figures 
3.1and 3.2). 
Figure 3.1: Platelet Aggregation Assessed by WBSPCA 30 seconds 
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Figure 3.1: Mean % of platelet aggregation in response to increasing concentration of 
ADP (0.3, 1, 3, 10, 30 and 100µmol/L) at 30 seconds after addition of ADP assessed by 
WBSPCA in patients taking clopidogrel, (N = 224). 
 
Figure 3.2:  Platelet aggregation assessed by WBSPCA 4 minutes 
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Figure 5: Mean percentage of platelet aggregation in response to increasing 
concentration of ADP (0.3, 1, 3, 10, 30 and 100µmol/L) at 4 minutes after addition of ADP 
assessed by WBSPCA in patients receiving clopidogrel, (N= 224). 
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3.4. Prevalence of Clopidogrel Responders and Non- Responders 
Assessed by WBSPCA 
The overall prevalence of clopidogrel responders in this study is 63% 
(N=142/224). The remaining 37% (N=82/224) were classified as non-
responders (t test) (figure 3.3). Demographic profiles of these patients are 
presented in table 3.3  
Table 3.3  
Parameters Clop non-resp (N=82) Clopl resp (N=142) 
Age 60 ( 32-87) 63 ( 39-86) 
Sex 58    (M) 94    (M) 
Risk factors   
Hypertension 50% 52% 
Diabetes mellitus 24% 21% 
Dyslipidaemia 68% 60% 
Previous h/o CAD 32% 30% 
Smoking 48% 60% 
 
Figure 3.3: Prevalence of Clopidogrel Responders and Non-
Responders (N=224) 
 
Figure 3.3: Prevalence of clopidogrel responders and non- responders in the study 
population (N=224).  Responders (N = 142/224, 63%) Non-responders (N = 82/224, 
37%).  
 
63%
(N = 
142/224)
37%
(N = 
82/224)
Responders
Non-Responders
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3.5. Interindividual Variation in the Platelet Aggregation Response to 
Clopidogrel 
The percentage of platelet aggregation in clopidogrel-treated patients 
shows marked interindividual variability as illustrated in figure 3.4. Again, 
the value of platelet aggregation induced by 10µmol/L of ADP after 4 
minutes was found to be most discriminating in demonstrating this. The 
maximum number of patients lay in the frequency of 15-30% and the least 
number of patients were found to have less than 15% of aggregation. 
However, our data did not demonstrate the normal distribution frequency  
found in other studies that used different methodologies (101). 
Figure 3.4: Interindividual Variation in Clopidogrel Response (N=224) 
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Figure 3.4: Interindividual variability in platelet aggregation to 10µmol/L of ADP 
measured at 4 minutes in patients treated with clopidogrel assessed by WBSPCA. 
(N=224) 
 
3.6. Ischaemic Outcomes in Clopidogrel Treated Patients Assessed 
by WBSPCA 
3.6.1. Demographic Details 
 The median age of the patients who suffered an ischaemic event during 
follow-up was 57(45-80) similar to the overall cohort (Table 3.2). One 
quarter of the cohort was diabetic (25%), a numerically higher proportion 
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than the overall cohort, and half of them were smokers (50%). 
Dyslipidaemia was the most common risk factor in this population (70%) 
and less than half were hypertensive (45%). 35% of the cohort had a 
previous history of MI. 93% of the study group had positive ECG findings 
and almost all of them were troponin positive. Βeta blockers (70%) and 
ACE-I (75 %) were underused in this group compared with the whole 
study population. 
 
3.6.2. Platelet Aggregation Details 
The aggregation data for 189 patients who have been assessed for clinical 
outcomes is presented in figure 3.5. The mean % of platelet aggregation 
(± SD) to 10µmol/L of ADP measured at 4 minutes is 46 ± 28%. The mean 
% of aggregation (± SD) to 10µmol/L of ADP measured at 30 seconds is 
81 ± 19%. The platelet micro aggregation in response to ADP occurs in 
early stages as demonstrated by the high mean % of aggregation at 30 
seconds. The reversal of this micro aggregation explains the lower mean 
% of aggregation obtained at 4 minutes (239). 
 
Figure 3.5: Platelet Aggregation Assessed by WBSPCA (N=189) 
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Figure 3.5: The mean % of aggregation (±SD) to increasing concentration of ADP (0.3, 
1, 3, 10, and 30 and100µmol/L) measured at 30 seconds and 4 minutes using WBSPCA 
(N=189).
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3.6.3. Incidence of Ischaemic Complications in Responders and Non-
Responders 
Out of the 189 patients assessed for ischaemic outcomes, 120 patients 
were found to be responders (120/189 = 63%) and the remaining 69 
patients were found to be non-responders (69/189 = 37 %), as assessed 
by the WBSPCA using 10µmol/L ADP as agonist measured at 4 minutes.  
The overall incidence of ischaemic complications was 20 out of 189.  
Among this 20, 11 events occurred in responders (11/120=9%) and 9 
events occurred in non-responders (9/69=14 %). There were no significant 
differences in their demographic characteristics. There were 5 ischaemic 
events related to interventions. Out of this, 3 were angiographically proven 
stent thrombosis and 2 were angiographically proven in-stent restenosis. 
The remaining patients either had NSTEMI with no angiographically 
proven lesions or with new lesions needing interventions including PCI 
with stenting or CABG. Of the three stent thrombosis events, 2 events 
occurred in non-responders and the remaining 1 in a responder. Although 
there was a marginal increase in the number of recurrent ischaemic 
events in non-responders (14%) compared with responders (9%), this was 
not statistically significant by Chi-Square test (P= 0.404, OR = 0.673, 95% 
CI = 0.306 to 1.612) (figure 3.6). 
Figure 3.6: Ischaemic Events in Responders and Non-Responders 
(N=20) 
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Figure 3.6: Ischaemic outcomes in responders and non-responders. Group 1 non-
responders (N=9/69 14%). Group 2 responders (N=11/120 9%) (P= 0.404). 
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Figure 3.7: Platelet Aggregation Measured at 30 Seconds 
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Figure 3.7: The mean (± SD) percentage of platelet aggregation in patients who 
developed ischaemic complications compared with those who did not measured 
at 30 seconds by WBSPCA. 
 
3.6.4. Platelet Aggregation in Patients with and without Ischaemic 
Complications (20/189 vs.169/189) 
The mean (± SD) of the percentage of platelet aggregation measured at 
30 seconds and 4 minutes by WBSPCA in patients who did or did not 
develop ischaemic complications is presented in figure 3.7 and 3.8. The 
mean percentage of platelet aggregation measured at 30 seconds in 
patients who sustained ischaemic events was 88 ± 19% and the same 
value for 4 minutes was 47 ± 28 %.  Likewise, the percentage of platelet 
aggregation in those who did not develop an ischaemic complication was 
82 ± 19 % and 45 ± 33% measured at 30 seconds and 4 minutes, 
respectively.  
The mean percentage of platelet aggregation measured at 4 minutes to 
10µmol/L of ADP in those who developed an ischaemic event was 45 ± 
33%. Similar data for those who did not develop an ischaemic event was 
43 ± 28%. There was no statistically significant difference in the median 
compared between the groups, (Wilcoxon- Signed rank test P= 0.808). 
This is demonstrated in figures 3.9.   
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Figure 3.8: Platelet Aggregation Measured at 4 Minutes (N=189) 
0.3 1 3 10 30 100
0
50
100
150 ISC NO ( N=169)
ISC YES ( N=20)
Increasing Concentration of ADP
% 
of
 p
lat
el
et
 ag
gr
eg
at
io
n
 
Figure 3.8: Mean percentage of platelet aggregation (±SD) to increasing concentration of 
ADP (0.3, 1, 3, 10, 30 and 100µmol/L) measured at 4 minutes in patients who did or did 
not develop ischaemic complications on treatment with clopidogrel measured by 
WBSPCA in hirudin anticoagulated whole blood(N=189) 
 
Figure 3.9: Ischaemic Outcomes 
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Figure 3.9: Box and whiskers plot demonstrating the range of platelet aggregation to 
10µmol/L of ADP measured at 4 minutes in two groups. Group 1- Occurrence of 
ischaemic events (N=20), Group 2- Nonoccurrence of ischaemic events (N= 169) 
(P=0.808) 
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3.7. Bleeding Complications – Details of Bleeding Events and 
Demographics of the Patients 
 The total number of bleeding events in this study was 33 out of 224 
patients. Out of these 33 events, 21 bleeds happened in the 189 patients 
taking clopidogrel and were considered for statistical analysis. The 
remaining 12 happened in patients either not taking clopidogrel at the time 
of bleed or were related to coronary artery bypass grafting (CABG). Of the 
21 bleeds, 2 were TIMI major bleeds consisting of one gastrointestinal 
bleeding (GI) bleed needing blood transfusion and one retroperitoneal 
bleed dropping haemoglobin to 6g/dl needing blood transfusion, 5 were 
right femoral artery haematoma following angiogram not needing blood 
transfusion or intervention, 14 were nuisance bleeding including 1 gum 
bleeding, 11 epistaxis (one needed nose packing) and 2 spontaneous 
bruises. This is summarized in table 3.4. 
Amongst the 21 patients with bleeding events, more than 85% of them 
were less than 75 years of age and the rest were more than 75 years. It 
was interesting to note that the majority of the bleeds occurred in non-
diabetic patients (17/21)  
Table 3.4 
Classification Interventional Related N=6 
 
Non-Interventional Related N=15 
 
 
TIMI Major 
 
1 (Retroperitoneal Bleed) 1 (GI Bleed) 
TIMI Minor 5 (Femoral haematoma) 
 11-Epistaxis 
 1 - Gum bleed 
 2 - Spontaneous bruises 
 
3.7.1. Incidence of Bleeding Complications in Responders and Non-
Responders 
The overall incidence of bleeding was numerically higher in responders (N 
= 15/120, 12.5%) compared with non-responders (N = 6/69, 9%). 
However, this was not statistically significant (N = 15/120 vs. 6/69, P = 
0.536, OR=1.368 95% CI= 0.506–3.698) (figure 3.10). 
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Figure 3.10: Bleeding Complications in Responders and Non-
Responders (21/189) 
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Figure 3.10: There was no significant difference in the incidence of bleeding between 
responders (N=15/129 15%) and non-responders (N=6/69 9%) (P=0.536)
 
3.7.2. Platelet Aggregation in Bleeders and Non-Bleeders 
The mean percentage of platelet aggregation in response to 10µmol/L of 
ADP measured at 30 seconds and 4 minutes between those with, and 
without bleeding events are 82 ±19% vs.87 ±13% and 39± 24% vs. 46 
±28% respectively. Figure 3.11 and 3.12 
Figure 3.11: Platelet Aggregation Measured at 30 Seconds N=189 
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Figure 3.11: Mean percentage of platelet aggregation (±SD) to increasing concentrations 
of ADP (0.3, 1, 3, 10, and 30 and, 100µmol/L) measured at 30 seconds in two groups 
(bleeders (N=21) and non-bleeders (N= 168) by WBSPCA in hirudin anticoagulated 
whole blood (N= 189).
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Figure 3.12: Platelet Aggregation Measured at 4 Minutes N=189 
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Figure 3.12: Mean percentage of platelet aggregation induced by increasing 
concentrations of ADP (0.3, 1, 3, 10, and 30 and100µmol/L) measured at 4 minutes 
between non- bleeders (B=168) and bleeders (N=21) by WBSPCA (N=189). 
 
 
Figure 3.13: Platelet Aggregation in Ischaemic (N=20) and Bleeding 
Outcomes (N=21) 
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Figure 3.13: Platelet aggregation in response to 10µmol/L of ADP measured at 4 minutes 
in two groups. Group 1-Patients who developed bleeding complications (N=21), Group 2- 
Patients who did not develop bleeding complications (N= 168) (P=0.791). 
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3.7.3. Platelet Aggregation Compared between Bleeders and Non-
Bleeders 
The mean (± SD) percentage of platelet aggregation in patients who bled 
(N=21/189) and did not (N=168/189) was 39 ± 24% and 48 ± 28% 
respectively. This was not statistically significant (Paired t test P = 0.791) 
(Figure 3.13). 
3.7.4. Platelet Aggregation Compared between Ischaemic and 
Bleeding Complications 
The mean (± SD) percentage of platelet aggregation in patients who 
developed an ischaemic complication (n=20) was 46 ± 31%. The 
respective value in patients who developed bleeding complications (N=21) 
was 39 ± 24%. The difference was not statistically significant (paired t test 
P= 0.496) (figure 3.14). 
Figure 3.14: Platelet Aggregation in Patients with Bleeding and 
Ischaemic Complications 
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Figure 3.14: Platelet aggregation in patients who developed an ischaemic and bleeding 
complications. Group 1- Ischaemic events positive (N= 20), Group 2- Bleeding events 
positive (N=21) (P= 0.496). 
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3.8. Discussion 
Our study assessed the utility of WBSPCA in determining the risk of 
ischaemic and bleeding events in patients treated with clopidogrel for 
ACS. Ischaemic events include CV related death, STEMII, NSTEMI, and 
stent stenosis or stent thrombosis needing revascularization. PCI-related 
increase in troponin alone was not considered as ischaemic event unless 
there were significant ECG findings/clinical symptoms or angiogram 
findings. Ischaemic events occurred in 20 out of 189 patients and bleeding 
events occurred in 21 out of 189 patients. There were no significant 
differences in the demographics of patients who developed ischaemic and 
bleeding complications compared to those who did not. The incidence of 
ischaemic event was numerically higher in non-responders compared to 
responders (14 % vs.9% P= 0.404). Similarly, the incidence of bleeding 
was higher in responders compared to non-responders (12.5 % Vs.9% P= 
0.536). The mean percentage of platelet aggregation measured at 4 
minutes of ADP interaction with the sample assessed by WBSPCA was 39 
± 24% in patients who had a bleeding event and 48 ± 28% in those who 
developed ischaemic complications. Despite numerical differences, 
neither of these values was significantly discriminating from those who did 
not sustain bleeding or ischaemic events. 
WBSPCA measures the fall in single platelet count that occurs with 
aggregation. When hirudin anticoagulation is used, aspirin has no effect 
on platelet aggregation induced by the standard platelet agonist ADP so 
that ADP induced aggregation can be used to selectively define the 
inhibitory effects of clopidogrel. ADP is a key platelet agonist which acts 
via subtypes P2   receptors namely P2Y1and P2Y12 receptors.  As 
clopidogrel is a P2Y12 antagonist, ADP is used to study the effect of 
clopidogrel. Addition of increasing concentrations of agonist will give 
increasing percentage of aggregation. Aggregation can be measured by 
the fall in single platelet count in the sample blood relative to the 
unstimulated whole blood sample (which acts as the control). A single 
platelet count of zero gives 100% aggregation (239). 
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The mean percentage of platelet aggregation (± SD) to 10µmol/L of ADP 
was 46 ± 28%. As with other studies(101, 244, 245), the platelet 
aggregation inhibition by clopidogrel as assessed by the WBSPA shows 
marked inter individual variations (101). The prevalence of non-
responders in our study was 37%. Different studies have used various cut-
off to define non-responders. One of the commonly used cut-off value is 
<10% decrease in aggregation values obtained at baseline and after 
treatment with clopidogrel using various platelet function testing assays 
most commonly  LTA (101). In one study, ≤10% absolute reduction in 
10µmol/L ADP-induced WBSPC aggregation from baseline to post 
clopidogrel time point was used. The prevalence of non-responders 
assessed by this definition was 37% for 300mgs of clopidogrel when the 
PFT was performed 4 hours post drug intake (245). In another study 
patients have been grouped as responders, semi responders and  non-
responders based on absolute platelet inhibition cut-off points of < 
10%,10%-30%,>30% respectively (246). The validity of this definition is 
questionable given the interindividual variability in baseline ADP induced 
platelet aggregation. It has been postulated that this method can potentially 
overestimate the ischaemic risk and underestimate bleeding risk 
(247,248). Hence the platelet reactivity on treatment has been proposed 
as a better measure of thrombotic risk which we have adopted (241). 
 
Several studies have consistently shown that the HPR is an independent 
risk factor for occurrence of ischaemic events following PCI (241). In our 
study, although there is no statistically significant difference in the 
occurrence of ischaemic events between the responders and the non-
responders, the mean percentage of platelet aggregation in those who 
developed ischaemic complications was higher than those who did not. In 
our study, patients were managed both medically and by interventions. In 
the future, a study that truly evaluates the utility of this tool in patients who 
are exclusively managed by interventions would be ideal to determine its 
precise utility that would suit the current clinical practice. 
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The sensitivity of WBSPCA in predicting the bleeding risk assessed by this 
study appears to be slightly better compared with the test’s ability to 
predict ischaemic events. There were two incidences of TIMI major bleed 
unrelated to CABG in this study. Both of them occurred in patients who 
were responders with the percentage of platelet aggregation value in the 
lowest group (12%, 29%). Similarly, although there was no statistically 
significant difference in the occurrences of bleeding events between the 
responders and non-responders, the mean percentage of platelet 
aggregation in patients who developed bleeding complications is less 
compared with those who did not. However, a larger study is required with 
more events to accurately determine the prognostic relevance of 
WBSPCA results in clopidogrel-treated patients. 
Clopidogrel has proven benefit in the treatment of thrombotic events in 
patients with ACS. The platelet aggregation inhibition achieved by 
clopidogrel is not consistent and subjected to interindividual variations. 
This has been referred to as clopidogrel resistance or more precisely 
HPR. HPR has been found to have an increased risk for MACE. The 
reason for this variable antiplatelet effect of clopidogrel is multifactorial. It 
includes noncompliance, absorption problem, smoking, drug-drug 
interaction, intrinsic variation in platelet function before exposure to 
medication, obesity, renal dysfunction, and DM. This is also the reasons 
why PFT is poor in predicting ischaemic events in PCI treated ACS 
patients. A 600 mg loading dose of clopidogrel as opposed to a 300 mg 
loading dose only partially overcomes some of these issues (249) 
Patients who are at increased risk for cardiac ischaemic events whilst on 
short term and long-term treatment with clopidogrel, as demonstrated by 
HPR has been identified by a number of ADP-dependent PFT. These 
include VerifyNow, Multiplate, TEG PlateletMapping system, PFA-
100System and VASP. Of these, the VerifyNow assay is the most widely 
used as it has the advantage of being a point-of-care tool (POCT) and 
very user friendly. In fact, large observational studies have shown an 
independent relationship between HPR as measured by POCT PFT and 
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ischaemic events in patients undergoing PCI. However, there are no 
robust data on the relationship between HPR and ischaemic events in 
ACS patients managed medically. Initial small studies suggested that 
individualizing the antiplatelet therapy as guided by the PFT might reduce 
ischaemic events. These data resulted in low-level recommendation for 
use of PFT in clinical guidelines from the AHA/ACC and ESC. However, 
three large prospective randomized controlled trials, GRAVITAS (2,800 
patients), ARCTIC (2,440 patients), and ANTARCTIC (877 patients), 
showed that personalized antiplatelet therapy based on point-of-care 
assessment of platelet function is not effective in reducing ischaemic 
events. Accepting the limitations of these trials, the final evidence does not 
support the concept of altering antiplatelet therapy based on PFT. Thus 
HPR may, at least partly, be a non-modifiable clinical risk factor in 
clopidogrel treated patients (249) 
Some but not all studies of clopidogrel-treated patients suggest a 
relationship between low platelet reactivity and bleeding events. However, 
the link is weaker than that between HPR and thrombotic events and there 
is no convincing evidence that changing clopidogrel therapy based on PFT 
can result in a reduction in bleeding events. 
 
3.9. Conclusion 
In summary, we have investigated the usefulness of WBSPCA which has 
not been studied before in the context of its clinical utility to predict 
ischaemic and bleeding complications in patients treated with clopidogrel. 
Ischaemic events tended to occur in individuals with higher level of platelet 
aggregation and bleeding complications in patients with lower level of 
platelet aggregation. The incidence of ischaemic events was numerically 
higher in non-responders and the incidence of bleeding complications was 
numerically higher in responders although not statistically significant. With 
the increasing use of point-of-care test in assessing platelet function in 
diverse clinical scenarios, there is a promising scope for WBSPCA to 
become one potential tool in the future, although more work is needed to 
validate its utility in specific clinical conditions. 
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Chapter 4: Utility of Whole Blood Single Platelet Counting Assay in 
Assessing the Efficacy of Aspirin
 
4.1. Background and Aim 
Aspirin has been in existence now for nearly 125 years and is one of the 
commonly used cardiovascular medications worldwide. Aspirin has gained 
an established role in the active treatment of ACS and in secondary 
prevention of CVD conditions. However aspirin alone was inferior in 
preventing MACE in patients with established CAD compared with a 
combination of aspirin and other antiplatelets like clopidogrel, prasugrel or 
ticagrelor (250). The reasons for the failure of aspirin to prevent vascular 
events solely is multifactorial and one of the aspects being the inability of 
aspirin to fight against the thrombus formation itself. These groups of 
patients are often referred to as aspirin low-responders (251). There is an 
increased incidence of MACE and other vascular complications in aspirin 
low-responders (252). Despite this wealth of information, monitoring the 
antiplatelet effects of aspirin is not recommended in routine clinical 
practice. The reason for this is largely due to lack of a single tool that can 
readily assess the antiplatelet effects of aspirin consistently. If that test is 
available, individually tailored antiplatelet therapy might gain wider 
acceptance. 
The aim of this study is to assess the utility of WBSPCA monitoring the 
efficacy of aspirin in patients treated for ACS. We also aim to obtain data 
regarding the association between platelet aggregation inhibition 
measured by WBSPCA and serum TXB2 in patients treated with aspirin. 
Results 
Platelet aggregation data is presented in 236 patients. Platelet 
aggregation data related to aspirin responders and low- responders and 
the incidence of ischaemic and bleeding complications are presented in 
189 patients. Platelet aggregation in response to AA and its relationship to 
urine 11- dehydro TBX2 is presented in 62 patients. Platelet aggregation in 
response to AA and its relationship with serum TBX2 is presented in 98 
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patients. Demographic details about the whole study (N= 236) and 
patients who were assessed for ischaemic and bleeding complication 
(N=189) are presented in chapter 3. Demographic details of the patients 
assessed for urinary TBX2 and serum TBX2 are presented in table 4.1 
 
Table 4.1 
Parameters Urine-TBX2 N=65 Serum –TBX2 N=98 
Age 60 60 
Sex 54/65 ( Male)  80/98 ( Male) 
Risk Factors   
Diabetes Mellitus 10/65 (16%) 16/98 (18 %) 
Hypertension 34/65 (55%) 47/98 (52%) 
Smoking 39/65 (63%) 63/98 (69 %) 
Dyslipidaemia 41/65 (66 %) 62/98 (69%) 
Previous H/O of IHD 16/65 (26 %) 21/98 (84 %) 
 
 
4.2. Descriptive statistical Data 
The median percentage of platelet aggregation with their intergroup range 
(IQ) in response to increasing concentrations of AA (0.1, 0.2, 0.4, 0.8,1 
mM) measured by WBSPCA at 30 seconds and 4 minutes are 
represented in figure 4.1 and 4.2 respectively. Detailed descriptive data 
presented in table 4.2 
 
Table 4.2: Descriptive Statistics of the Platelet Aggregation at 30 
Seconds and 4 Minutes by WBSPCA (N=236) 
 
N=236 0.1AA 30S 0.2AA 30S 0.4AA 30S 0.8 AA 30S 1 AA 30S 
Mean % 7 7 9 28 39 
Median % 6 6 7 23 35 
IQ range % 8 8 9 31 43 
N=236 0.1AA 4M 0.2AA 4M 0.4AA 4M 0.8AA4M 1AA 4M 
Mean % 14 15 17 25 34 
Median % 15 15 16 20 23 
IQ range% 11 11 13 17 36 
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Figure 4.1: Platelet Aggregation in Response to Increasing 
Concentrations of AA Measured at 30 Seconds by WBSPCA (N=236) 
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Figure 4.1: Percentage of platelet aggregation measured by increasing 
concentration of AA (0.1, 0.2, 0.4, 0.8, 1mM) measured at 30 seconds by 
WBSPCA. Data is represented as median with their IQ range N=236. 
 
 
Figure 4.2: Platelet Aggregation to Increasing Concentration of AA 
Measured at 4 Minutes by WBSPCA (N=236) 
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Figure 4.2: Percentage of platelet aggregation in response to increasing 
concentrations of AA (0.1, 0.2, 0.4, 0.8,1 mM) measured by WBSPCA at 4 
minutes. Data is represented as median with (IQ) range. N=236 
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4.3. Interindividual Variation of Platelet Aggregation in Patients 
Treated with Aspirin 
Platelet aggregation in response to 0.8mM AA was taken into 
consideration to assess the interindividual variation to the antiplatelet 
effect of aspirin. Patients were categorized according to their percentage 
of platelet aggregation at intervals of 10%. Predominantly the percentage 
of aggregation was found to be less than 50% with maximum frequency in 
the range of 20% followed by 10%. The data was not normally distributed 
(Shapiro–Wilk normality test W= 0.792), (figure 4.3).  
Figure 4.3: Interindividual Variation of Platelet Aggregation in 
Patients Treated with Aspirin 
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Figure 4.3: Interindividual variation in the percentage platelet aggregation in 
patients treated with aspirin. (N=236). 
 
4.4. Prevalence of Aspirin Responders and Low Responders 
The prevalence of aspirin responsiveness as assessed by this study is 
76% (N=180/236). The rest of the patients, 24% were defined a slow-
responders to the effect of aspirin (N=56/236). Considering the overlap 
between both aspirin and clopidogrel response, 52 % of patients were 
responders to both aspirin and clopidogrel, (N= 122/236), 24% (N=58/236) 
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responded only to aspirin but not to clopidogrel, 11% (N=26/236) 
responded only to clopidogrel but not aspirin, and 13% of patients did not 
show adequate platelet aggregation inhibition to both aspirin and 
clopidogrel (N= 30/236). The data is presented in figure 4.4. Their 
demographic profile is presented in table 4.3 
Table 4.3 
Parameters Asp Resp 
Clop Resp 
N=122 
Asp Low-Resp 
Clop Resp 
N=26 
Asp Resp 
Clop Non- Resp 
N=58 
Asp Low-Resp 
Clop Non-Resp 
N=30 
Age 60 (32-88) 60 (37-80) 63 (40-86) 64 (39-83) 
Male 62% 69% 55% 87% 
Risk Factors     
Hypertension 52% 52% 58% 54% 
Diabetes Mellitus 20% 26% 25% 21% 
Dyslipidaemia 60% 52% 72% 61% 
Previous H/0 IHD 27% 43% 32% 36% 
Smoking 58% 65% 58% 39% 
 
Figure 4.4: Prevalence of Aspirin and Clopidogrel Non-Responders 
 
 
 
Figure 4.4: Prevalence of aspirin and clopidogrel responsiveness and non-
responsiveness as assessed by WBSPCA, (N=236). 
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4.5. Incidence of Ischaemic and Bleeding Events 
The incidence of ischaemic events in patients taking aspirin was 11% (N= 
20/189) and the incidence of bleeding complications was 11% (N=21/189). 
The incidence of aspirin responders among the 189 patients was 75% (N 
= 142/189). The incidence of aspirin low-responders were 25% (N= 
47/189).  
4.6. Ischaemic Events – Platelet Aggregation 
The median percentage of platelet aggregation in patients who developed 
ischaemic events was 23 % with an IQ range of 15 % in response to 
0.8mM AA measured at 4 minutes. The median percentage of platelet 
aggregation in patients who did not develop ischaemic events was 20% 
with an IQ range of 17%.  The mean percentage of platelet aggregation 
(±SD), between both the groups is presented in figure 4.5. There were no 
statistically significant differences in the median between both the groups, 
(Wilcoxon signed rank test, P=0.715). 
Figure 4.5: Platelet Aggregation in Patients who Developed 
Ischaemic Events and Not  
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Figure 4.5: Mean percentage of platelet aggregation in response to 0.8mM AA 
measured at 4 minutes is 29% in patients who developed ischaemic events and 
24% in patients who did not develop ischaemic events,(P= 0.715). 
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4.7. Incidence of Ischaemic Events in Aspirin Responders and Low- 
Responders 
20 out of 189 patients developed ischaemic events whilst on aspirin. Of 
these 13 events occurred in patients who were responders to aspirin (N=13 
/142, 9%) and 7 events occurred in patients who were low-responders to 
aspirin (N=7/47, 15%). The incidence of ischaemic events were higher in 
aspirin low-responders compared with those who were aspirin responders. 
However, the difference was not statistically significant, Chi Square test 
(P=0.268, OR=0.576 and 95% CI=0.261-1.449) (figure 4.6). 
Figure 4.6: Incidence of Ischaemic Events in Responders and Low-
Responders  
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Figure 4.6: Ischaemic events occurred in 9% of responders and 15% of low-
responders to aspirin (P= 0.268). 
 
4.8. Bleeding Complications in Responders and Low-Responders to 
Aspirin 
The median percentage of platelet aggregation in response to 0.8mM of 
AA measured by WBSPCA at 4 minutes in patients who developed 
bleeding complications was 16% with an IQ range of 8%. The median 
percentage of platelet aggregation in response to0.8mM of AA measured 
by WBSPCA at 4 minutes in patients who did not develop bleeding 
complications was 21% with an IQ range of 17%.  There was no 
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statistically significant difference in the median, (Mann Whitney U test, P= 
0.076) (Figure 4.7). 
Figure 4.7: Platelet Aggregation in Bleeding Complications  
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Figure 4.7: Mean percentage of platelet aggregation in bleeders is 20% and in 
non-bleeders is 26% (P= 0.076). (Total number = 189. Bleeding happened in 
21/189). 
 
4.9. Incidence of Bleeding Events in Responders and Low-
Responders 
Bleeding complications occurred in 21 patients (N= 21/189, 11%). Of the 
21 events 19 happened in responders and the remaining 2 occurred in 
low-responders (N= 19/142, 13% vs. 2/47, 4%). Although the incidence 
was higher in aspirin responders, this was not statistically significant, (Chi 
Square test P=0.085, OR = 3.476 and 95% CI = 0.778-15.53) (Figure 4.8). 
4.10. Platelet Aggregation -Ischaemic and Bleeding Complications 
The mean percentage of platelet aggregation in patients who developed 
ischaemic complications was higher than those who developed bleeding 
complications (29±22% vs. 20 ±14%). There was a statistically significant 
difference in the median between the two groups (P= 0.017) (figure 4.9). 
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Figure 4.8: Bleeding Complications in Aspirin Responders and Low-
Responders to Aspirin 
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Figure 4.8: Bleeding complications occurred in 13% of responders and 4% of 
low-responders (P= 0.085). (N=21/189) 
 
Figure 4.9: Platelet Aggregation in Ischaemic and Bleeding Events 
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Figure 4.9: The mean percentage of platelet aggregation in response to 0.8mM 
AA measured at 4 minutes is 29±22% for ischaemic complications and 20 ±14 % 
for bleeding complications (P= 0.017). 
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4.11. Correlation of Platelet Aggregation Assessed by WBSPCA and 
Urine 11- dehydro TXB2 Levels. 
In 62 patients urine 11-dehydro TXB2 levels were measured. The median 
increase in urine TXB2 was 406pg/ml with an IQ range of 621pg/ml. There 
was no correlation between the urine 11-dehydro TXB2 levels and the 
percentage of platelet aggregation in response to 0.8mM of AA measured 
by WBSPCA at 4 minutes, (Spearman’s correlation co-efficient r=0.030, 
P= 0.814). Among the 62 patients 39 (63%) were found to be responders 
and the remaining 23 (37%) were low-responders. The median of the urine 
11-dehydro TXB2 in responders is 406pg/ml with an IQ range of 625pg/ml. 
The median of the same in low-responders is 420pg/ml with an IQ of 582 
pg/ml. There was no significant difference in the median between the two 
groups, (Wilcoxon Signed–rank test, P=0.466) (Figure 4.10) 
Figure 4.10: Correlation between Platelet Aggregations in Response 
to AA and Urine 11-dehydro TXB2 Levels (N=62) 
 
Figure 4.10: Correlation between platelet aggregations in response to 0.8mM AA 
and urine TXB2 levels (r= 0.030, P= 0.814). (N=62 
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4.12. Correlation between Platelet Aggregations Assessed by 
WBSPCA and Serum TXB2 Levels 
 
Serum TXB2 levels were measured in 98 patients. The median value of 
the serum TXB2 is 14pg/ml with an IQ range of 51-206pg/ml. There was a 
moderate, but significant correlation between the serum TXB2 levels and 
platelet aggregation in response to 0.8 mM AA assessed by WBSPCA, 
(Spearman’s correlation co-efficient r = 0.368, P=0.000) (Figure 4.11). 
 
Figure 4.11: Correlation between Platelet Aggregations Assessed by 
WBSPCA at 4 Minutes and Serum TBX2 Levels 
 
 
Figure 4.11: Correlation between serum TBX2 and percentage of platelet 
aggregation in response to 0.8mM of AA (r= 0.368, P= 0.000). 
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55 out of 98 (56%) patients were aspirin responders and 43 out of 98 
(44%) were aspirin low responders. The median increase in serum TXB2 
levels in responders against aspirin low responders were 8pg/ml and 
27pg/ml respectively. There was a significant difference in the median 
between the two groups, (Wilcoxon-signed rank test, P=0.015). The ROC 
analysis was not effective enough to discriminate a cut-off value to identify 
responders from low responders (AUC=0.550, upper bound 0.637, lower 
bound 0.463 and P=0.225). 
 
Serum TXB2 levels and ischaemic/bleeding outcomes were available in 61 
patients. The median serum TXB2 level in bleeders (11/61 18%) was 
8pg/ml with an IQ range of (0-146pg/ml). The respective data for those 
who did not develop bleeding complications (N = 50/61 82%) was 12pg/ml 
with an IQ range of (0- 42pg/ml). The difference in the median was not 
significant (Wilcoxon–Signed rank test P=0.465). Likewise, ischaemic 
events occurred in (N = 12/61 20%) of the patients. There was no 
difference in the median between those who developed ischaemic 
complication and did not (371± 13-2000pg/ml vs. 8± 0-2000pg/ml, P= 
0.301). 
 
4.13. Correlation between Urine 11-dehydro TBX2 and Serum TBX2 
63 patients had their serum and urine TBX2 levels measured. There was 
no correlation between both the parameters, (Spearman’s correlation 
coefficient r= - 0.017, P= 0.96) (figure4.12). 
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Figure 4.12: Correlation between Serum and Urine TBX2 (N=63) 
 
Figure 4.12: Correlation between Serum and Urine TBX2(r=-0.017, P=0.96) 
(N=63). 
 
4.14. Discussion 
This study aimed to glean information regarding the utility of WBSPCA in 
assessing the efficacy of aspirin in patients with ACS.  This assay as a 
tool to measure the platelet aggregation in relation to aspirin has not been   
widely studied and hence defining aspirin low responders was difficult. 
Low response to aspirin has been defined as  platelet aggregation ≥ 30 %  
and those with a value of <30 % were considered to be  to aspirin 
responders using LTA in response to 0.5mM of AA (253). In one study, 
aspirin low responders were defined as platelet aggregation induced by 
AA ≥ 30% (254) which is adopted in our study. 
The prevalence of aspirin low-responders in our study was 24%.  The 
prevalence of aspirin low-responders in other studies varies between 5 to 
40%. Clinical, demographical, genetic factors, and physiology of platelet 
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aggregation all have been attributed to this phenomenon (253). There is 
no single PFT that has been advocated as a standard to measure aspirin 
low-response which by itself can be a dynamic process (255). In one 
meta-analysis the prevalence of aspirin low- responders was higher when 
whole blood counting assay such as platelet function analyzer 100 assay 
was used, compared with LTA (256). 
The incidence of ischaemic events was higher in the low-responders group 
compared to the responders, but failed to gain statistical significance 
(P=0.268, OR =0.576). The median percentage of platelet aggregation 
was higher in patients who developed ischaemic complication compared 
with those who did not, but not statistically significant (P=0.715). In one 
study with a sample size of 120 patients with peripheral artery disease 
(PAD), the prevalence of aspirin resistance as assessed by VerifyNow 
assay was 26%. Aspirin resistance was associated with significantly 
higher rates of MACE. In a meta-analysis conducted by Krasopoulos and 
colleagues, which included 2,930 patients with CV disease from 20 
studies, the prevalence of aspirin resistance was 28% (810 patients). CV-
related events occurred in 41% of these patients (256, 257). 
The ISAR-ASPI (Intracoronary Stenting and Antithrombotic Regimen- 
Aspirin and Platelet Inhibition) assessed the utility of high on aspirin 
platelet reactivity (HAPR) as a possible prognostic biomarker in PCI 
treated patients. This is a large study that included 7,090 consecutive PCI 
treated patients. Platelet function was assessed with Multiplate analyzer 
before PCI. Death and stent thrombosis at one year were measured. 
1,414 patients were found to have HAPR as measured by the Multiplate 
measurement. There was a significant risk of death and stent thrombosis 
at one year in patients who had HAPR (6.2% vs.3.7% P= <0. 0001). On 
the other hand, the ADAPT-DES trial that included 8,665 PCI treated 
patients did not show any significant association between HAPR and 
ischaemic outcomes including death and stent thrombosis at one year. 
The precise reason for this wide variation in outcome is unknown. 
Possible explanations include timing of blood sampling, type of PFT 
employed, and different cut-off point to define HAPR.  To be more specific, 
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in the ADAPT-DES study blood testing was performed day one post-PCI 
and VerifyNow PFT was used to assess platelet function. The prevalence 
of HAPR in the ISAR-ASPI study was 20 % and 5.6% for the ADAPT-DES 
study (258) 
Similarly, the incidence of bleeding complications tended to be higher in 
patient who responded well to aspirin compared with those who were low-
responders though this was not statistically significant (P=0.085, OR= 
3.476). The median percentage of platelet aggregation is lower in patients 
who developed bleeding complications compared with those who did not, 
but not significant (P=0.076). The importance of aspirin and clopidogrel 
hyper responders and its clinical implications in causing bleeding 
complications is now being increasingly recognized(254). In one study, the 
incidence of CABG related bleeding was higher in aspirin hyper responders 
compared to normal responders and hypo responders (259). This study 
used PFA-100 to assess aspirin response. The incidence of bleeding was 
found to be higher in hyper responders to aspirin in Japanese patients 
(260). The incidence of minor bleeding was found to be high in patients 
treated with aspirin and who were found to be hyper responders to the 
same having the need for discontinuation of treatment with aspirin (261). 
There was no correlation between the urinary 11-dehydro TXB2 and 
platelet aggregation in response to 0.8mM AA measured by WBSPCA at 4 
minutes (P=0.466). A recent study in Chinese patients have failed to 
establish any correlation or agreement between the urine 11-dehydroTXB2 
levels and platelet aggregation  measured by LTA (262). Moreover it has 
been well acknowledged that the measurement of urinary 11-dehydro 
TXB2 is not a reliable tool to estimate the effect of aspirin on platelet 
aggregation (253). 
The serum TXB2 levels were significantly lower in responders compared 
with patients who were low-responders to aspirin. There was a statistically 
significant positive correlation between the serum TXB2 levels and platelet 
aggregation in response to 0.8mM AA measured by WBSPCA at 4 
minutes (r=0.368, P=0.000). In one study Gerber et al showed a 
significant correlation between serum TXB2 and five other PFT namely 
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VerifyNow point-of-care system, Cone and Plate analyzer, Whole blood 
aggregometry using electrical impedance and with PFA-100. In whole 
blood aggregometry AA, ADP and collagen were used as agonist (263). 
To the best of our knowledge our study is the first to demonstrate a 
correlation between serum TXB2 and WBSPCA. 
In summary, we observed a numerically higher incidence of ischaemic 
events in aspirin low responders as assessed by WBSPCA and an 
increased incidence of bleeding complications in responders. There was a 
statistically significant correlation found between serum TXB2 levels and 
platelet aggregation in aspirin treated patients assessed by WBSPCA. No 
difference was found in the levels of serum TXB2 in patients who developed 
ischaemic and bleeding complications although numerically the values 
were higher in the ischaemic group and lower in the bleeding groups. 
There was no correlation between the urine 11-dehydro TXB2 and serum 
TXB2 as well as the platelet aggregation indicating the non-specific nature 
of urinary measurement of TXB2. 
4.15. Conclusion 
The platelet aggregation assessed by WBSPCA in patients treated with 
aspirin correlated well with serum TXB2 levels considered to be the gold 
standard to measure aspirin response. The incidence of ischaemic events 
was numerically higher in aspirin low–responders and the incidence of 
bleeding events was numerically higher in aspirin responders although the 
difference was not statistically significant. The median percentage of 
platelet aggregation was higher in patients with ischaemic complications 
and lower in patients with bleeding complications, again not statistically 
significant. HAPR as a biomarker to predict clinical outcomes in aspirin 
treated patients although not well accepted cannot be dismissed as an 
option just as yet given the fact that there is no universal PFT that has 
been accepted to test this parameter. As long as the quest for the ideal 
PFT continues, WBSPCA can always be a potential option that can be 
considered if more information is available through large scale studies.  
144 
 
Chapter 5: Comparison of Whole Blood Single Platelet Counting 
Assay and Light Transmission Aggregometry in Assessing Platelet 
Aggregation in Patients Treated with Clopidogrel 
 
5.1. Background and Aim 
Clopidogrel, a P2Y12 inhibitor plays a crucial role in the treatment of ACS 
both in medical management and by intervention.  Despite the introduction 
of newer P2Y12inhibitors like prasugrel and ticagrelor, clopidogrel still 
remains the most common drug used globally in this class of medications 
due to its wide availability and cost effectiveness.  However, the clinical 
benefits obtained through clopidogrel are relatively limited. One among the 
various reasons attributed to this failure of clopidogrel to prevent thrombotic 
events despite treatment is the significant interindividual variation in the 
degree of platelet inhibition achieved by the drug (101). At the same time 
increasing evidence suggest that bleeding complications are common in 
patients who are hyper responders to P2Y12 inhibitors particularly 
clopidogrel (264). This raises important safety issues as patients with ACS 
are more likely to receive a cocktail of antiplatelets and anticoagulants, 
and currently these are unmonitored. It has been increasingly 
acknowledged that future research is warranted in order to assess an 
individual’s risk for bleeding, to guide the use of  antiplatelet and 
antithrombotic medications (265). 
None of the PFT is considered to be gold standard to monitor the effects 
of clopidogrel although a few points-of-care test (POCT) have been 
recommended accepting their limitations (265). We have shown in the 
previous two chapters that the incidence of ischaemic events were 
numerically higher in clopidogrel and aspirin non-responders and the 
incidence of bleeding events were numerically higher in responders to 
clopidogrel and aspirin assessed by WBSPCA. Previous studies have 
shown the effectiveness WBSPCA to monitor the efficacy of GP IIb/IIIa 
inhibitors (244). We aim to determine the correlation between WBSPCA 
and LTA, the gold standard for measuring platelet aggregation, in 
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assessing the platelet aggregation inhibition in response to ADP in 
clopidogrel treated patients. 
5.2. Results-Demographics 
Platelet testing was performed in 63 patients. Demographic data is 
available in 60 patients which are summarized in Table 5.1. Dyslipidaemia 
and hypertension were identified as the most common risk factor in this 
study, 62% and 60 % respectively. Half of the patients were smokers. 13 
% of the patients had diabetes. 2/3rd of the patients were treated for 
NSTEMI (68%) and the remaining for either STEMI or UA. All patients 
received aspirin, clopidogrel, LMWH for treatment of ACS and 
unfractionated heparin in the lab before proceeding to PCI.  
Table 5.1: Demographic and Clinical Characteristics (N=60) 
 
Age 62 ± 22 
Men 71% 
Risk Factors 
Hypertension 60% 
Diabetes 13% 
Dyslipidaemia 62% 
Smoking 50% 
Previous coronary artery disease 35% 
Diagnosis 
NSTEMI 68% 
STEMI 15% 
Unstable Angina 17% 
Medications  
Aspirin 100% 
Clopidogrel 100% 
LMWH 100% 
Heparin 100% 
GP IIb-IIIa Inhibitor (Reopro) 10% 
β Blocker 91% 
ACEI/ARB 94% 
Statins 100% 
Angiogram Findings 
Single vessel disease 55% 
Double vessel disease  32% 
Triple vessel disease 13% 
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Figure 5.1: Mean Percentage of Platelet Aggregation Assessed by 
WBSPCA (N= 63) 
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Figure 5.2: Mean percentage of Platelet Aggregation Assessed by 
LTA (N=63) 
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Figure 5.1: Mean (± SD) percentage of platelet aggregation in 
response to increasing concentrations of ADP (0.1, 0.3, 1, 3, 10, 30, 
and 100 µmol/L) assessed by WBSPCA. 
 
Figure 5.2: Mean (± SD) percentage of platelet aggregation in 
response to 2, 5 and 20µmol/L of ADP assessed by LTA. 
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5.3. Platelet Aggregation Data 
The mean percentage of platelet aggregation in response to 10µmol/L 
ADP at 4 minutes assessed by WBSPCA was 61 ± 15%. Similar values 
for 5µmol/L ADP and 20µmol/L ADP measured at maximum time point 
assessed by LTA were 31 ± 15% and 37 ± 17% respectively, presented in 
figure 5.1 & 5.2. Discriptive data is presented, (Appendix 4). 
5.4. Correlation between WBSPCA and LTA 
Increasing concentrations of ADP (2, 5, and 20 µmol/L) using LTA assay 
was correlated with 10µmol/L of ADP measured at 4 minutes using 
WBSPCA. Platelet aggregation in response to 2, 5, 20µmol/L of ADP at 
maximum time points assessed by LTA was normally distributed so was 
platelet aggregation in response to 10µmol/L of ADP measured at 4 
minutes assessed by WBSPCA. 
5.4.1. Correlation between 10µmol/L-ADP-WBSPCA and 2µmol/L-
ADP-LTA 
The percentage of platelet aggregation in response to 10µmol/L of ADP 
assessed by WBSPCA was correlated with platelet aggregation in 
response to 2µmol/L of ADP measured as maximum and final response 
(end of 5 minutes after the addition of agonist ADP) assessed by LTA. 
Spearman’s correlation for 2µmol/L of ADP at final and Pearson’s 
correlation for 2µmol/L of ADP at maximum time point were used. 
Moderate but statistically significant correlation existed between 2µmol/L 
of ADP measured at maximum time point in LTA and 10µmol/L of ADP 
measured at 4 minutes in WBSPCA (r= 0.503 P<0.0001). However, there 
was no correlation between 2µmol/L of ADP measured at final time point 
assessed by LTA and 10µmol/L of ADP measured at 4 minutes assessed 
by WBSPCA (r= 0.253, P= 0.045). 
5.4.2. Correlation between 5µmol-ADP-LTA and 10µmol/L- ADP -
WBSPCA 
Using Pearson’s correlation, the platelet aggregation in response to 
5µmol/L of ADP measured at maximum time point assessed by LTA was 
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correlated with platelet aggregation in response to 10µmol/L of ADP 
measured at 4 minutes assessed by WBSPCA. There was a strong 
positive correlation between platelet aggregation assessed by WBSPCA 
and LTA which was statistically significant (r=0.611 P< 0.0001) (figure 
5.3).  
Figure 5.3: Correlation between 10µmol/L-ADP-WBSPCA and 
5µmol/L- ADP-LTA (N=63) 
 
Figure 5.3:  Strong positive linear correlation which was statistically significant   
(r = 0.611, P < 0.0001, R2 = 0.373) (N=63) 
 
Similarly, Spearman’s rank correlation was employed to study the 
correlation between the platelet aggregation in response to 10µmol/L of 
ADP measured by WBSPCA after 4 minutes of the agonist contact with 
blood (data normally distributed) and platelet aggregation in response to 
5µmol/L of ADP assessed by LTA after 5 minutes of agonist contact (data 
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not normally distributed). There was a moderate positive, non-linear 
correlation between both the parameters that was statistically significant, 
but with a weak co-efficient of determination (r= 0.567, P < 0.001, R2 
0.206) (figure 5.4). 
Figure 5.4: Correlation between 10µmol/L-ADP-WBSPCA and 5µmol/L 
ADP-LTA (N=63) 
 
Figure 5.4: There was a moderate non-linear positive correlation (r = 0.567) that 
was statistically significant, (P< 0.001) with weak co-efficient of determination (R2 
= 0.206) (N=63). 
 
5.4.3. Correlation between 20µmol/L-ADP-LTA and 10µmol/L- ADP-
WBSPCA 
Pearson’s correlation showed a moderate positive correlation between the 
platelet aggregation in response to 20µmol/L of ADP measured at 
maximum time point of the agonist contact with the blood assessed by 
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LTA and platelet aggregation in response to 10µmol/L of ADP assessed 
by WBSPCA (r= 0.507) which was statistically significant (P < 0.0001). 
However, the co- efficient of determination was weak (R2 of 0.257) 
(figure5.5). 
Figure 5.5: Correlation between 10µmol/L-ADP-WBSPCA and 
20µmol/L-ADP-LTA (N=63) 
 
Figure 5.5: Moderate positive correlation was seen (r=0.507) that was 
statistically significant (P < 0.0001). 
 
There was a moderate positive correlation in platelet aggregation in 
response to 20µmol/L of ADP measured at final time point assessed by 
LTA and platelet aggregation in response to 10µmol/L of ADP measured 
at 4 minutes assessed by WBSPCA (r=0.599) that was statistically 
significant (P< 0.0001)(figure 5.6). A summary of all the correlation co-
efficient (r) and their statistical significance values P are presented in table 
5.2. 
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Figure 5.6: Correlation between 10µmol/L-ADP-WBSPCA and 
20µmol/L- ADP-LTA (N=63) 
 
Figure 5.6: A moderate positive correlation (r= 0.599) which was statistically 
significant (P<0.0001) with a weak co–efficient of disintegration (R2=0.332) 
(N=63). 
 
Table 5.2: Correlation co-efficient r and P between 10µmol/L-ADP- 
WBSPCA and Varying Concentration of ADP-LTA 
Time of contact ADP  r P 
Max 2µmol/L   0.503 <0.0001 
Final 2µmol/L   0.253 0.045 
Max 5µmol/L 0.611 <0.0001 
Final 5µmol/L  0.567 <0.0001 
Max 20µmol/L   0.507 <0.0001 
Final 20µmol/L  0.599 <0.0001 
 
Max  = Maximum time point of contact with the agonist 
Final = Final time point of contact with the agonist 
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5.5. Agreement between WBSPCA and LTA – The Kappa Statistics 
 
Although a moderate to strong  correlation was demonstrated between 
WBSPCA and LTA they  failed to agree significantly. Using the defined 
cut- off, many patients who were identified as non-responders by 
WBSPCA were identified as responders by LTA. 
 
5.5.1. Agreement between 10µmol/L-ADP-WBSPCA and 5µmol/L-
ADP-LTA 
The incidence of responders and non-responders  as identified by 
WBSPCA using 10µmol of ADP as agonist in clopidogrel treated patients 
was 40%(N=25/62) and 60 % (N = 37/62) respectively. Similar incidences 
as assessed by LTA with 5µmol/L of ADP as agonist measured at final 
time points was 77% (N= 48/62) and 23% (N=14/62) (figure 5.7).  
Figure 5.7: Incidenceof Responders and Non-Responders Assessed 
by WBSPCA and LTA 
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Figure 5.7:All patients who were identified as responders by LTA were also 
identified as responders by WBSPCA (N=25). 23 patients who were defined as 
non-responders in WBSPCA were categorized as responders in LTA. 
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All the patients identified as responders by WBSPCA were also 
categorized as responders by LTA (N = 25/48). The remaining 14 patients 
who were classed as non-responders by LTA were categorized 
asresponders by WBSPCA. There was a fair agreement between both the 
test (kappa co-efficient = 0.279)(Figure 5.8). 
Figure 5.8 : Agreement between 5µmol/L-ADP-LTA and 10µmol/L- 
ADP-LTA
 
 
Figure 5.8:There was a fair agreement between10µmol/L of ADP- WBSPCA and 
5µmol/L –LTA,(kappa co-efficient = 0.279). 
 
 
5.5.2. Agreement between 10µmol/L-ADP-WBSPCA and 20µmol/L-
ADP-LTA 
The incidence of responders and non-responders to clopidogrel assessed 
by LTA with stimulation by 20µmol/L of ADP as agonist after maximum 
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time of contact with the agonist was 73% (N = 45/62), 27% (N = 17/62) 
respectively.As with 5µmol/L of ADP in LTA, all the patients who were 
identified as responders by WBSPCA were also grouped as responders 
by LTA (N= 24). However 25 patients who were classed as responders by 
LTA were classed as non-responders in WBSPCA (Figure 5.10). There 
was a fair agrement between both the assays (kappa co- efficient 0.311) 
(Figure 5.9). 
 
Figure 5.9: Agreement between 20µmol/L-ADP-LTA and 10µmol/L-
ADP-WBSPCA
 
Figure 5.9: There was a fair agreement between platelet aggregation in 
response to 10µmol/L of ADP measured at 4 minutes assessed by WBSPCA and 
20µmol/L of ADP measured at maximum time point in  LTA (kappa co-efficient = 
0.311). 
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Figure 5.10: Incidence of Responders and Non-Responders  
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Figure 5.10:Of the 37 patients who were identified as non-responders in the 
WBSPCA, 21 were classed as responders by LTA. 
 
 
5.6. ROC Curve Analysis 
A ROC curve analysis was performed using LTA as standard and 
WBSPCA for comparison. The platelet aggregation in response to 
20µmol/L and 5µmol/L of ADP as agonist measured after maximum point 
of contact with the sample assessed by LTA was compared with 10µmol/L 
of ADP measured at 4 minutes in WBSPCA. Considering 20µmol/L of 
ADP in LTA (AUC = 0.762, upper bound = 0.851 lower bound = 0.672). A 
cut–off of 59 % (< 60 %) in WBSPCA was 63% sensitive and 90% specific 
in discriminating responders from non-responders. A value of 69%            
(< 70%) was 48% sensitive and 98% specific in identifying responders 
from non-responders (Figure 5.11). 
Considering 5µmol/L of ADP, (AUC = 0.803, upper bound = 0.884, lower 
bound = 0.722). A cut–off of 60% (< 60%) was 60% sensitive and 97% 
specific in identifying responders from non-responders. Likewise a cut-off 
of 70% was 49% sensitive and 100% specific in defining responders from 
non-responders, (figure 5.12). 
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Figure 5.11: ROC Analysis 20µmol/L of ADP measured at Maximum 
Time LTA as Control (N=63) 
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Figure 5.11: (AUC = 0.762, Lower Bound = 0.672, Upper Bound = 0.851) (N=63) 
 
 
Figure 5.12: ROC Analysis 5µmol/L of ADP measured at Maximum 
Time LTA as Control (N=63) 
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Figure 5.12: (AUC = 0.803, Lower Bound = 0.722, Upper Bound = 0.884) 
(N=63). 
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5.7. Discussion 
Although numerous tests are available to determine platelet function, the 
search for the ideal test still continues. Different cut-off values were 
advocated by different tests to discriminate clopidogrel responders from 
non-responders. Given the same test, for example the LTA, which used to 
be considered as the gold standard, various structured prospective studies 
have used different percentages of platelet aggregation to discriminate 
clopidogrel responders from non-responders. In one study, Lau and 
colleagues categorized the patients as clopidogrel non-responders, low 
responders and responders depending on the relative inhibition of platelet 
aggregation in response to 20µmol/L of ADP assessed by LTA. A platelet 
aggregation of <10% was classed as responders, 10-29% as low 
responders and > 30% as  non-responders (266).Other clinicians have 
used a cut-off value ranging between <10% to <40% to differentiate non-
responders from responders (267). In the CREST study, the patients were 
categorized as high post treatment platelet reactivity and low post 
treatment reactivity. The high post–treatment platelet reactivity was 
defined as >75th percentile for 5 and 20µmol/L ADP-stimulated 
aggregation (268). Furthermore, a patient who has been classed as 
responder by one test may well be a non-responder using the criteria set 
for another test. There is no uniformity in the prevalence of non-
responders assessed by different  test (269). However, we do have some 
clarity on this subject now and there are accepted values for an individual 
test that identifies rather high on-treatment platelet reactivity to 
clopidogrel.  They include PRI > 50% by VASP-P analysis, > 235 to 240 
PRU units by VerifyNow assay, > 46% maximal 5-µmol/l ADP–induced 
aggregation and > 468 arbitrary aggregation units/min in response to ADP 
by Multiplate analyzer.  
 
When we explore the reasons for such ambiguity in defining clopidogrel 
responders and non-responders, two main reasons need consideration. 
One is the significant interindividual variation in the inhibition of platelet 
aggregation to clopidogrel and the other, the pitfalls in the invitro 
measurement of platelet aggregation per se, and the limitations of various 
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tests that measure the platelet aggregation. This has been discussed in 
the introduction chapter. 
Interindividual variation to the platelet aggregation in response to ADP in 
clopidogrel treated patients is a well-documented phenomenon and 
several factors are known to cause this. Genetic reasons and drug 
interactions, particularly with those metabolized by CYP activity, need to 
be taken into consideration.  Other clinical parameters like high BMI, 
diabetes mellitus (particularly insulin dependent DM), and HPR in the 
context of ACS all contribute to the variability in response to clopidogrel 
(101). 
Similarly, measuring platelet aggregation using different PFT has its own 
limitations(270). It is well agreed that platelets exert their actions in a 
complex multifactorial fashion and it’s very difficult to measure all the 
modifications of platelet function by a single test(271). The ideal PFT 
should be able to study the global stimulus by various agonists rather than 
individual agonist particularly if employed for comprehensive assessment 
of antiplatelet and anticoagulant medications.  Furthermore none of the 
tests is able to measure the contribution of thrombin-induced platelet 
activation towards clot formation since the tests are performed in the 
presence of an anticoagulant that prevents the formation and/or action of 
thrombin in order to prevent fibrin formation and consequent 
coagulation(269). Although LTA is considered as gold standard, it does 
not precisely measure all aspects of platelet function (271). Strong 
evidence exist regarding how poorly the available PFT namely LTA, VASP 
and VerifyNow  agree with each other despite a strong correlation(269). 
The prevalence of non-responders assessed by WBSPCA in our study is 
60%. By LTA it is 23% and 27% for 5µmol/L of ADP measured at final time 
point and 20µmol/L of ADP measured at maximum time point respectively. 
As with other studies there is a substantial discrepancy in the prevalence 
of clopidogrel non-responders assessed by LTA and WBSPCA. 
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The level of correlation in our study between WBSPCA and LTA is 
predominantly moderate, but statistically significant and there is a strong 
correlation for 5µmol/L of ADP measured at maximum time point in LTA 
and 10µmol/L of ADP in WBSPCA (r=0.611, P <0.001). A fair correlation 
between WBSPCA and LTA has been previously reported by Storey and 
colleagues who used the tool to measure the platelet inhibition achieved 
by GP IIb/IIIa inhibitors (244). Limited data is available regarding the 
correlation between WBSPCA and LTA in measuring the platelet 
aggregation inhibition in patients treated with clopidogrel. Never-the-less, 
the results of our study suggest that the WBSPCA and LTA correlate the 
same in comparison with other PFT. 
In one study  that compared LTA with VASP and VerifyNow assay a 
correlation coefficient of 0.55 and 0.64 were obtained for VASP and 
VerifyNow respectively (272). In another study that compared Multiplate 
impedance platelet aggregometry (IPA) with that off LTA using ADP as the 
agonist significant correlation was found with an r value of 0.73(273). 
WBSPCA and LTA failed to agree with each other with a kappa statistic in 
the range of fair agreement, (0.279 for 5µmol/L of ADP) and (0.311 for 
20µmol/L of ADP). Again, limited data is available comparing WBSPCA 
and LTA in assessing agreement. LTA measures macro aggregation and 
WBSPCA measures micro aggregation and this could explain the lack of 
agreement between both the assays. Reviewing the evidence on  the 
concordance of other assays with LTA the results seems to be similar to 
our results, with a kappa value of 0.35 and 0.36 for VASP and VerifyNow 
respectively (272). However, a statistically significant agreement was 
found between LTA and Multiplate IPA with a kappa value of .74(273). 
The ROC analysis suggests that a cut-off of <70% in WBSPCA with 
10µmol/L ADP as agonist measured at 4 minutes is more specific and 
equally sensitive in discriminating responders from non-responders using 
LTA as reference. Although in our study we have adopted a cut-off value 
of <60%, in other studies a cut-off value of <70% has been adopted(274). 
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In summary, our study demonstrated that WBSPCA correlates moderately 
but with statistical significance with LTA. Although there was a fair 
agreement only, this is acceptable given the fact that LTA predominantly 
measures macro aggregation and WBSPCA measures micro aggregation. 
The flow cytometric VASP assay has now been recommended to assess 
the platelet function on the P2Y12 receptor. The main limitations of the 
assay are that it is labour intensive and expensive, hence more suitable as 
a research tool than as a point-of-care assay. The available VerifyNow 
point-of-care tool also lacks concordance with LTA and further data is 
needed on the same before advocating it as the preferred assay for 
platelet function. Given this caveat for the need for an ideal test, the 
WBSPCA might have a role in assessing the platelet aggregation 
inhibition in patients treated with P2Y12 inhibitor like clopidogrel and newer 
agents like prasugrel. 
5.8. Conclusion 
In conclusion, there is a highly significant and moderate correlation 
between LTA and WBSPCA in the assessment of ADP-induced platelet 
aggregation in clopidogrel-treated ACS patients. 
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Chapter 6: Percutaneous Coronary Intervention, Related increase in 
Troponin and its Relationship with Platelet Aggregation and 
Inflammatory Markers. 
 
6.1. Background and Aim 
Currently cardiac troponins are considered to be the gold standard 
biochemical markers for the diagnosis of myocardial necrosis (275).  
Myocardial necrosis subsequent to percutaneous intervention is a 
common occurrence (276). Troponin elevation occurs in about a quarter of 
patients who undergo PCI. Troponin elevation post PCI has been 
associated with increase in long-term adverse outcomes. It is 
recommended that post–procedure biomarker assay is performed when 
an intra-procedural angiographic complication is identified or a patient has 
signs or symptoms suggestive of MI during or after PCI. However 
measuring the   troponin levels after all elective PCI is not recommended 
routinely (277). PCI-related MI (Type 4a) is diagnosed when there is 
troponin elevation within 48hrs post procedure of 5 x upper limit of normal 
(ULN) with either symptoms of myocardial ischaemia, new ischaemic ECG 
changes or documented complications during the procedure (278). HPR at 
the time of PCI is associated with an increased incidence of post PCI 
myonecrosis and increased incidence of recurrent CV events following 
PCI(279). However, no study has so far used WBSPCA to evaluate the 
platelet reactivity at the time of PCI in patients who are treated with aspirin 
and clopidogrel and its relation with post PCI  
We aim to investigate the relationship between post PCI myonecrosis and 
non-responsiveness to antiplatelet agents namely clopidogrel and aspirin 
in patients with ACS assessed by WBSPCA.    
6.2. Results - Demography 
WBSPCA and LTA were performed in all 63 patients. Of these 55 patients 
had both pre and post PCI cTnI data available and were included in this 
analysis. For the purpose of this analysis, we used the same threshold as 
provided in the 3rd Universal Definition of MI to indicate significant PCI 
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related myonecrosis, that is an increase in cTnI of more than 5 times the 
ULN (>0.5ng/ml). The demographic details of this patient group are 
presented in table 6.1 
Table 6.1 
Demographic data N = 50/55   
Age 62   
Sex 50 39(M) 16(F) 
Risk Factors   Yes No 
Diabetes Mellitus 50 6/50 44/50 
Hypertension 50 30/50 20/50 
Smoking 50 26/50 24/50 
Dyslipidaemia 50 31/50 1/50 
CKD 50 4/50 46/50 
Previous H/o IHD 50 15/50 35/50 
NSTEMI 50 34/50  
STEMI 50 7/50  
Unstable Angina 50 9/50  
 
6.3. Procedure-Related Elevation in cTnI 
The median (IQ range) of the cTnI values before PCI was 0.10 (0.10-0.57 
ng/ml), and post PCI levels were 0.62 (0.18-2.02 ng/ml). There was a 
statistically significant difference in the median compared between both 
the values. (Mann Whitney U test P < 0.0001). Data were not normally 
distributed by Shapiro-Wilk normality test, (w=0.5136). The mean with SE 
data is presented in figure 6.1.   
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Figure 6.1: Troponin I Elevation Related to PCI (N=55) 
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Figure 6.1: Mean (±SE) values of cTnI levels pre and post PCI (P<0.0001) 
(N=55) 
 
 
6.4. Incidence of PCI Related Myonecrosis 
In this study, the proportion of patients who met the criterion for significant 
PCI related release of troponin was 38% (N = 21/55). In the remaining 62 
% who did not meet the criterion, 24 % had some increase in cTnI 
following PCI. The mean (±SD) percentage of platelet aggregation in 
patients who did not have PCI related release of troponin was 62 ± 25 % 
and that of those who had PCI related release of troponin was 60 ± 27%. 
There was no difference in the median compared between the groups (P= 
0.578, figure 6.2) 
6.5. Incidence of PCI Related Myonecrosis in Responders vs. Non-
Responders Assessed by WBSPCA 
The incidence of clopidogrel responders was 40% as assessed by 
WBSPCA. The incidence of PCI-related myonecrosis in responders was 
41% and in non-responders was 36%. This was not statistically significant, 
(Fishers exact test P = 0.782), (figure 6.3). The mean (± SD) increase in 
cTnI in responders was 0.86 (± 1.36 ng/ml) and that of non-responders 
was 1.08 (± 2.40 ng/ml). There was no difference in the median compared 
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between the values, (Mann Whitney U test P = 0.478). The mean with SE 
value is presented in figure 6.4. 
 
Figure 6.2: Platelet Aggregation as Assessed by WBSPCA in PCI 
Related Myonecrosis (N=55) 
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Figure 6.2: No difference in platelet reactivity in those who developed PCI 
related myonecrosis as assessed by WBSPCA (N= 55) (P= 0.578). 
 
Figure 6.3: Incidence of post PCI Myonecrosis in Responders and 
Non-Responders to Clopidogrel Assessed by WBSPCA (N=55) 
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Figure 6.3: There was no significant difference in the incidence of PCI related 
myonecrosis between responders and non-responders (P= 0.782) (N=55) 
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Figure 6.4: The Increase in cTnI Compared between Responders and 
Non-Responders to Clopidogrel as Assessed by WBSPCA (N=55) 
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Figure 6.4: There was no difference in the mean elevation of cTnI compared 
between responders and non-responders as assessed by WBSPCA (P= 0.478) 
(N=55) 
 
6.6. Incidence of PCI Related Myonecrosis in Responders vs. Non-
Responders to Clopidogrel Assessed by LTA 
When assessed by LTA with 20µmol/L of ADP as agonist measured as 
maximal response, the incidence of clopidogrel responders was 76%.  PCI 
related myonecrosis happened in 44% of the responders and 23% of the 
non-responders. The difference in the incidence was not statistically 
significant (Fishers exact test P=0.211) (figure 6.5). The mean (± SD) 
increase in cTnI in responders was 0.96 (±1.61 ng/ml) and that of non-
responders were 1.10 (± 3.13 ng/ml). The difference in the median was 
not statistically significant, (Mann Whitney U test P= 0.398) (figure 6.6). 
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Figure 6.5: PCI Related Myonecrosis in Responders and Non-
Responders as Assessed by LTA (N=55) 
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Figure 6.5: No significant difference in the incidence of PCI related myonecrosis 
between responders and non-responders assessed by LTA (P=0.211). 
 
Figure 6.6:  PCI Related Myonecrosis in Responders and Non-
Responders as Assessed by LTA 
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Figure 6.6: There was no significant difference in the mean increase in cTnI 
between responders and non-responders (P= 0.398).
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6.7. Correlation between Post-PCI Myonecrosis and Platelet 
Aggregation in Response to 10µmol/L ADP Assessed by WBSPCA 
 
Pearson’s correlation showed no correlation between platelet aggregation 
measured by WBSPCA in response 10µmol ADP measured at 4 minutes 
and PCI-related troponin release. Pearson’s correlation coefficient 
(r=0.013, P=0.926 and R2 =1.677 Figure 6.7) 
Figure 6.7: Correlation between PCI-Related Myonecrosis and 
Platelet Aggregation Assessed by WBSPCA (N=55) 
 
 
 
Figure 6.7: There was no correlation between the PCI related myonecrosis and 
platelet aggregation as measured by WBSPCA. (r =0.013, P= 0.926, R2 =1.677). 
 
 
 
r = 0.013 P=0.926 
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6.8. PCI-Related Myonecrosis and its Relation with Platelet Reactivity 
in Aspirin-Treated Patients Assessed by WBSPCA 
55 patients had available complete data on AA-induced platelet 
aggregation and were included in the analysis. Using the study definition, 
36/55 (65%) patents were found to be aspirin responders and the 
remaining 19/55 (35%) patients were low-responders to aspirin. The mean 
± SD elevation in troponin in aspirin responders was 0.82 ± 1.60ng/ml. 
The corresponding value in aspirin low- responders was 1.31 ± 2.69ng/ml. 
There was no difference in the median between the groups (Mann 
Whitney U test, P= 0.233, figure 6.8). 
Figure 6.8: Mean Increase in Troponin between Responders and 
Low-Responders to Aspirin Assessed by WBSPCA (N=55) 
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Figure 6.8: cTnI increase in aspirin responders and low-responders (P=0.233) 
 
6.9. Platelet Aggregation Assessed by WBSPCA and its Relation to 
PCI Related Myonecrosis 
Of the 55 patients, 21 patients met the criterion for significant PCI related 
myonecrosis (38%). The mean ±SD percentage of platelet aggregation in 
patients who had PC related myonecrosis was 35 ± 25 % and for those 
who did not develop PCI related myonecrosis was 24 ± 11 %. There was 
no difference in the median compared between both the categories, Mann 
Whitney U test P= 0.125 (figure 6.9). Of the 21 patients who the criterion 
for significant PCI related myonecrosis, 12 were responders to aspirin (N = 
12/36, 33%). The remaining 9 patients were low–responders to aspirin (N 
= 9/19, 47%) (Figure 6.10) 
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Figure 6.9: Platelet Aggregation Assessed by WBSPCA in Aspirin 
Treated Patients and its relation with PCI Related Myonecrosis (N=55) 
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Figure 6.9: Percentage of platelet aggregation in patients who developed PCI 
related myonecrosis compared with those who did not develop the same (P= 
0.125) (N=55) 
 
Figure 6.10: Incidence of PCI Related Myonecrosis in Aspirin Treated 
Patients (N=55) 
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Figure 6.10: The incidence of PCI related myonecrosis was higher in aspirin low-
responders compared to responders (47% vs. 33%, N=55) 
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6.10. Correlation of PCI Related Myonecrosis and Platelet 
Aggregation Assessed by WBSPCA in Aspirin Treated Patients 
Spearman’s nonlinear correlation showed no correlation between the PCI 
related myonecrosis and platelet aggregation in response to 0.8mM AA in 
aspirin treated patients at the time of PCI measured by WBSPCA at 4 
minutes. Correlation co-efficient (r=0.148, P=0.280, figure 6.11). 
Figure 6.11: PCI Related Myonecrosis and its Correlation to Platelet 
Aggregation at the Time of PCI Assessed by WBSPCA (N=55) 
 
 
Figure 6.11: PCI related myonecrosis and its correlation with platelet 
aggregation assessed by WBSPCA in aspirin treated patients (r= 0.148, P= 
0.280). 
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6.11 PCI-Related Myonecrosis Compared between Diabetics and 
Non-diabetics 
The mean percentage of platelet aggregation in diabetics with PCI related 
myonecrosis was 75% assessed by WBSPCA stimulated by 10µmol/L 
ADP and 34% measured by LTA using 20µmol/L of ADP as agonist. The 
mean percentage of platelet aggregation in patients who were non-
diabetic with no PCI related myonecrosis was 55% assessed by WBSPCA 
and 14% measured by LTA (figure 6.12). The detailed descriptive data is 
attached (Appendix 5). 
 
Figure 6.12: Platelet Aggregation in Diabetics and Non-Diabetics with 
or Without PCI Related Myonecrosis 
 
Figure 6.12: The mean percentage of platelet aggregation in diabetics with PCI 
related myonecrosis was 76%-WBSPCA and 34%-LTA. 55%-WBSPCA and 14% 
LTA were the similar value in non-diabetic without PCI related myonecrosis. 
 
6.12. Relationship between Pre PCI-Inflammatory Markers and PCI 
Related Myonecrosis 
There was no significant difference in the mean (±SD) of pre-PCI levels of 
inflammatory markers namely CRP, sCD40L, IL-6 and TNF-α in patients 
who developed PCI related myonecrosis with those who did not develop 
the same, (Mann Whitney U test P >0.05).  Data presented in table 6.2, 
(figure 6.16-6.19). 
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Table 6.2: Inflammatory Markers Pre PCI and PCI Related 
Myonecrosis 
Inflammatory 
markers N cTnI <0.5 ng/ml cTnI> 0.5 ng/ml P 
CRP pre-PCI (mg/dl) 54 7.150±10.8 6.94±10.06 0.097 
sCD40L pre-PCI 
(ng/ml) 54 2.23±0.95 2.30±1.36 0.401 
IL-6 pre-PCI (pg/ml) 54 26.84±20.55 19.63±14.55 0.174 
TNF-α pre-PCI (pg/ml) 49 11.06±6.73 9.71±5.23 0.460 
 
 
Figure 6.13: CRP pre-PCI Compared with PCI-Related Myonecrosis  
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Figure 6.13: There was no significant difference in CRP levels pre-PCI in 
comparison with those who developed PCI related myonecrosis (P=0.097, N=54) 
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Figure 6.14: sCD40L pre-PCI Compared with PCI Related 
Myonecrosis (N= 54) 
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Figure 6.14: There was no difference in the levels of pre-PCI sCD40L in those 
who had PCI related myonecrosis (P=0.401, N=54) 
 
Figure 6.15: IL-6 pre-PCI vs. PCI Related Myonecrosis (N=54)  
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Figure 6.15: There was no difference in the levels of IL-6 pre-PCI in those who 
had PCI related myonecrosis (P = 0.174, N=54) 
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Figure 6.16: TNF-α pre-PCI vs.  PCI Related Myonecrosis (N=49) 
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Figure 6.16: There was no difference in the levels of pre-PCI TNF-α in those 
who PCI related myonecrosis (P = 0.460, N=49) 
 
6.13. Discussion 
We studied the relationship between PCI related myonecrosis and its 
relationship with platelet reactivity at the time of PCI in patients treated 
with aspirin and clopidogrel. There was a statistically significant rise in PCI 
related release in cTnI (P=0.0014). There was non-significant difference in 
the incidence of PCI related myonecrosis in clopidogrel non-responders 
compared to responders assessed by both WBSPCA and LTA. Similarly, 
no significant difference was found in the mean percentage of platelet 
aggregation in patients who had PCI related myonecrosis compared to 
those who did not. The release of cTnI following PCI was numerically 
higher in clopidogrel non-responders than responders. There was no 
correlation between PCI related release in cTnI and platelet reactivity in 
response to 10µmol/L of ADP at the time of PCI in patients treated with 
clopidogrel assessed by WBSPCA. 
 
The incidence of PCI related myonecrosis was numerically higher in 
aspirin low responders compared to responders, but not statistically 
significant. The mean percentage of platelet aggregation in response to 
0.8mM AA at the time of PCI was higher in the patients who developed 
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PCI related myonecrosis. Similarly, the mean increase in cTnI post PCI 
was higher in aspirin low-responders compared to responders. There was 
no correlation between platelet aggregation in response to 0.8mM AA and 
post PCI release of cTnI. 
No study has so far compared platelet reactivity at the time of PCI 
assessed by WBSPCA and occurrence of PCI related myonecrosis. 
However mixed results have been published with other point-of-care tools. 
Cuisset and colleagues have demonstrated an increased incidence of 
periprocedural MI (PMI) in patients who were non-responders to 
clopidogrel assessed by point- of-care assay(206). On the contrary, Buch 
and colleagues found no association between periprocedural MI and 
platelet aggregation inhibition assessed by Rapid Platelet Function Assay 
P2Y12 assay (280). In the BRIEF-PCI study, there was no increased 
incidence of PCI-related myonecrosis in aspirin or clopidogrel non-
responders (281). In the ARMYDA-PRO study the incidence of 
periprocedural MI occurred more often in patients who had a higher 
platelet reactivity unit (PRU) assessed by Verify-Now assay (282). Patti 
and colleagues have shown that the incidence of PCI related myonecrosis 
is higher in clopidogrel non-responders undergoing elective PCI for low to 
moderate risk CAD (283). 
The 2012 ACCF consensus document on PCI related myonecrosis has 
acknowledged that, troponin release in the context of PCI is related to 
adverse outcomes only when the release is due to ischaemic events 
unrelated to the procedure, or the troponin release is caused by 
intraprocedural complications and when the baseline troponin is high. 
Moreover defining the PCI related  myonecrosis as increase in troponin 5 
times above the ULN may be too sensitive a criterion which has increased 
the incidence of PCI related myonecrosis to 33% when compared to 
previous studies where the incidence was only 20%  when older 
generation less sensitive assays were used (278). HPR is now being 
increasingly recognized as an independent risk factor for future 
occurrences of MACE regardless of the PCI-related increase in 
myonecrosis (284). Its relevance in the incidence of PCI related 
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myonecrosis is debatable. Our study has provided preliminary data on the 
relationship between clopidogrel non-responders assessed by WBSPCA 
and its relationship to the incidence of PCI-related myonecrosis. 
6.14. Conclusion 
In our study, the incidence of PCI-related myonecrosis was not 
significantly different in clopidogrel responders compared to responders. 
The incidence of post PCI myonecrosis is numerically higher in aspirin low 
responders compared to responders. The mean increase in cTnI was 
higher in clopidogrel non-responders and aspirin low responders, but not 
significant. A study with a large sample size is required to assess whether 
the results of WBSPCA-assessed platelet reactivity at the time of PCI is 
associated with the incidence of post-PCI myonecrosis. 
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Chapter 7: Relationship between Plasma Inflammatory Markers and 
Platelet Aggregation in Patients Undergoing Percutaneous Coronary 
Intervention. 
 
7.1. Introduction 
Atherosclerosis is well acknowledged as an inflammatory condition (285, 
286). Platelets, when activated, not only are involved in thrombus 
formation but also contribute to an inflammatory process following 
vascular injury (287). Various inflammatory markers from diverse sources 
are released during the active process of plaque rupture and thrombus 
formation. Of note are sCD40L, predominantly released by the platelets 
but also from the macrophages, and interleukin-6 (IL-6) and TNF-α 
released by the macrophages and T cells. In addition, CRP is released 
from the hepatocytes and adipocytes in response to IL-6 and TNF-α (288). 
These inflammatory markers are increased during the acute presentation 
of ACS and during PCI. Aspirin and clopidogrel are recognized treatment 
options for a spectrum of disease conditions including UA, NSTEMI, 
STEMI, acute ischaemic stroke and symptomatic PVD (289). Inhibition of 
platelet aggregation can modulate the release of both platelet related 
inflammatory markers, particularly sCD40L, and non-platelet systemic 
inflammatory markers such as IL-6, TNF-α and CRP (290). 
 Aspirin and clopidogrel, in addition to inhibiting platelet aggregation, also 
have anti-inflammatory effects, which can be indirect (291, 292). Several 
studies have demonstrated a mixed relationship between HPR assessed 
by various platelet function tests and increased inflammatory markers in 
patients with CAD treated either medically or by PCI (293-295). However, 
little evidence exists regarding the utility of WBSPCA in evaluating the 
platelet reactivity in patients treated with aspirin and clopidogrel and its 
relationship with the inflammatory markers. 
 
We aimed to study the relationship between aspirin low responders as 
assessed by WBSPCA and its relationship with inflammatory markers 
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namely CRP, IL-6 and TNF-α. In addition, we assessed whether variable 
P2Y12 receptor blockade by clopidogrel assessed by WBSPCA and LTA 
leads to variability in inflammatory response as measured by CRP and 
sCD40L in patients undergoing percutaneous coronary intervention. 
 
7.2. Results - Demography 
WBSPCA and LTA were performed in all 63 patients. Although we aimed 
to check the inflammatory markers viz. CRP, IL-6, TNF-α and sCD40L at 
three time points, namely at baseline before PCI (B) 2-4 hours following 
PCI (4H) and 18-24 hours after PCI (24H), there are some missing values. 
Hence patients in whom complete set of information was available, 
including inflammatory markers at all three time points (B, 4H, and 24H) 
and their corresponding platelet aggregation data were only considered for 
the analysis. In that respect, we included data on CRP analysed on 52 
patients, TNF-α on 49 patients, IL-6 on 52 patients and sCD40L on 52 
patients. A detailed demographic data on these patients is already 
presented in chapter 3. 
 
7.3. Descriptive Statistics of Inflammatory Markers 
Except for the sCD40L-B levels, inflammatory marker levels were not 
normally distributed. There was a significant increase in the level of CRP-
24H from CRP-B, 4.42 (± 13.57mg/dl, P=0.003). Such difference was not 
seen with the CRP-4H, 1.28 (± 8.68mg/dl, P= 0.127). Although there was 
a marginal increase in sCD40L-4H and sCD40L-24H, it was not 
statistically significant (P= 0.557, P= 0.115). The IL-6-4H was elevated 
from IL-6-B, 4.65 (± 16.41pg/ml, P=0.073). There was no increase in IL-6-
24H from IL-6-B 3.28 (± 14.47pg/ml, P= 0.242). The TNF-α-4H and TNF-
α-24H were marginally elevated compared to TNF-α-B (B= 10.39 ± 
6.07pg/ml, 4H= 10.93 ± 6.85pg/ml, 24H=10.68 ± 6.30pg/ml). There were 
some extreme outliers in the CRP levels. Particularly, one value 
determined the results obtained regarding all analysis pertaining to CRP. 
There was no clinical correlation as to why an extreme increase in CRP 
was seen in that particular patient. Hence, we considered this value to be 
anomalous and removed it in all our further analysis of CRP. Considering 
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this change, there was no significant increase in CRP-24H from CRP-B. 
The data are attached (Appendix 6). The mean with SE value of each 
inflammatory marker are presented in figure 7.1-7.4. 
Figure 7.1: CRP (N= 52) 
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Figure 7.1: There is a statistically significant difference CRP-24H and CRP-B 
(N=52) 
 
Figure 7.2: sCD40L (N=52) 
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Figure 7.2: There is no significant difference between sCD40L-24H and 
sCD40L-B (N=52) 
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Figure 7.3: TNF-α (N=49)      
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Figure 7.3: There is no significant difference between TNF-α-24H and TNF-α-B 
(N=49) 
 
Figure 7.4: IL-6 (N=52) 
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Figure 7.4: There is no significant difference between IL-6-24H and IL-6-B 
(N=52) 
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7.4. Post PCI Release in sCD40L and Clopidogrel Response 
The relationship between platelet aggregation in response to 10µmol/L of 
ADP measured at 4 minutes assessed by WBSPCA and to three 
concentrations of ADP namely 2, 5, 20µmol/L assessed by LTA in patients 
treated with clopidogrel and sCD40L release before and after PCI was 
studied in 52 patients. Patients were categorized into groups based on the 
percentage of platelet aggregation. The mean increase in sCD40L levels 
in each group was compared by ANOVA. 
7.4.1. SCD40L-4H and its Relation with Platelet Aggregation in 
Response to 10µmol/L of ADP Assessed by WBSPCA 
Platelet aggregation in response to 10µmol/L of ADP in clopidogrel treated 
patients was categorized in to four groups. Group 1= percentage of 
platelet aggregation 0-< 30%, group 2= 30-<60%, group 3= 60- <90%, and 
group 4= percentage of platelet aggregation> 90%. Their corresponding 
differences in the levels of sCD40L namely sCD40L-B, sCD40L-4H, 
sCD40L-24H were compared by one way ANOVA. 
Of the 52 patients studied, 9 were classed as group 1, 11 patients 
belonged to group 2, 25 patients were in group 3, and 5 patients were 
classed as group 4.  The mean (± SD) of the sCD40L-4H in group 1 was 
1.98 (± 0.65ng/ml) and in group 4 was 2.69 (±1.11ng/ml). The values in 
group 2 and 3 were not much different at 2.53 (± 1.43ng/ml) and 2.53 (± 
1.14ng/ml) respectively.  There was no difference in the mean compared 
between all the groups (P=0.588 F= 0.648) by one way ANOVA .The 
mean with SE for each group is presented in figure 7.5. Their ANOVA 
table is attached (Appendix 7). 
7.4.2. SCD40L-24H and its Relation with Platelet Aggregation in 
Response to 10µmol/L of ADP Assessed by WBSPCA 
The mean (± SD) increase in sCD40L-24H in group 1 was 1.74 
(±0.75ng/ml). Similar data for group 2, 3, 4 are 2.13 (± 0.86nm/ml), 2.66 (± 
1.08ng/ml), 3.72 (± 0.92ng/ml) respectively. There was a statistically 
significant difference in the mean compared between group1 and group 4, 
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as well as group 2 and group 4 (P=0.004, F=5.221).Mean with SE 
presented in figure 7.6. Details of statistics attached (Appendix 8) 
Figure 7.5: sCD40L-4H Compared between All the Groups of Platelet 
Aggregation Assessed by WBSPCA (N= 52) 
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Figure 7.5: No differences in the mean compared between the groups ( N=52) 
 
Figure 7.6: sCD40L-24H Compared between all Groups of Platelet 
Aggregation Assessed by WBSPCA (N=52) 
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Figure 7.6: Significant difference in the mean between group 1 and group 4, 
group 2 and group 4 (P= 0.004, F= 5.22). 
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7.4.3. SCD40L-24H and its Relation with Platelet Aggregation in 
Response to 5µmol/L of ADP Assessed by LTA 
The percentage of platelet aggregation in response to 5µmol/L of ADP in 
clopidogrel treated patients assessed by LTA measured at final time point 
was divided into three groups. Group 1 = 0%, Group 2= 0 -< 14% and 
group 3=> 14%.16/52 was categorized in group 1, 22/52 in group 2, and 
12/22 in group 3. The mean (± SD) value of sCD40L in group 1 was 2.16 
(± 0.91ng/ml) and that of group3 was 2.86 (±1.09ng/ml). There was no 
significant difference in the means between the groups (P = 0.242, F= 
1.46).Mean with SE is presented in figure 7.7. ANOVA table attached 
(Appendix 9). 
Figure 7.7: sCD40L-24H Compared between all Groups of Platelet 
Aggregation Assessed by LTA (N=52) 
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Figure7.7: There was no difference in the mean (P= 0.242).
 
7.4.4. SCD40L-24H and its Relation with Platelet Aggregation in 
Response to 20µmol/L of ADP Assessed by LTA 
The percentage of platelet aggregation in response to 20µmol/L-ADP in 
clopidogrel-treated patients measured by LTA at maximum time point was 
categorized as three groups. Group 1 = percentage of platelet aggregation 
< 25%, Group 2 = 25-< 50 % and group 3 >50 %. 13/52 of patients were in 
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group 1, 24/52 were in group 2 and 13/52 were in group 3. The mean (± 
SD) of sCD40L in group 1 was 2.24 (±0.95ng/ml) and that of group 3 was 
2.47 (±0.95ng/ml). There was no difference in the mean between the 
groups (P = 0.570, F= 0.569). The mean with SE is presented in figure 
7.8. The ANOVA table is presented in Appendix 10. 
Figure 7.8: sCD40L-24H Compared between all Groups of Platelet 
Aggregation Assessed by LTA (N=52) 
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Figure7.8: No difference in the mean compared between the groups (P= 0.570). 
 
7.5. Correlation between sCD40L and Platelet  Aggregation in 
Clopidogrel Treated Patients 
Spearman’s linear correlation demonstrated  a  moderate but significant 
correlation between platelet  aggregation in response to 10µmol/L ADP 
measured at 4 minutes assessed by WBSPCAand sCD40L-B (r=0.274, 
P= 0.031). Likewise a modertae but significant postive correlation was 
seen between platelet aggregation in response to 10µmol/L ADP 
measured at 4 minutes assessed by WBSPCA and sCD40L-24H (r= 
0.343, P= 0.008,figure7.9). There was no correlation between the platelet 
aggregation assessed by LTA and the levels of sCD40L at 24H (r= 0.154, 
P= 0.251 for 20µmol/L). The detailed table with all correlation co-efficient 
is attached (Appendix 11). 
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Figure 7.9: Correlation between  sCD40L-24H and Platelet 
Aggregation  Measured by WBSPCA (N=52) 
 
 
 
Figure 7.9: Moderate, but significant correlation between platelet aggregation 
and sCD40L -24H (r= 0.343, P= 0.008).
 
7.6. CRP and its Relationship with Platelet Aggregation in Response 
to Aspirin and Clopidogrel 
51 patients were considered for analysis. They were grouped into four 
categories. Aspirin/clopidogrel responders (N =13/51), aspirin responders 
only (N = 19/51), clopidogrel responders only (N = 7/51) and 
aspirin/clopidogrel non-responders (N = 12/51). The mean (± SD) level of 
the CRP-4H in the aspirin/clopidogrel responders was 4.55 (± 4.02mg/ml) 
and that of aspirin/clopidogrel non-responders was 5.24 (± 6.32mg/ml). 
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Although the means were numerically high in the non-responders, it was 
not significant (P > 0.05, figure 7.10). Considering CRP-24H, the mean (± 
SD) level of CRP in the aspirin/clopidogrel responders was 5.12 (± 
4.63mg/ml) and that of the aspirin/clopidogrel non-responders were 5.71 
(± 6.62mg/ml). There was no difference in the mean compared between 
the groups (P > 0.05, figure 7.11). 
Figure 7.10: CRP-4H (N=52) 
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Figure 7.10: Median difference in the CRP-4H levels between aspirin/clopidogrel 
responders and non- responders measured (P> 0.05) (N=52) 
 
Figure 7.11: CRP-24H (N=52) 
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Figure 7.11: Median difference in the CRP- 24H levels between 
aspirin/clopidogrel responders and non-responders (P > 0.05) (N=52)
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7.6.1. Correlation between Platelet  Aggregation  in Response to 
0.8mM AA and CRP 
Spearman’s correlation showed fair but significant correlation between 
platelet aggregation in response to 0.8mM AA measured at 4 minutes 
assessed by WBSPCA and CRP-4H (r= 0.274, P=0.039, figure 7.12). 
There was no correlation with CRP measured at other time points.Detailed 
r and p value of all the correlations between aspirin and CRP is attcahed 
(Appendix 12). 
Figure 7.12: Correlation between CRP-4H and Platelet Aggregation in 
Response to 0.8mM AA (N=52) 
 
 
 
Figure 7.12: A fair but significant correlation was seen between CRP-4H and 
platelet aggregation in response to 0.8mM AA (r= 0.274, P= 0.039) (N=52) 
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7.6.2. Correlation between Platelet  Aggregation  in Response 
10µmol/L ADP and CRP 
There was no correlation between platelet aggregation in response to 
10µmol/L ADP measured at 4 minutes assessed by WBSPCA and CRP-
24H in clopidogrel-treated patients, Spearman’s correlation co-efficient (r= 
-0.158, P=0.235, figure 12). No correlation was seen with CRP measured 
at other time points, data attached (Appendix 12). 
 
Figure 7.13: Correlation between Platelet  Aggregation  in Response 
to10µmol/L ADP and CRP-24H (N=52) 
 
 
Figure 7.13: Correlation between CRP-24H and platelet aggregation in response 
to 10µmol/L ADP (r= -0.158, P= 0.235) (N=52). 
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7.7. TNF-α and its Relationship with Platelet Aggregation in 
Response to 0.8mM AA in Aspirin Treated Patients 
49 patients were considered for analysis (N = 39/49, 80%) of patients 
were aspirin responders, remaining (N = 10/49, 20%) were aspirin low-
responders. The mean (± SD) levels of TNF-α-4H in aspirin responders 
was 10.40 (± 7.46pg/ml) and that of the low-responders was11.75 (± 
5.84pg/ml). There was no significant difference in the mean (Wilcoxon 
signed rank test P= 0.324, figure 7.14). Similar values for TNF-α-24H was 
10.30 (± 7.12pg/ml) and 11.27 (± 4.87, P= 0.456, figure 7.15).   
Figure 7.14: TNF-α 4H   Figure 7.15: TNF-α 24H 
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Figure 7.14: No difference in the mean between responders and low-responders 
(P= 0.324) (N=49) 
Figure 7.15: No difference in the mean between responders and low-responders 
(P= 0.456) (N=49) 
 
7.7.1. Correlation between TNF-α and Platelet Aggregation in 
Response to 0.8mM AA in Aspirin Treated Patients 
Spearman’s correlation showed a moderate but significant correlation 
between TNF-α-4H and platelet aggregation in response to 0.8mM AA 
measured at 4 minutes assessed by WBSPCA in aspirin-treated patients, 
(r= 0.307, P= 0.025, figure 7.16). Fair and significant correlation was seen 
with TNF-α measured at other time points (Appendix 13). 
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Figure 7.16: Correlation between TNF-α-4H and Platelet Aggregation 
in Response to 0.8mM AA in Aspirin Treated Patients (N=49) 
 
 
Figure 7.16: Correlation between TNF-α-4Hand platelet aggregation in response 
to 0.8mM AA (r= 0.307, P=0.025, R2 = 0.057) (N=49)
 
7.8. IL-6 and its Relationship with Platelet Aggregation in Response 
to Aspirin 
52 patients were considered for analysis. 33/52 (64%) were aspirin 
responders and the remaining (N=19/52, 36%) were aspirin low-
responders. The mean (± SD) value of IL-6-4H in aspirin responders was 
28.29 (± 23.00pg/ml) and in low-responders was 22.72 (±1 4.84pg/ml). 
There was no significant difference in the mean (Wilcoxon signed rank test 
P= 0.794, figure7.17). Likewise the mean (± SD) value of IL-6-24H in 
aspirin responders was 29.16 (± 21.89pg/ml) and that of non-responders 
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was 22.72 (± 14.84pg/ml). There was no significant difference in their 
mean, (Wilcoxon signed rank test P= 0.481, figure 7.18). 
Figure 7.17: IL-6-4H   Figure 7.18: IL -6-24H 
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Figure 7.17:  No difference in the mean (P=0.794) (N=49) 
Figure 7.18:  No difference in the mean (P=0.481) (N=49)
 
7.8.1. Correlation between IL-6 and Platelet Aggregation in Response 
to 0.8mM AA in Aspirin Treated Patients 
There was no correlation between IL-6 levels at any point in time (B, 4H, 
24H) and platelet aggregation in response to 0.8mM AA assessed by LTA. 
Data are included in Appendix 14. 
 
7.9. Incidence of Ischaemic Events 
61 patients out of 63 patients completed 12 months follow up. Ischaemic 
events occurred in 8 patients. Of these, four patients developed in stent 
re-stenosis. One had an acute presentation two days following the 
procedure with stent thrombosis. One patient died. This was an elderly 
patient who had a multivessel PCI and ventricular fibrillation (VF) arrest 
during the procedure and was successfully resuscitated. He died at one 
month following the procedure. One patient presented with NSTEMI and 
was referred for CABG surgery. One patient presented with ACS and was 
found to have a new lesion that needed to be stented. There was no 
difference in the levels of inflammatory markers in this group compared 
with those who did not have any ischaemic events.        
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7.10. Discussion 
To summarize the findings of our study, there was no significant increase 
in the levels of inflammatory markers related to PCI at B, 4H and 24H. 
This is seen in all four markers studied. SCD40L levels were significantly 
higher in group 4 of the patients who had a platelet aggregation >90 % 
compared with those in group 1, platelet aggregation <30%. This was 
however seen only in the levels measured at 24H, not with 4H and in 
particular only when assessed by WBSPCA and not by LTA. There was a 
moderate, but significant positive correlation between platelet aggregation 
in response to 10µmol/L of ADP assessed by WBSPCA and sCD40L 
levels at 24H. TNF-α levels correlated well with platelet aggregation in 
response to aspirin. CRP was no different in clopidogrel responders and 
non- responders. CRP was numerically higher in aspirin non-responders 
compared to responders. No difference was seen in the levels of TN-Fα 
and IL-6 in aspirin responders and non-responders. Neither the 
inflammatory markers nor post-PCI myonecrosis were any different in 
patients who developed MACE compared with those who did not.   
Atherosclerosis, thrombus formation and inflammation are interlinked. 
Hence it’s logical to accept that effective suppression of platelet 
aggregation may also have an ant-inflammatory response (296). 
Prevailing evidence suggests that aspirin has an effect on levels of CRP, 
IL-6 and TNF-α (288). Similarly, the levels of sCD40L were reduced in 
patients who received clopidogrel compared with placebo who were 
already on aspirin. However there was no significant reduction in the level 
of CRP in this study (297). 
 Mixed evidence prevails over the role of aspirin and clopidogrel in 
reducing the levels of inflammatory markers. On balance, aspirin seems to 
have a consistent effect in reducing the levels of CRP and clopidogrel in 
reducing the levels of sCD40L as found in our study also (288, 297). Again 
the increase in sCD40L was significant only 18-24 hours post PCI, but not 
immediately after the PCI as found by Quinn and colleagues (298). In this 
study they did not find any relation between clopidogrel pretreatment and 
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the rise of CRP post PCI. In another study by Azar and colleagues, there 
was no difference in the levels of CRP in patients who received 
clopidogrel compared with placebo, but a reduction in the levels of 
sCD40L was observed (297). 
In our study, there was a strong positive correlation between platelet 
aggregation and plasma sCD40L levels. This correlation was not found 
with other inflammatory markers like CRP, IL-6 and TNF-α in patients 
treated with clopidogrel. Similar findings have been reported by Qing Yang 
and colleagues (299).    
CRP has been positively linked with the incidence of post-PCI 
myonecrosis. Our study failed to demonstrate this in a significant manner 
although numerically the mean increase in CRP levels was higher in 
patients who developed post-PCI myonecrosis compared with those who 
did not (276).   
The limitations of our study are small sample size and, although 
prospective, it was not a randomized study. The loading dose of 
clopidogrel varied between 300 and 600 mg. When comprehensively 
assessing all data together, the sample size was further reduced due to 
some missing values. There were some extreme outliers at least with the 
results of CRP who influenced the results to a greater extent. These 
abnormal levels could not be explained by clinical events. There was no 
accepted cut-off for inflammatory markers discriminating elevated levels 
from non-elevated levels. The presentations of the patients were not 
uniform. Although they were acute presentations, they varied in their 
clinical diagnosis from UA to STEMI and the time of interventions varied 
from 2 days from their presentation to more than 7 days. The outcomes 
were too small in numbers to make any conclusion about the role of 
inflammatory markers in predicting the outcomes.  
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7.11. Conclusion 
sCD40L levels were significantly higher in patients with percentage of 
platelet aggregation > 90% in response to 10µmol/L ADP treated with 
clopidogrel and low in patients with a percentage of platelet aggregation < 
30% in response to 10µmol/L ADP assessed  by WBSPCA. There was a 
positive correlation between platelet aggregation in response to 10µmol/L 
of ADP assessed by WBSPCA and sCD40L levels 18-24 hours post PCI. 
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Chapter 8: Discussion and Conclusions 
 
To summarize the findings of our study 
 The incidence of ischaemic events was numerically higher in 
clopidogrel non-responders compared to responders but this 
difference was not statistically significant. The incidence of bleeding 
events was numerically higher in clopidogrel responders compared 
to non-responders although not significant. The mean percentage 
of platelet aggregation was higher in patients who developed 
ischaemic complications compared to those who developed 
bleeding complications. 
 The incidence of ischaemic events was higher in aspirin low-
responders compared to aspirin responders. Likewise the incidence 
of bleeding complications was higher in aspirin responders 
compared to low-responders, but not statistically significant. The 
mean percentage of platelet aggregation in response to 0.8mM AA 
was higher in patients who developed ischaemic complications and 
lower in patients who developed bleeding complications. There was 
moderate but significant correlation between platelet aggregations 
in response to 0.8mM AA measured at 4 minutes by WBSPCA and 
serum TXB2 levels. 
 There was moderate  and significant correlation between WBSPCA 
and LTA 
 The incidence of post PCI myonecrosis was no different in 
clopidogrel non-responders compared to responders. The 
incidence of post PCI myonecrosis was higher in aspirin low-
responders compared to responders, but not significant. There was 
no association between the levels of pre PCI inflammatory markers 
and the extent of post PCI related myonecrosis. 
 The levels of sCD40L 18-24 hours post PCI was significantly higher 
in patients whose percentage of platelet aggregation was more 
than 90% compared to patients whose percentage of platelet 
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aggregation was either less than 30% or between 30-60%.There 
was a moderate, but significant correlation between sCD40L levels 
18-24hours post PCI and percentage of platelet aggregation in 
response to 10µmol/L of ADP assessed by WBSPCA in 
clopidogrel-treated patients. There was moderate and significant 
correlation between TNF-α levels and percentage of platelet 
aggregation in response to 0.8mM AA in aspirin-treated patients.  
Limited data are available about WBSPCA in monitoring the efficacy of 
clopidogrel and aspirin. However, previous studies have shown that 
WBSPCA could be a useful tool in monitoring the antiplatelet effect of GP 
IIb/IIIa inhibitors (244). There is compelling evidence to suggest a strong 
association between HPR and future periprocedural and long term clinical 
outcomes notwithstanding the lack of an optimal method to define HPR 
and risk stratify the patients (300). In the majority of the prospective 
studies, clopidogrel has been widely studied: the higher the residual 
platelet reactivity, the higher the risk of cardiovascular adverse events 
(301). 
HPR on clopidogrel treatment using LTA has been linked with recurrent 
ischaemic events although this test is not specific for the P2Y12 pathway. 
Platelet reactivity index, determined by VASP phosphorylation assay, has 
also been associated with recurrent ischaemic events after PCI and most 
importantly has a strong negative predictive power below a certain cutoff. 
The VASP assay however does not include the contribution of the P2Y1 
receptor to the platelet response. The VerifyNow assay is a user friendly 
bedside tool. A higher PRU value assessed by this assay is associated 
with adverse cardiovascular events. Most clinical trials linking low 
response to clopidogrel with clinical outcomes have employed LTA and 
VerifyNow assay.  Although we now have cut-off values that define HPR 
for each PFT, these values may have different weights in different 
settings, like urgent versus elective PCI, and periprocedural setting versus 
maintenance treatment phase. Moreover, these cutoff values had 
significant negative predictive values for recurrence of ischaemic events 
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compared to positive predictive value. It is important to acknowledge that  
although HPR is a major risk factor for future thrombotic events, many 
other factors contribute to these events(241).  
In our study we have shown that clopidogrel non-responders, as defined 
using WBSPCA, had a numerically higher incidence of ischaemic events 
conversely the mean percentage of platelet aggregation in clopidogrel 
treated patients was higher in those who developed ischaemic events.  
Gaglia et al attempted to evaluate the degree of agreement and 
correlation among VASP, LTA and VerifyNow assay in patients on 
clopidogrel therapy undergoing PCI. HPR was defined according to the 
latest consensus recommendation. It was found that there was only a fair 
degree of agreement between those tests. Nevertheless, although the 
agreement among tests may be modest, it still remains that the  individual 
tests have  all demonstrated significant correlation with occurrence of 
adverse CV outcomes beyond a certain cut-off value adopted by 
consensus (302). In our study we found that there was a moderate and 
significant correlation between WBSPCA and LTA. 
Guidelines have rather mixed recommendations regarding the applicability 
of PFT in patients treated with antiplatelets. The 2012 update of the 
Society of Thoracic Surgeons guidelines stated that, in patients treated 
with antiplatelets, a point-of-care test to assess platelet function may be 
useful in identifying patients with high residual platelet reactivity and hence 
with less risk for bleeding during CABG (303). The 2014 ACC/AHA 
guideline for the management of patients with NSTE-ACS does not 
recommend PFT to determine platelet inhibitory response (304). The 2015 
ESC guidelines for the management of ACS in patients with NSTEMI do 
not recommend the routine performance of PFT. In addition, the document 
notes that, “PFT may be considered in selected patients treated with 
clopidogrel including those with a history of stent thrombosis, suspected 
non-compliance, as well as persistent high on-treatment platelet reactivity 
or high bleeding risk in the presence of stents in critical coronary 
segments” (62).   
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Lately PFT have gained an important role in the monitoring of modern 
antiplatelet therapy but still uncertainties remain about its clinical utility. 
The indications for PFT in the field of CV medicine is not just restricted to 
monitoring the effects of antiplatelets, but also have an extended role in 
acute care settings like CABG and PCI. These interventions are prone to 
thrombotic and bleeding complications regardless of the use of 
antiplatelets and antithrombotics. Hence obtaining baseline information 
pertaining to platelet function is suggested to improve the outcomes of the 
procedure. Moreover the need to use antiplatelets and antithrombotics in 
this clinical situation is likely; hence it is even more compelling to screen 
patients for their platelet function. The platelet count, its response and the 
distribution of platelet receptors on the platelets is varied. Therefore the 
way in which each individual responds to antiplatelet therapy is unique 
and forms a strong basis for individualizing their treatment based on their 
platelet function (305). 
Growing evidence suggests that platelet hyper-reactivity by itself is an 
independent risk factor for future MACE and platelet hyper-reactivity is 
present in all CV risk conditions like smoking, hypertension, obesity and 
diabetes. Hence PFT as a routine screening test to predict future adverse 
CV events is a remote possibility (306). Equally PFT might become a valid 
tool to predict bleeding complications, at least in high risk patients, such 
as those taking anticoagulants along with antiplatelets and in the  elderly 
population (265). 
Until the introduction of the newer P2Y12 inhibitors like prasugrel and 
ticagrelor, clopidogrel, and its less safe predecessor ticlopidine, remained 
the only other antiplatelet agent to be used in conjunction with aspirin for 
the treatment of ACS in both medically managed patients and patients 
treated by PCI. Although prasugrel and ticagrelor are now recommended 
for the treatment of ACS in preference to clopidogrel, except in those with 
contraindications or with an indication for oral anticoagulant therapy, 
clopidogrel still has a class I indication in the treatment of ACS. This is 
because the newer agents are not widely available globally or may not be 
affordable in some healthcare settings (307).This makes clopidogrel the 
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most widely used antiplatelet agent globally. Interindividual variation in the 
platelet aggregation response in clopidogrel treated patients led to the 
concept of individualizing the loading dose of clopidogrel (300mg, 600mg 
and 900mg) dependent on the platelet reactivity. Currently that model is 
not recommended as dose adjustment failed to establish clinical benefits 
(227, 233). 
Plateletworks is a point-of-care tool that works on the principle of single 
platelet counting techniques. It uses ADP as agonist and hence is used to 
measure the effect of P2Y12 inhibitor particularly clopidogrel. It has good 
results in monitoring the effectiveness of GP IIb/IIIa inhibitor (308). It 
measures platelet micro aggregation as opposed to LTA that measures 
platelet macro aggregation. Plateletworks has demonstrated good 
agreement with LTA assay in measuring the effectiveness of clopidogrel in 
patients undergoing PCI (309), although the assay is more time 
dependent. WBSPCA works on the same principle as PlateletWorks. It 
uses ADP as agonist and has shown promising results in monitoring GP 
IIb/IIIa inhibitors (244, 310). In our study we have shown that that mean 
platelet aggregation assessed by WBSPCA in patients presenting with 
ACS and treated with antiplatelets was higher in patients who developed 
ischaemic complications and was low in patients who developed bleeding 
complications. WBSPCA is a simple test that is cost effective and user 
friendly. This could be considered in the context of assessing the baseline 
platelet reactivity of an individual before commencing antiplatelet 
medications. 
Our study has several limitations. Patients belonged to all spectrum of 
ACS including UA/NSTEMI and STEMI. In addition, patients were treated 
both medically without any interventions and with interventions. Patients 
received varying dose of clopidogrel ranging from 75 mg of maintenance 
dose alone to 300 and 600 mg of loading dose followed by 75 mg of 
maintenance dose. The definitions for responders and non-responders to 
clopidogrel and aspirin were not standardized. The sample size is small 
and the original design of the project is to obtain sample data on the utility 
of this test in assessing the efficacy of clopidogrel. Hence our study was 
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not adequately powered to detect ischaemic and bleeding events. When 
the study was conducted between 2005 and 2009, limited information was 
available about PFT in general. However with the evidence from more 
large scale studies that was published subsequently, we now have better 
clarity on the role of PFT in clinical scenarios particularly its role in high 
risk and low risk ACS. Moreover we currently have precise cut-off and a 
consensus about the definition of HPR based on different PFT. This 
information was not available to us during the conduct of this study. At the 
same time, the work has suffered some delay and the data that we now 
have might be slightly outdated. However, as WBSPCA is not widely 
studied the information generated from this study surely adds to the 
wealth of knowledge that we have about the subject and will certainly form 
a platform for future work. 
Available evidence does not support PFT-guided antiplatelet therapy for 
the treatment of ACS. However, this conclusion is drawn from studies 
related to CAD. More evidence is warranted in other disease conditions 
where aspirin and clopidogrel are equally used like stroke, TIA, neuro-
interventions, PAD and left ventricular assist device. A number of small 
studies have shown some initial promising results in these clinical settings 
and in the paediatric age group. More large scale studies are needed to 
confirm the findings of such small studies. Until future studies exclude the 
usefulness of PFT in the above mentioned clinical scenarios, we cannot 
dismiss the usefulness of PFT prematurely. As long as there is an utility 
for PFT, WBSPCA can always be a potential tool as our study although 
small in size has produced results comparable with other large scale 
studies with other PFT. Other potential use of PFT is to monitor 
compliance to antiplatelet therapy. PFT can also help us to determine 
timing of cardiac surgery following withdrawal of clopidogrel particularly in 
whom an early surgery is indicated who otherwise has to wait for the 
guidelines stipulated time before surgery could be done. Assessing the 
usefulness of WBSPCA assay to particularly predict bleeding outcomes 
offers scope for future research (249). 
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It has been suggested that the ability of the PFT to assess the hazard ratio 
for a given complication should be taken into account in assessing its 
clinical utility since HPR to ADP is a risk factor and not a diagnosis (311). 
P2Y12 based PFT assess the overall effectiveness of the receptor and not 
necessarily just the effect of the P2Y12 inhibitors on the receptor, this 
concept needs consideration while interpreting the results of the assay 
(312). HPR to ADP does not appear to predict future events in medically 
managed ACS patients and in low risk ACS patients (313). Hence platelet 
function testing in this group is not recommended. Low platelet reactivity 
(LPR) to ADP is associated with increased bleeding complications in 
patients treated with P2Y12 receptor inhibitors. LPR to ADP is an 
independent risk factor for bleeding in patients undergoing PCI (314). In 
the future, we might aim to establish a therapeutic window for each P2Y12 
inhibitor where the combined risk of bleeding and thrombotic events is 
minimized. 
 Both LTA and VASP are not recommended as routine tests to assess the 
HPR to ADP as they are very cumbersome and methodological errors are 
possible (265). Simple POCT are preferred over these assays in clinical 
settings. WBSPCA has the potential to meet the above said criteria. VASP 
and LTA play a crucial role as research tools to assess HPR to ADP. 
WBSPCA is a simple, cost effective and user friendly assay that has the 
ability to monitor the efficacy of aspirin, GP IIb/IIIa inhibitors and P2Y12 
inhibitors. We have shown in our study that the assay correlates 
moderately with LTA, and serum TXB2.  Globally, clopidogrel still remains 
the widely used P2Y12 inhibitor in addition to aspirin in the management of 
ACS both medically and by intervention. Availability and cost are the 
advantages of clopidogrel over the newer agents like prasugrel and 
ticagrelor in countries with limited healthcare expenditure. In such setting, 
use of PFT-guided therapy may be an option in high risk individuals 
undergoing PCI. Given this scenario, there is a huge potential for a point-
of-care instrument that can give reliable and quick results based on which 
therapeutic decisions can be made. This gives a promising hope for tools 
like WBSPCA. 
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Conclusion 
The overall consensus about the ideal test is one which accurately 
predicts both ischaemic and bleeding risks. A simple but sophisticated tool 
that gives reliable and reproducible information and that meets quality 
control standards based on which clinical judgments could be safely taken 
is highly needed. Future work on whole blood single platelet counting 
assay can determine its usefulness as an effective tool to monitor the 
effects of P2Y12 inhibitors. 
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10. Appendix 
 
Appendix 1-Consent Form 
 
 
 
 
  
 
 
CONSENT FORM 
 
 
Title of Project: Pilot study of the relationship between inhibitory effects of antiplatelet agents and 
safety and efficacy in patients with acute coronary syndromes: towards designing the optimal 
monitored antiplatelet strategy 
 
(A study of the effects of routine anti-clotting drugs in patients with unstable angina and heart 
attacks) 
 
Name of Researcher: DR. ROBERT F. STOREY 
 
 
       Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 30th September   
 2004 Version 3 for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,    
 without giving any reason, without my medical care or legal rights being affected. 
 
3. I agree to take part in the above study.        
 
 
________________________ ________________ ____________________ 
Name of Patient Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
 
 1 for patient;  1 for researcher 
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Appendix 2- Amendment  
 
  
 
 
 
NOTICE OF SUBSTANTIAL AMENDMENT 
 
 
For use in the case of all research other than clinical trials of investigational medicinal products 
(CTIMPs).  For substantial amendments to CTIMPs, please use the EU-approved notice of 
amendment form (Annex 2 to ENTR/CT1) at http://eudract.emea.eu.int/document.html#guidance. 
 
To be completed in typescript by the Chief Investigator and submitted to the Research Ethics 
Committee that gave a favourable opinion of the research (“the main REC”).  In the case of multi-site 
studies, there is no need to send copies to other RECs unless specifically required by the main REC. 
 
Further guidance is available in section 5 of our Standard Operating Procedures available at 
www.corec.org.uk/applicants/help/docs/SOPs.doc. 
 
 
Details of Chief Investigator: 
 
 
Name: Dr Robert F. Storey 
Address: 
 
 
 
Clinical Sciences Centre 
Northern General Hospital 
Sheffield 
Telephone: 0114 2714192 
E-mail: r.f.storey@shef.ac.uk 
Fax: 0114 2619587 
 
 
Full title of study: 
 
: Pilot study of the relationship between 
inhibitory effects of antiplatelet agents and 
safety and efficacy in patients with acute 
coronary syndromes: towards designing the 
optimal monitored antiplatelet strategy 
 
Name of main REC: 
 
 
North Sheffield 
 
 
REC reference number: 
 
 
NS2003 11 1800 
 
 
Date study commenced: 
 
 
6 October 2004 
Protocol reference (if applicable), 
current version and date: 
 
 
Version 4, 8 November 2005 
 
 
Amendment number and date: 
 
 
Amendment no. 3, 8 November 2005 
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Appendix 3 
 
  
Pilot study of the relationship between the inhibitory effects of antiplatelet agents 
and safety and efficacy in patients with acute coronary syndromes: towards 
designing the optimal monitored antiplatelet strategy 
 
Schedule of questions for outpatient telephone interview 
 
Before contacting patients by telephone, the hospital information system will be 
interrogated to ensure there is no record of death since the last contact and the General 
Practice surgery will be contacted to ensure the same. 
 
The following questions will be asked during the telephone interview at 30 days: 
 
1. Have you had any further admissions to hospital since you were discharged 
from the Northern General Hospital on …(date)…? 
2. Have you had any new problems since that date? 
3. Have you had any problems with bruising or bleeding since that date? 
4. Have you required any further treatment for your heart condition since that 
date? 
5. Have any changes been made to your medication since that date, such as 
stopping any medication, or are any changes planned? 
6. Have you required any blood tests since that date and, if so, have you been 
informed of any abnormal results? 
 
The following questions will be asked during the telephone interview at 3 months and 
at 12 months: 
 
7. Have you had any further admissions to hospital since on our last telephone 
discussion on …(date)…? 
8. Have you had any new problems since that date? 
9. Have you had any problems with bruising or bleeding since that date? 
10. Have you required any further treatment for your heart condition since that 
date? 
11. Have any changes been made to your medication since that date, such as 
stopping any medication, or are any changes planned? [If appropriate] What 
was the reason, if any, for the change in medication? 
12. Have you required any blood tests since that date and, if so, have you been 
informed of any abnormal results? 
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Appendix 4 - Descriptive Statistics of Platelet Aggregation Assessed 
by LTA and WBSPCA 
 
 
 
 
 
 
 
 
 
♠ Light transmission aggregometry     ♣  Whole blood single platelet counting assay 
 
 
  
ADP Concentrations N Minimum Maximum Mean SD 
ADP 2max♠ 63 .01 55.000 22.79 12.78 
ADP 2fiinal♠ 63 .01 42.000 2.56 7.34 
ADP 5max♠ 62 .01 62.000 30.89 15.11 
ADP 5final♠ 62 .01 61.0000 8.87 14.22 
ADP 20max♠ 62 .01 70.0000 37.35 16.59 
ADP 20final♠ 62 .01 66.00000 19.13 18.814 
ADP 10min♣ 63 .01 94.0200 61.21 26.69 
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Appendix 6    
 
Table 1: Descriptive statistics of inflammatory markers 
Inflammatory 
markers 
N 
KS normality 
test Mean ± SD Median with IQR P value 
CRP base 52 no 8.92±21.72 4.13±(1.72-7.82) 
 CRP 2-4hr 52 no 10.20±22.51 4.61±(1.97-8.62) 
 CRP 18-24hr 52 no 13.34±33.23 4.50±(2.36-9.17) 
 CRP 2-4-base 52 no 1.28±8.68 0.20±(-0.30-0.82) 0.1272 
CRP 18-24-
base 52 no 4.42±13.57 0.48±(-0.04-2.20) 0.0031 
sCD40L-B 52 yes 2.21±0.93 2.09±(1.48-2.78) 
 sCD40L-4H 52 no 2.41±1.12 2.02±(1.68-2.78) 
 sCD40L-24H 52 no 2.43±1.11 2.00±(1.73-3.20) 
 sCD40L-4H-B 52 no 0.20±0.98 0.05±(-0.38-0.42) 0.5569 
sCD40L-24H-B 52 no 0.22±0.76 0.04±(-0.14-0.42) 0.1151 
TNF-α-B 49 no 10.39±6.07 8.60±(6.36-11.62) 
 TNF-α-4H 49 no 10.93±6.85 9.02±(7.00-12.15) 
 TNF-α-24H 49 no 10.68±6.30 9.36±(6.31-12.24) 
 TNF-α-4-B 49 no 0.54±2.49 0.12±(-0.76-1.36) 0.2884 
TNF-α-24H-B 49 no 0.29±2.99 0.25±(-0.94-1.40) 0.3654 
IL-6-B 52 no 23.52±19.39 
16.78±(6.40-
38.30) 
 
IL-6-4H 52 no 28.17±21.09 
24.00±(9.02-
44.33) 
 
IL-6-24H 52 no 26.80±19.70 
21.15±(8.65-
44.95) 
 IL-6-4H-B 52 no 4.65±16.41 3.13±(-5.05-11.71) 0.0728 
IL-6-24H-B 52 no 3.28±14.47 2.45±(-5.80-7.58) 0.2419 
* KS = Kolmogorov-Smirnov normality test: only sCD40LB is normally distributed 
*There is a significant difference in the elevation of CRP-24H from CRP-B  P=0.0031 
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Appendix 7 - ANOVA Analysis of the sCD40L-4H Compared  
with WBSPCA 
 
ANOVA Mean Diff q 95% CI of Diff P<0.05 
0-<30% vs. 30-<60% -0.56 1.53 -1.93 to 0.81 No 
0-<30% vs. 60-<90% -0.55 1.76 -1.74 to 0.63 No 
0-<30% vs. >90% -0.71 1.59 -2.42 to 0.99 No 
30-<60% vs. 60-<90% 0.01 0.02 -1.10 to 1.11 No 
30-<60% vs. >90% -0.16 0.36 -1.80 to 1.49 No 
60-<90% vs. >90% -0.16 0.41 -1.66 to 1.33 No 
 
 
Appendix 8 - ANOVA Analysis of the sCD40L-24H and 
 its Relationship with 10 ADP – WBSPCA 
 
ANOVA Mean Diff q 95% CI of Diff P<0.05 
0-<30% vs. 30-<60% -0.39 1.26 -1.56 to 0.78 No 
0-<30% vs. 60-<90% -0.92 3.45 -1.93 to 0.09 No 
0-<30% vs. >90% -1.98 5.17 -3.43 to -0.54 Yes 
30-<60% vs. 60-<90% -0.53 2.14 -1.47 to 0.41 No 
30-<60% vs. >90% -1.59 4.29 -2.99 to -0.19 Yes 
60-<90% vs. >90% -1.06 3.15 -2.33 to 0.21 No 
 
 
Appendix 9 - ANOVA analysis of the sCD40L-24H  
and itsRelationship with 5 ADP final –LTA 
 
ANOVA Mean Diff q 95% CI of Diff P<0.05 
0% vs. 0-<14% -0.348 1.39 -1.21 to 0.51 No 
0% vs.<14% -0.70 2.41 -1.70 to 0.30 No 
0-<14% -0.36 1.29 -1.30 to 0.59 No 
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Appendix 10 - ANOVA analysis of the sCD40L-24H  
and its relationship with 20 ADP max – LTA 
 
ANOVA Mean Diff q 95% CI of diff P<0.05 
>25% vs. 25-49% -0.40 1.51 -1.32 to 0.52 No 
>25% vs. 50% -0.25 0.82 -1.30 to 0.80 No 
25-49% vs. 50% 0.16 0.58 -0.76 to 1.07 No 
 
 
 
Appendix 11 - Correlation co-efficient andP values of inflammatory 
markers in relationwith 0.8mM AA measured by WBSPCA 
 
 
CRP-
B 
CRP-
4H 
CRP-
24H TNF-B 
TNF-α 
4H 
TNF-α 
24H IL- 6B 
IL-6-
4H 
IL-6-
24H 
r 0.182 0.274 0.160 0.291 0.307 0.270 0.062 0.132 0.061 
P 0.156 0.039 0.229 0.028 0.025 0.051 0.630 0.329 0.652 
 
 
Appendix 12 - Spearman’s correlation co-efficient and p values of 
inflammatory markers in relation with 10 ADP   measured by WBSPCA 
 
 CRP B CRP-4H CRP-24H sCD40L-B sCD40L-4H sCD40L -24H 
R -0.015 -0.125 -0.158 0.274 0.205 0.343 
P 0.907 0.354 0.235 0.031 0.129 0.0085 
 
 
 
Appendix 13 - Spearman’s correlation co-efficient and P values of 
inflammatory markers in relation with 20 ADP max measured by LTA 
 
 CRP B CRP 2-4 CRP 18-24 sCD40LB sCD40L-4H sCD40L-24H 
R 0.1737 0.03298 0.06119 0.2031 0.07146 0.1545 
P 0.1806 0.8093 0.6512 0.1164 0.6041 0.2511 
 
